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GENERAL PERSPECT IVE
From radical mastectomy to less invasive breast-conserving surgery
Breast cancer is the most common form of cancer among women. It affects women of 
all ages, and an estimated 12-13% of women will develop breast cancer. This means that 
approximately 1 in 8 women will be diagnosed with breast cancer over the course of 
their lifetime, and translates into 13,000 new cases of breast cancer each year in the 
Netherlands.1 
The introduction of widespread mammographic screening, better imaging techniques, 
improved patient awareness and breast self-examination have all contributed to an 
increase in early diagnoses. Accordingly, survival rates have improved and an increasing 
number of patients present with operable disease.2-4 Surgery, therefore, continues to play 
a prominent role in the curative management of breast cancer. 
Breast cancer surgery has changed dramatically over recent decades. Radical mastectomy 
was introduced over 100 years ago and required an en bloc removal of the breast, the 
muscles of the chest wall and the axillary lymph nodes.5-7 During the second half of 
the 20th century, more limited operations were promoted, based on suggestions that 
less radical surgery might be just as effective as the more extensive operations then 
performed.8,9 During the 1970s, the first randomised clinical trials were conducted 
with the goal of determining that less invasive surgery, such as the modified radical 
mastectomy or even breast-conserving surgery (BCS) combined with radiotherapy, 
could achieve local recurrence rates and overall survival rates similar to more invasive 
approahes.10-13 For early-stage breast cancer, BCS is now accepted as a viable alternative 
to modified radical mastectomy and can be safely offered to most breast cancer patients, 
provided that additional radiotherapy is administered. When following national 
guidelines, over 75% of breast cancer patients qualify for breast-conserving treatment, 
and this is now the accepted care standard for the increasing number of women with 
early-stage breast cancers.14,15
AN ESTIMATED 1 IN 8 WOMEN WILL BE DIAGNOSED WITH INVASIVE 
BREAST CANCER OVER THE COURSE OF THEIR LIFETME
BREAST CANCER SURGERY HAS CHANGED DRAMATICALLY OVER THE 
PAST DECADES
BREAST-CONSERVING THERAPY HAS BECOME THE STANDARD 
SURGICAL TREATMENT
Proefschrift_Nicole_v17.indd   10 04-12-12   15:25
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Towards more limited axillary surgery 
While the surgical management of breast cancer has changed dramatically, until only 
the last decade complete axillary lymph node dissection was the standard approach 
in the axillary lymph node basin, despite the fact that the majority of patients are 
node-negative and do not require this procedure for cure. The axillary lymph node 
dissection is a potentially disabling procedure with a high morbidity, a high risk of 
complications, and a deteriorating effect on cosmetic outcome.16,17 In the 1990s, the so-
called ‘sentinel lymph node biopsy’ was developed, a minimally invasive technique for 
identifying axillary metastasis in clinical node-negative patients.18,19 The introduction of 
the sentinel node procedure has removed the need for an axillary lymph node dissection 
in patients who have a negative sentinel node and therefore a low probability of axillary 
metastasis.20-24 The “Triple Technique” is commonly used for the sentinel node procedure, 
and consists of combined pre-operative lymphoscintigraphy, the intra-operative use of 
blue dye, and the handheld gamma probe to intra-operatively visualise and localise the 
sentinel node.25-27 This technique is now accepted as a practical, accurate, and minimally 
invasive alternative to axillary lymph node dissection for the identification of nodes 
containing metastases, and prevents several thousand patients in the Netherlands each 
year from undergoing an unnecessary complete axillary lymph node dissection.28 Recent 
trials even showed that among patients with limited sentinel lymph node metastases, 
the use of sentinel lymph node biopsy alone did not result in poorer survival when 
compared with complete axillary lymph node dissection.29 In the near future, axillary 
lymph node dissection may therefore be completely replaced by the minimally invasive 
sentinel node procedure for nodal staging. In most cases, the sentinel node procedure is 
performed first and is followed by the surgery of the breast, in the same surgical session.
THE SENTINEL NODE PROCEDURE FOR NODAL STAGING AVOIDS THE 
NEED FOR AN AXILLARY LYMPH NODE DISSECTION IN THE MAJORITY 
OF PATIENTS
 
BREAST- CONSERV ING THERAPY
Breast-conserving therapy refers to the surgical removal of the breast tumour in all 
cases followed by radiotherapy to eradicate residual tumour cells. The main advantage 
of breast-conserving therapy over mastectomy is physical preservation of the breast with 
sparing of healthy breast tissue, thereby improving cosmetic outcome. The criteria for 
BCS are relative; although initially confined to patients with unifocal, small tumours 
(<3 cm), BCS may be suitable for women with larger breasts with (i) tumours >3 cm in 
diameter, (ii) multifocal tumours confined to the same quadrant and (iii) large tumours 
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being downstaged by neoadjuvant chemotherapy. The size of the tumour relative to the 
breast volume is a critical factor in determining feasibility of conservation surgery and 
ensuring an optimal cosmetic result.
Primary goal of breast-conserving surgery
The primary goal of a breast-conserving procedure is to achieve a complete resection of 
the breast cancer with adequate, tumour-free resection margins (typically defined as the 
absence of either invasive or intraductal disease at the inked margin). Tumour-positive 
margins (grossly discernible tumour (> 4 mm) at the surgical resection margin) are 
associated with an increased risk of local recurrence, signifying the need for a second 
surgery to obtain definite clear pathological margins via re-excision or even mastectomy; 
focally positive margins (an area of ≤ 4 mm with tumour at the surgical resection margin) 
require either additional surgery or external beam radiotherapy, with a directed boost to 
the tumour bed. These additional treatments are psychologically stressful to the patient, 
reduce the patient’s well-being and increase hospital costs. Moreover, the removal of 
additional tissue or the administration of boost irradiation leads to a worsened cosmetic 
result.31,37,58 Although the achievement of adequate tumour-free resection margins is the 
most important goal the surgeon, studies worldwide report a high incidence of positive 
margins in BCS (> 20%).11,12,30-37
THE PRIMARY GOAL OF BREAST-CONSERVING SURGERY IS TO 
ACHIEVE A COMPLETE TUMOUR RESECTION, AND TO PREVENT LOCAL 
RECURRENCE THROUGH ADEQUATE TUMOUR-FREE RESECTION 
MARGINS 
TUMOUR-POSITIVE MARGINS REQUIRE ADDITIONAL BOOST-
RADIOTHERAPY, A RE-EXCISION, OR EVEN A MASTECTOMY TO OBTAIN 
DEFINITE CLEAR RESECTION MARGINS
RATES OF TUMOUR-INVOLVED RESECTION MARGINS IN BREAST-
CONSERVING SURGERY ARE HIGH (> 20%)
 
Secondary goal of breast-conserving surgery
If the oncological aims can be achieved and adequate clear margins obtained, a secondary goal 
of BCS is to achieve a satisfactory cosmetic outcome with the breast. The cosmetic outcome 
following surgery is a factor crucial to body image, patient satisfaction and the quality of life 
of breast cancer patients.59-61 However, cosmetic results following breast-conserving therapy 
vary widely and studies from a wide range of countries have reported cosmetic failure rates 
of up to 40%, with satisfactory cosmetic outcomes in only 60-80% of patients.36,38,39,62 
Proefschrift_Nicole_v17.indd   12 04-12-12   15:25
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The most appropriate moment to assess cosmetic outcome is at least 2 years 
postoperatively, due to the long-term effects of radiation.36,60,64 Frequently used subjective 
evaluation methods include patient self-evaluation and panel evaluation. Patient self-
evaluation is valuable because the experience of the patient is central to assessment of 
quality of life, but patients tend to report consistently better scores than professionals. 
Panel-evaluation, in which a panel consisting of six professionals and non-professionals 
evaluates 4-point view pictures of the breasts, is a very reliable alternative.39,61 A frequently 
used and well-validated objective method to evaluate breast asymmetry is Breast 
Retraction Assessment (BRA), but it is only moderately correlated for tumours located 
in the lower quadrant and skin changes are not taken into account.63,64 In general, a 
combination of cosmetic assessment methods will produce the most reliable results. 
THE SECONDARY GOAL OF BREAST-CONSERVING SURGERY IS TO 
ACHIEVE A SATISFACTORY COSMETIC OUTCOME WITH THE BREAST 
THE COSMETIC OUTCOME OF THE BREAST FOLLOWING SURGERY IS 
CORRELATED STRONGLY TO PATIENT WELL-BEING AND QUALITY OF 
LIFE 
COSMETIC FAILURE RATES FOLLOWING BREAST-CONSERVING 
SURGERY ARE HIGH (UP TO 40%)
The factors determining cosmetic results following breast-conserving therapy are well-
known and include the site of the tumour in the breast, the type of incision, the volume 
of resected breast tissue, postoperative complications such as wound infection, the 
type of axillary surgery and the amount of radiotherapy administered. Overall, the key 
determinant of a poor cosmetic outcome is removal of a large volume of healthy breast 
tissue.31,33,36-41 Regardless of the size of the breast, excision volumes exceeding 85 cm3 
result in a significantly higher rate of cosmetic failures.31,33,36,37 Surgeons should therefore 
completely excise the tumour, while sacrificing as little healthy breast tissue as possible.
A common pitfall is that in an effort to avoid inadequate resection margins and 
subsequent re-excision, an unnecessarily wide resection of healthy breast tissue is carried 
out. It should be noted that there is no need to excise a tumour with a large volume of 
adjacent breast tissue. The size of the tumour-free resection margin (>1mm) and local 
recurrence or overall survival are unrelated, and higher risks of local recurrence have 
been shown only with evident involvement of tumour on the inked resection margins. 
As a practical and reasonable guideline for surgery is to obtain a safe and cosmetically 
acceptable resection margin of 5-10 mm.32,34,65 
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THE KEY DETERMINANT OF A POOR COSMETIC OUTCOME IS THE 
VOLUME OF RESECTED BREAST TISSUE 
AVOIDING INADEQUATE RESECTION MARGINS AND SUBSEQUENT 
RE-EXCISION MAY RESULT IN UNNECESSARILY WIDE RESECTION OF 
HEALTHY BREAST TISSUE
A SAFE AND COSMETICALLY ACCEPTABLE MARGIN OF 5-10 MM 
HEALTHY BREAST TISSUE SHOULD BE OBTAINED 
The Calculated Resection Ratio
A calculated resection ratio (CRR) has been introduced to allow calculation of excess 
healthy tissue resection, whereby the specimen volume is compared to the ‘optimal 
specimen volume’ using two separate parameters, (i) the tumour diameter and (ii) the 
excision volume. As previously stated, in an ideal situation only the tumour plus a 5-10 
mm resection margin will be resected. The optimal resection volume can be calculated 
as the spherical volume of the tumour itself, with an added 1.0 cm margin of healthy 
breast tissue. The mathematical formula applied for calculating the optimal resection 
volume is therefore 4/3 π (1/2 diameter + 0.5 (or 1.0) cm)3. The CRR is calculated for each 
tumour excision by dividing the specimen volume (measured by volume replacement 
in the operating theatre) by its optimal specimen volume.14,18,24This CRR indicates the 
excess of tissue resection. In a perfect excision, the specimen volume is smaller than, 
or equal to the optimal resection volume and the CRR is £ 1.0. A CRR of 2.0 implies that 
the specimen volume is twice the size of the optimal specimen volume, i.e. twice as 
large as it should be.
 Optimal resection volume (ORV)             Total resection volume (TRV)
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THE CALCULATED RESECTION RATIO ALLOWS EXCESS HEALTHY 
BREAST TISSUE RESECTION TO BE DETERMINED
THE CALCULATED RESECTION RATIO = TOTAL RESECTION VOLUME / 
OPTIMAL RESECTION VOLUME
IF THE CALCULATED RESECTION RATIO IS £ 1.0, AN OPTIMAL VOLUME 
RESECTION VOLUME HAS BEEN ACHIEVED
A CALCULATED RESECTION RATIO > 1.0 IMPLIES RESECTION OF EXCESS 
OF HEALTHY BREAST TISSUE
Surgical accuracy of breast-conserving surgery
As stated above, achieving both complete tumour excision and optimal volume resection 
can be challenging for the surgeon The surgeon must localise areas of tumour extension 
into surrounding tissue and precisely identify the required margin during the operation, 
in order to remove as little healthy tissue as possible. Of all breast cancers, approximately 
75% are palpable and 25% are nonpalpable. Standard practice entails the surgeon 
removing a palpable breast cancer with guidance by intra-operative palpation. The 
adequacy of cancer removal during palpation-guided surgery (PGS) is based on a surgeon’s 
recall of the pre-operative imaging (mammography, ultrasound, and sometimes MRI) 
as well as on experience and tactile abilities. However, palpation of the tumour mass 
during this ‘blind’ procedure can be problematic, and this is illustrated by the two major 
drawbacks of this type of surgery: the high rate of margin positivity, and the excessively 
large resection volumes due to attempts to achieve tumour-free resection margins.12,33,38,58,71 
Although it can be safely concluded that PGS is highly inaccurate, despite these major 
shortcomings, palpable breast cancer excision is still largely guided by palpation only, 
without the assistance of intra-operative localisation tools.
For nonpalpable breast cancer, several techniques are available for intra-operative 
guidance during the excision. Wire-localisation is considered the “gold standard”. This 
procedure depends on the pre-operative insertion of a guide wire in the proximity the 
tumour, enabling intra-operative tumour localisation and excision. Following tumour 
resection, the specimen is then sent to the radiology department for radiography, which 
will check the completeness of the excision. Wire-localisation is associated with a number 
of disadvantages however. Firstly, the procedure is technically demanding, depending on 
both the wire placement by the radiologist and on the experience and three-dimensional 
orientation abilities of the surgeon who still has to estimate the precise location of 
the wire tip. Secondly, the insertion of the wire can be uncomfortable for the patient, 
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and carries a risk of wire transaction, dislocation, or migration. Finally and most 
importantly, wire-localisation is inaccurate, resulting in a considerably high rate of 
tumour-positive resection margins with large resection volumes.48,53,72 The limitations 
of wire-localisation have prompted the development and implementation of alternative 
approaches, including the extensively studied ultrasound-guided surgery (USS) method. 
48,49,53-57,72 USS has proven to be an easily available and practical method, and results in 
a highly accurate tumour-excision when compared to wire-localisation. Despite this, 
many surgeons still use wire-localisation as the standard localisation procedure during 
nonpalpable breast cancer excision. 
SURGICAL ACCURACY IN BREAST-CONSERVING SURGERY IMPLIES 
COMPLETE TUMOUR EXCISION AND OPTIMAL VOLUME RESECTION
DESPITE THE INACCURACY OF PALPATION-GUIDED SURGERY, THIS 
SURGICAL METHOD IS STILL THE WORLDWIDE STANDARD FOR 
PALPABLE BREAST CANCER EXCISION
ALTHOUGH WIRE-GUIDED SURGERY IS HIGHLY INACCURATE, THIS 
SURGICAL METHOD IS STILL THE WORLDWIDE STANDARD FOR 
NONPALPABLE BREAST CANCER EXCISION
 
Intra-operative ultrasound to improve surgical accuracy
Ultrasonography (US) refers to sound of any frequency greater than 20 kilohertz, which 
is above the frequency at which humans can normally hear. All sound, including 
ultrasound, travels through different tissues at different rates of speed. The point at 
which adjacent tissues with different sound speeds meet is referred to as an acoustic 
interface. When sound hits an acoustic interface, an echo is created. Medical US is 
essentially a means of producing visual images based on echoes that occur at such 
acoustic interfaces. Crystals within the US transducer are capable of generating and 
receiving sound waves based on mechanical energy that is converted into electrical 
energy. The electrical energy can be imaged in the US monitor. The resolution of US 
images has been greatly improved by computer-enhancement capabilities and the 
availability of high-frequency transducers. Although US at higher frequencies penetrates 
less deeply, it provides images of greater resolution.73
US machines have become more portable in recent years, resulting in the availability 
of US in the operating theatre and allowing the emergence of US as an attractive 
guidance tool during surgery. Intra-operative US has a number of advantages, including 
safety, speed, high accuracy, extensive imaging information and wide applicability. 
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The technique is frequently used during operative procedures for guidance or assistance, 
and due to its safety and ease of use, intra-operative US can be performed at any time 
during the course of an operation and can be repeated as often as necessary. Precise 
three-dimensional information on the size and shape of target lesions can be obtained 
by imaging the organ or the lesion with multiple views from various directions, and 
results are obtained immediately due to the real-time aspect of US imaging. Furthermore, 
intra-operative US can be easily applied directly following surgical procedures, to ensure 
procedural success before closure. Having reached a certain skill-level, surgeons can 
perform intra-operative US reliably within a short period of time.74 
Intra-operative US was first introduced in 1988 as a method of excising a breast carcinoma 
under direct vision.42 During breast cancer excision, real time US guidance is used 
to direct the surgeon during tumour excision and the US is repeatedly applied from 
different angles, in or around the wound, while continuously monitoring the lesion and 
ensuring the maintenance of adequate resection margins. This approach obviates the 
need for additional unpleasant interventions before surgery, and avoids difficulties with 
logistic organisation. Immediately following removal, the specimen can be examined 
with US ex vivo, and complete excision of the breast tumour determined. A 14-MHz US 
probe is used for intra-operative breast US and even small lesions such as 2-mm cysts 
or 3-mm tumours can be detected with such high frequency.  A linear array T-shaped 
probe is used that is small enough to be manipulated in a narrow operative field and 
connected to an US system. The probe should be covered with a sterile glove and plastic 
sheath filled with sterile acoustic gel.73-76
US is widely available and is a reliable localisation method, since most invasive breast lesions 
are visible as well-defined, solid, hypo-echoic masses. Earlier studies clearly showed the 
efficacy of USS for nonpalpable tumours with respect to tumour-free resection margins and 
the smaller volume of healthy breast tissue resection, compared with wire-guided surgery. 
A possible complicating factor, however, is that this technique may require the presence of 
an expert in US imaging to be present in the operating theatre.42-54 
US is generally performed in the hospital setting by a radiologist, but the need for intra-
operative evaluation of breast cancer means that surgeons must perform and master US-
guided breast procedures, particularly in settings where dedicated radiologists are not readily 
available at all times. Most surgeons have little experience with US, and a major obstacle 
to the use of US among surgeons is difficulty with learning the technique. Despite this, it 
has been shown that with appropriate instruction and experience, breast surgeons are able 
to familiarise themselves with the US technique and can attain a level of competency that 
enables them to independently perform US-guided BCS.44,48,49,77-79 
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In general, all palpable breast masses are visible to US.47 Although the efficacy of USS for 
nonpalpable tumours has been clearly demonstrated, thus far only one prospective study, 
by Moore et al., has evaluated USS for palpable invasive ductal breast cancer. In this study, a 
group of 27 patients received USS and a second group of 24 patients received surgery without 
the use of imaging techniques. The rate of margin positivity was significantly lower in the USS 
group (3% vs. 29% [p<0.05]), while excision volumes were also somewhat smaller (104 cc and 
114 cc, respectively).80 Surprisingly, the results of this trial have not become widely known, 
and PGS has remained the worldwide standard for the excision of palpable breast cancer.
ULTRASOUND-GUIDED SURGERY HAS BEEN PROVEN TO BE HIGHLY 
ACCURATE FOR NONPALPABLE BREAST CANCER EXCISION
WITH APPROPRIATE INSTRUCTION AND EXPERIENCE, BREAST 
SURGEONS ARE ABLE TO PERFORM ULTRASOUND-GUIDED BREAST-
CONSERVING SURGERY INDEPENDENTLY
ALTHOUGH PALPABLE BREAST TUMOURS ARE V ISIBLE TO 
ULTRASONOGRAPHY, ULTRASOUND-GUIDED SURGERY HAS NOT BEEN 
APPLIED TO PALPABLE BREAST CANCER EXCISION
Oncoplastic breast surgery
Although the majority of breast tumours can be successfully treated by standard BCS, 
some lesions may be difficult to excise without the risk of cosmetic deformity, even when 
a highly accurate tumour-excision can be achieved (for example, in patients with large 
breast tumours in relation to breast size). In these cases, special approaches to resection 
can be considered. These new surgical approaches, referred to as ‘oncoplastic breast 
surgery’, involve surgery based on oncological principles during which the techniques of 
plastic surgery are used, mostly for reconstructive and cosmetic reasons.66-68 Oncoplastic 
breast surgery is a broad term that can be applied to several different combinations of 
oncological and plastic techniques; the term may refer to technically simple volume-
displacement operations, to excision of the tumour by reduction mammoplasty, or to 
various techniques of volume replacement using local or distant flap reconstructions. 
The use of oncoplastic breast surgery may improve the final cosmetic result, while 
permitting the surgeon to remove the tumour with a greater volume of surrounding 
normal breast tissue. This may thereby increase the chance of microscopic clearance with 
tumour-free margins, and may also improve local control rates. Possible disadvantages of 
oncoplastic surgery may be difficulties in identifying the post-operative radiation field 
and the widening of the radiation field due to a larger wound bed, with a deterioration 
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of cosmetic outcome as a consequence. Another disadvantage is that sites of tumour-
positivity may be hard to identify in a reconstructed breast, and, in specific cases, it may 
be difficult to avoid a subsequent mastectomy.
The implementation of oncoplastic surgery has proceeded rapidly and is now widely 
practiced in renowned breast units. Although several studies have been published 
evaluating the use of oncoplastic surgery, the quality of these studies has been sub-
optimal, with indications for use of oncoplastic techniques (i.e. use of an algorithm) and 
the long-term oncological and cosmetic outcomes remaining unclear.68-70 Furthermore, 
although oncoplastic breast surgery shows promise, a higher surgical accuracy with 
standard BCS may dramatically improve both oncological and cosmetic outcomes as well.
ONCOPLASTIC BREAST SURGERY INVOLVES SURGERY BASED ON 
ONCOLOGICAL PRINCIPLES DURING WHICH THE TECHNIQUES OF 
PLASTIC SURGERY ARE USED, MOSTLY FOR RECONSTRCUCTIVE AND 
COSMETIC REASONS 
THE INDICATIONS FOR USE OF ONCOPLASTIC TECHNIQUES AND THE 
LONG-TERM ONCOLOGICAL AND COSMETIC OUTCOMES REMAIN 
UNCLEAR
ALTHOUGH ONCOPLASTIC BREAST SURGERY SHOWS PROMISE, A 
HIGHER SURGICAL ACCURACY WITH STANDARD BREAST-CONSERVING 
SURGERY MAY IMPROVE BOTH ONCOLOGICAL AND COSMETIC 
OUTCOMES AS WELL
 
OUTLINE OF THE THESIS
This thesis examines the hypothesis that an unnecessarily large resection of adjacent 
healthy breast tissue along with the breast tumour is a consequence of the importance 
of and attempts at achieving optimal oncological control in daily practice. In Chapter 2, 
the association between excess volume resection and breast-conserving surgery (BCS) 
for palpable and nonpalpable breast cancer is examined. 
Several methods for intra-operative tumour localisation are currently in use. In Chapter 
3, the three most commonly used BCS methods for nonpalpable invasive breast cancer are 
evaluated for efficacy in obtaining adequate resection margins and resection volumes. 
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Previous studies have reported that a physical deformation of the breast specimen occurs 
in the period between the surgical procedure and the pathological examination, or 
following the use of chemical fixation. This ‘shrinkage’ phenomenon may interfere with 
the accuracy of the final margin assessment. In Chapter 4, all changes in specimens in 
the period from excision to pathological evaluation are recorded, taking special note of 
the influence of formalin fixation.
Intra-operative guidance with ultrasonography (US) may improve the ability to spare 
healthy breast tissue, while maintaining or even improving the oncological margin 
status for palpable breast cancer excision. In Chapter 5, this hypothesis is described in 
a randomised controlled trial protocol. 
Most surgeons have little experience with intra-operative US. In Chapter 6, the 
performance of surgeons during training in US-guided excision of palpable breast cancer 
is evaluated. 
In Chapter 7, the efficacy of USS is compared with standard PGS for palpable breast 
cancer in a multicentre, randomised controlled clinical trial. This trial evaluated the 
effectiveness of USS in improvig the rate of tumour-free resection margins while sparing 
healthy breast tissue.
A major obstacle to the use of USS is the additional expenditure needed, particularly the 
costs of purchasing a high-end US system and the cost of the extra operative time required 
for USS. On the other hand, an improved margin clearance may save the expenses of 
subsequent treatment due to tumour-involved margins. In Chapter 8, a cost-benefit 
analysis was performed alongside our randomised trial, weighing the additional costs 
of USS compared to PGS against the benefits of USS in terms of reductions in costs of 
re-treatments.
In Chapter 9, the various oncoplastic techniques with their advantages, limitations and 
indications are summarised, and the oncological and cosmetic outcomes of the various 
oncoplastic procedures are systematically reviewed and evaluated. 
Chapter 10 provides a summary of this thesis and considers future perspectives.
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Excessive resections in  
breast-conserving surgery
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ABSTRACT
Background The main determinant of cosmetic outcomes following breast-
conserving surgery (BCS) for breast cancer is the volume of resection. 
The importance of achieving optimal oncological control may lead to an 
unnecessarily large resection of breast tissue. The aim of this study is to evaluate 
excess resection volume in BCS for cancer by determining a calculated resection 
ratio (CRR).
Materials and methods This retrospective study was conducted in four affiliated 
institutions and involved 726 consecutive patients with T1-T2 invasive breast 
cancer treated by BCS between January 2006-2009. The pathology reports were 
reviewed for tumour palpability, tumour size, surgical specimen size and 
oncological margin status. The optimal resection volume (ORV) was defined as 
the spherical tumour volume with an added 1.0 cm margin of healthy breast 
tissue. The total resection volume (TRV) was defined as the ellipsoid volume of 
the surgical specimen. CRR was determined by dividing the TRV by the ORV.
Results Of all tumours, 72% (525/726) were palpable, and 28% (201/726) were 
nonpalpable. The tumour stage was T1 in 492 patients (67.8%) and T2 in 234 
patients (32.2%). The median CRR was 2.5 (0.01 – 42.93). Margin status was 
positive or focally positive in 153 patients (21.1%). Lower tumour stage was 
associated with a higher CRR (factor 0,61 (P<0,0001) and a lower positive margin 
rate ((P = 0.064). Accordingly, the median CRR of the nonpalpable lesions was 
higher than that of the palpable lesions (3.1 and 2.2, respectively; P<0.01), and 
the involved margin rate was lower (17.4% and 22.5%, respectively; P=0.13). Of 
patients with a CRR > 4.0, 10.7% still had tumour involved margins.  
Conclusions This study clearly shows that BCS is associated with excessive 
resection of healthy breast tissue while clear margins are not assured. Surgical 
factors should be modified to improve surgical accuracy.
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INTRODUCTION
Breast-conserving surgery (BCS) with adjuvant radiotherapy is the treatment of choice for 
women with early-stage breast cancer. The introduction of widespread mammographic 
screening, better imaging techniques, improved patient awareness and breast self-
examination have all contributed to an increase in early diagnoses (1,2). Accordingly, 
the number of BCS procedures has increased, and the five-year disease-free survival rate 
for node-negative breast cancer is excellent (3-5).
The main advantage of BCS over a mastectomy is preservation of the breast with improved 
cosmetic outcomes. A good cosmetic outcome leads to less anxiety and depression and 
a higher self-esteem (6-9). However, large studies scoring cosmesis by panel evaluation 
or digitizer measurements consistently show that the cosmetic results following BCS 
are disappointing in up to 40% of patients. Cosmetic failures are defined as pronounced 
breast asymmetry and skin alterations such as retraction of the scar. Factors determining 
these cosmetic outcomes include the site of the tumour in the breast, the volume of 
the resected breast tissue, postoperative wound complications and the amount of 
radiotherapy, including the radiotherapy boost (10-17). Overall, the key determinant of 
cosmetic outcome is the total volume of breast tissue resection. A number of studies 
found that if the size of the lump exceeds 50 to 85 cm3, the rate of cosmetic failure is 
significantly higher, regardless of the size of the breast (11,13,15,17).
Theoretically, the optimal size of the lump is determined by the volume of the tumour 
plus an added 1.0 cm margin of tumour-free breast tissue (18,19). In this situation, 
locoregional disease control is obtained without jeopardising cosmetic outcomes 
through a large resection. However, achieving both goals in the same operation may be 
a considerable challenge. The primary aim of BCS is to prevent tumour-positive resection 
margins because they are associated with an increased risk of locoregional recurrence 
and require a subsequent re-excision (18-22). Preserving a cosmetically acceptable breast 
is probably only a secondary aim. It is hypothesised that in daily practice, the importance 
of and attempts at achieving optimal oncological control lead to an unnecessarily large 
resection of adjacent healthy breast tissue along with the tumour.
The aim of this study was to assess excess breast tissue resection in BCS by determining 
the calculated resection ratio (CRR), which is the total resection volume (TRV) divided 
by the optimal resection volume (ORV). The TRVs were calculated based on pathology 
reports. The ORVs were calculated based on the tumour sizes with an added 1.0 cm 
margin of healthy breast tissue.
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MATER IALS AND METHODS
In this retrospective study, all consecutive patients undergoing BCS at the VU Medical 
Centre (Amsterdam, the Netherlands) and three affiliated hospitals over a three-year 
period (January 2006 - 2009) were identified. The pathology reports were reviewed for 
patients with invasive breast carcinomas identified in a surgical specimen. Patients with 
pre-operatively diagnosed multifocal disease, a history of previous surgical treatment 
or radiation therapy of the affected breast or of neo-adjuvant therapy were excluded 
from the study. 
Tumour palpability was reported for all included patients. For palpable breast cancer, 
tumour resection is guided by palpation. The resection of a nonpalpable breast cancer 
is performed using intra-operative guidance by wire localisation, ultrasonography or 
radio-guided occult lesion localisation (ROLL). 
The three dimensions (in cm) of the surgical specimens were registered. If re-excision 
was performed during the initial surgery, the dimensions of the re-excised specimen 
were added to the original specimen. The tumour stage (T1a-T2) and the diameters of 
the tumours (mm) as given in the final conclusion were reported. 
The following tumour histopathologic subtypes were identified and categorised according 
to the World Health Organisation (WHO) classification: invasive ductal carcinoma, 
invasive lobular carcinoma and other types of carcinoma. The presence and amount 
of additional DCIS was calculated and categorised. The oncological margin status was 
defined as negative, focally positive or positive according to the WHO classification of 
breast tumours and the Dutch national guidelines. The presence of additional DCIS at the 
margin was not considered in the calculation of focally positive or positive margin rates. 
If no residual cancer cells were found within 1 mm of the inked margin, the margin was 
considered negative. For negative margins, the distance to the nearest margin (mm) was 
noted. Margins were considered focally positive when cancer cells invaded the resection 
margin in a maximum of two microscopic slides or when cancer cells were situated 
within 1 mm of the inked margin. Margins were considered positive when cancer cells 
were microscopically present at the inked resection margin.
Calculation of volumes and the resection ratio
Two separate parameters, the tumour diameter and the three dimensions of the surgical 
specimen, were used to calculate the tumour volumes, the ORVs and the TRVs. The 
tumour was defined as sphere and the tumour volume was calculated using the diameter 
of the tumour (in cm) as mentioned in the pathology report. Thus, the formula applied 
mathematically for calculating the tumour volume was 4/3 π r 3. An ORV was calculated 
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for each tumour. The ORV was defined as the spherical volume of the tumour itself with 
an added 1.0 cm margin of healthy breast tissue. (Figure 1.a., see Appendices). Margins of 
1.0 cm were chosen in this study as they are both technically feasible and cosmetically 
acceptable. The mathematical formula applied for calculating the ORV was 4/3 π (r + 
1.0 cm)3. The TRV represents the volume of the surgical specimen and was defined as an 
ellipsoid. It was calculated using the three dimensions of the surgical specimen (cm), 
as measured by the pathologist. The mathematical formula applied to calculate the 
TRV was 4/3 π a ·b ·c , with a, b, and c representing half of each of the three dimensions 
of the surgical specimen. If re-excision was performed during the initial surgery, the 
re-excision volumes were calculated as well, and the TRV was calculated as the sum of 
the resection volumes.
The TRVs were compared to the ORVs to determine the excess breast tissue resection. 
This excess was defined by a ratio (CRR) and calculated by dividing the TRV by the ORV 
(CRR = TRV / ORV). In a perfect excision, the TRV is equal to the ORV, and the CRR is 1.0. If 
the TRV is twice the size of the ORV, the CRR is 2.0. In addition, the ORV was subtracted 
from the TRV. The remaining volume represented the absolute volume that was excised 
in excess (Excess tissue resection = TRV – ORV). 
Statistical analyses
The data were analysed using the Statistical Package for the Social Sciences (SPSS 
statistical software, Version 15.0; SPSS, Inc., Chicago, IL, USA). The mean was used when 
there were symmetrical distributions of the outcomes. However, the median was used 
when the distribution was skewed. Groups were tested for homogeneity of variance 
using Levene’s test. Groups were compared using Student’s t-test, Wilcoxon’s rank sum 
test, Chi2 or exact test where appropriate. The relationship between tumour diameter, 
tumour volume and CRR was studied by regression models. Results are presented with 
the corresponding P value. All reported P-values are two-sided and the error of probability 
for significance was set at 5% (P<0.05). 
R ESULTS
In total, 744 women who were treated with BCS for invasive T1-2N0-1 breast carcinoma 
were identified. Eighteen patients (2.4%) were excluded because of incomplete surgical 
specimen data. 
Of all of the patients, 525 (72.3%) presented with a palpable tumour. The tumour was 
nonpalpable in 201 patients (27.7%). Of all of the tumours, 646 (89.0%) were diagnosed as 
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invasive ductal carcinoma, 57 (7.9%) were invasive lobular carcinoma and 23 (3.2%) presented 
as another type of carcinoma. Seventeen tumours (2.3%) were staged T1a, 132 (18.2%) were 
T1b, 343 (47.1%) were T1c and 234 (32.2%) were T2. The mean tumour diameter was 17 mm 
(range 1.3–48 mm), and the median tumour volume was 1.77 cm3 (range 0.01–57.91 cm3).  
The median ORV calculated for all included tumours with a 1.0 cm margin of resection was 
22.45 cm3 (range 5.06 – 164.64 cm3). The median TRV based on the three dimensions of the 
surgical specimens was 62.83 cm3 (range 0.20–524.12 cm3). The CRR, as calculated by dividing 
the TRV by the ORV, ranged from 0.01 to 42.9 with a median of 2.5. The median excess tissue 
resection was 33.71 cm3 (range -87.24-508.52 cm3). There were negative margins in 573 tumours 
(78.9%), focally positive margins in 96 (13.2%) and positive margins in 57 (7.9%). The presence 
and categorised amount of additional DCIS is stated in Table 1. Of all patients, 8.7% had an 
extensive component of DCIS along with the invasive carcinoma. In 58.5% (374/573) of the 
negative resections, the distance to the nearest margin was < 0.50 cm (mean 0.17 cm), whereas 
the CRR was > 1.0 (median 3.4; range 0.01-42.9). In these cases, it can be concluded that the 
tumour was located eccentrically in the surgical specimen (Figure 1.b., see Appendices).
Table 1.  Presence of additional DCIS along with the invasive carcinoma
DCIS N (%)
No 394 (54.3%)
Minor 269 (37.0%)
Major 63 (8.7%)
Total 726 (100%)
Minor DCIS = the presence of DCIS in the invasive tumour or within several mm’s surrounding the invasive tumour. 
Major DCIS = a more extensive DCIS component surrounding the invasive tumour.
The median tumour volumes, ORVs, TRVs and CRRs as well as the margin status for 
each of the tumour stages are depicted in Table 2. A more advanced tumour stage was 
associated with an increase of TRV (TRV1/3 = 3.454 + 0.372*diameter, P< 0.0001)). However, 
more advanced tumour stage also resulted in a lower CRR (1 cm increase of tumour 
diameter resulted on the average in a change of CRR by a factor 0.61 (P<0.0001) (Figure 2). 
Further analysis showed that an increase of tumour stage was associated with higher 
rates of positive and focally positive margins (P = 0.064). By contrast, lower tumour stages 
were associated with higher CRR, i.e., small tumours had relatively more excess tissue 
resection compared to large tumours (Figure I.b.). However, smaller tumours presented
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Figure 2. The median ORV, TRV, and CRR for increasing tumour-stages.  
The ORVs (cm3) were calculated by adding a chosen 1.0 cm tumour-free margin to the tumour volumes; the 
TRVs (cm3) were calculated from the three dimensions of the surgical specimen as given in the pathology 
report; the CRR represents the TRV divided by the ORV (CRR= TRV/ORV). 
Table 2. Tumour volumes, ORVs, TRVs, CRRs and margin status for T1a, T1b, T1c 
and T2 stage tumours. 
Tumour stage T1an=17 (2.3%)
T1b
n=132 (18.2%)
T1c
n=343 (47.3%)
T2
n=234 (32.2%)
Tumour volume Median (cm
3) 
(range)
0.014
(0.01-0.06)
0.27 
(0.07–0.38)
1.77 
(0.52-3.59)
7.24 
(4.19-57.91)
ORV Median (cm
3) 
(range)
6.37
(5.06-7.99)
11.49
(8.18-12.77)
21.95
(14.14-31.06)
44.60
(33.51-164.64)
TRV Median (cm
3) 
(range)
40.84
(15.71-159.17)
46.46
(1.26-395.11)
57.73
(4.58-524.12)
78.54
(0.20-523.60)
CRR TRV / ORV (Median) (range) 6.8 (2.2-30.6) 4.0 (0.2-42.9) 2.7 (0.3-33.6) 1.6 (0.01-11.0)
Margin status Negative 15 (88.2%) 111 (84.1%) 272 (79.3%) 175 (74.8%)
Focally positive 2 (11.8%) 12 (9.1%) 51 (14.9%) 31 (13.2%)
Positive 0 (0.0%) 9 (6.8%) 20 (5.8%) 28 (12.0%)
n = number of patients. The volumes of the tumours (cm3) as calculated from the diameters given in the 
pathology report; the ORVs (cm3) as calculated by adding a chosen 1.0 cm tumour-free margin to the 
tumour volumes; the TRVs (cm3) as calculated from the three dimensions of the surgical specimen given in 
the pathology report; the CRRs as calculated by dividing the TRVs by the ORVs; “negative” margin status 
represents clear margins, “focally positive” represents focally involved margins and “positive” represents 
involved margins.
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with lower rates of positive and focally positive margins. Table 3 shows that a smaller 
CRR was associated with a higher positive margin rate (P<0.0001). Interestingly, 10.7% of 
patients still had positive or focally positive margins when the CRR was > 4.0. 
A comparison of the palpable and the nonpalpable tumours revealed that the median 
nonpalpable tumour volume was 0.90 cm3 and the median palpable tumour volume 
was 2.57 cm3 (P<0.01). Accordingly, the median CRR for the nonpalpable lesions was 
higher than that of the palpable lesions (3.1 and 2.2, respectively; P<0.01), whereas the 
rate of focally positive and positive margins was lower (17.4% and 22.5%, respectively; P 
= 0.13). With regard to histopathological tumour subtypes, the ductal and the lobular 
carcinomas both showed a median CRR of 2.5. The rate of focally positive and positive 
resection margins was higher for the lobular carcinomas than the ductal carcinomas 
(40.4% and 19.5%, respectively; P<0.01).
Regarding the volume of resected breast tissue, earlier studies showed that excision 
volumes exceeding 50 to 85 cm3 may result in pronounced disfiguration of the breast. 
In our series, 244 patients (33.6%) presented with TRVs exceeding 85 cm3. In 134 (54.9%) 
of these patients, the tumour stage was T1 and a maximum resection volume of 33.51 
cm3 would have been sufficient (this is the ORV for a tumour size of 2 cm and an added 
1 cm margin of healthy breast tissue). In 241 (98.8%) of these patients, the CRR was > 1.0 
(median 4.7, range 0.5-42.9), implying that excess tissue was resected. It can therefore 
be concluded that in 33.2% (241/726) of our patients, excessive tissue resection resulted 
in impairment of the cosmetic outcome.
Table 3. Influence of the CRR on margin status.
Total 
n=726
CRR 0.0-1.0 
88 (12.1%)
CRR 1.0- 2.0 
197 (27.1%)
CRR 2.0- 3.0
148 (20.4%)
CRR 3.0-4.0
87 (12.0%)
CRR > 4.0
n=206 (28.4%)
Margin 
status
Negative 52 (59.1%) 150 (76.1%) 117(79.1%) 70 (80.5%) 184 (89.3%)
Focally 
positive
19 (21.6%) 30 (15.2%) 21 (14.2%) 10 (11.5%) 16 (7.8%)
Positive 17 (19.3%) 17 (8.6%) 10 (6.8%) 7 (8.0%) 6 (2.9%)
The CRR represents the TRV divided by the ORV. A margin status defined as “negative” represents clear margins, 
“focally positive” represents focally involved margins and “positive” represents involved margins.
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DISCUSSION
This study on BCS clearly shows that in many cases, an unnecessarily large volume of 
healthy breast tissue is excised along with the tumour, while clear margins are not 
assured. The resection volumes were two and a half times greater than the optimal 
excision volumes, even with the reasonably large margin of 1.0 cm of healthy breast 
tissue chosen to define the optimal volumes. Especially for the small and the nonpalpable 
tumours, the excisions were relatively large. 
With regard to the absolute resection volumes, it is striking that in over a third of our 
patients, more than 85 cm3 was excised. In these patients, the cosmetic outcome will 
definitely be impaired as shown in earlier studies (11,13,15,17). In almost all of these 
patients, excess tissue was excised; over half of these patients presented a tumour size 
of less than 2 cm, and a 33.51 cm3 volume resection would have been sufficient. This 
excessive resection leads to a tremendous distortion of the breast parenchyma and 
necessitates larger boost fields, which also reduces the cosmetic outcome. Cosmetic 
outcomes were not studied in our retrospective study, but it would be interesting to 
assess the effects of this excessive resection on cosmesis.
A remarkable finding is that despite the large amount of normal breast tissue resection, 
the tumour was often located eccentrically in the surgical specimen, and the margins 
were positive or focally positive for invasive carcinoma (DCIS not even taken into account) 
in over 20% of patients. Even in the excessively large resections corresponding to four 
times the optimal excision volume 10.7% of the margins were still found to be positive 
or focally positive. In addition to the cosmetic result, the oncological margin status is a 
very important outcome for the patient. Positive margins may result in a second resection 
or a mastectomy with the goal of obtaining clear pathologic margins, as focally positive 
margins require an additional radiation boost on the tumour bed. Both options lead to 
psychological stress for the patient as well as impairment of the cosmesis.
It was expected that the palpable tumours would be more easily excised than the 
nonpalpable tumours. However, the rate of positive margins was higher for the palpable 
tumours. This finding may be explained by the fact that the palpable tumours presented 
with larger tumour volumes, which were shown to result in a higher rate of involved 
margins. The association of the lobular carcinomas with a higher percentage of positive 
margins compared to the ductal carcinomas substantiates the results of previous reports 
(23,24).
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Resection margins of 1.0cm were chosen in this study to calculate the optimal excision 
volumes. Local recurrence and overall survival are unrelated to a tumour-free resection 
margin above 1mm (18,19,25,26). However, it seems reasonable to pursue a technically 
more feasible 1.0cm margin around the lesion with the expectation that the final 
microscopic margin will be tumour-free by at least 1mm. The formula for the prediction 
of these optimal excision volumes was based on the assumption that tumours are 
spherical, whereas in actuality they may vary in shape. The formula for the prediction 
of the specimen volumes was based on the assumption that the excision volume is 
ellipsoid. In fact, specimens might actually be cylindrical, spherical, cuboid or ovoid. 
These assumptions were made for simplicity as they allowed easy calculation from the 
measurements of the pathology reports, in a retrospective manner. However, the earlier 
described 40 to 50% flattening of breast specimens after surgical removal (the “pancake 
phenomenon”) was not taken into account (27). A limitation in the calculations might 
be that they do not deal with associated DCIS while the DCIS component may very well 
be an important factor for planning excisions. Of all specimens, 339 (46.7%) presented 
with additional DCIS. Sixty-three patients (8.7%) had an extensive component of DCIS. 
Only in these cases, the CRR may realistically / in actuality be lower than reported. 
Therefore, in our opinion, the presence of additional DCIS is only a minor limitation 
in the calculations, and the predicted volumes as well as the proposed methods for 
comparing the TRV to the ORV will nonetheless be grossly adequate for estimating the 
excessive resection of healthy breast tissue.
The findings of this study suggest that a smaller volume of breast tissue can be excised 
without compromising the oncological margin status. To achieve the highest surgical 
accuracy, a more concentric location of the tumour within the surgical specimen should 
be attempted. Improvement of surgical accuracy is, however, not easily accomplished, 
and surgical factors should be modified. In daily practice, the resection of palpable 
breast cancer is guided by palpation. The adequacy of the removal of the cancer is 
based on pre-operative imaging techniques (mammography and ultrasonography) and 
the experience and tactile abilities of the surgeon. If the surgeon has any doubts about 
the adequacy of the excision, either an additional resection is performed, or the margins 
are confirmed by intra-operative frozen-section evaluation. In our series, positive or 
focally positive margins were present at first excision in nearly a quarter of the patients, 
despite the excessive resection of breast tissue around the palpable lesion. Apparently, 
the lack of intra-operative orientation and concerns of inadequate resection margins 
with subsequent re-excision lead to an unnecessarily wide resection, while negative 
margins are not even guaranteed.
Nonpalpable breast cancers are localised during the surgery by various imaging modalities. 
The current standard is the hook-wire localisation technique, but this technique is not 
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without shortcomings. Wire-guided excisions are often inadequate and depend both 
on the accuracy of wire placement by the radiologist and on the experience and three-
dimensional orientation of the surgeon. The wire insertion, performed pre-operatively 
under mammographic or ultrasound guidance, can be an uncomfortable procedure for 
the patient and involves logistic problems in terms of coordinating services. Additionally, 
there is a risk of wire migration between the time of insertion and the beginning of the 
surgery (28,29). More recently the radio-guided occult lesion localisation (ROLL) method 
has been introduced and has gained some popularity in Europe. In this technique, 
radioactive serum albumin particles are injected into the tumour under mammographic 
or ultrasonographic guidance, and a gamma probe is used intraoperatively to locate the 
tumour and guide the excision. ROLL and wire-localisation are similarly effective, but 
ROLL is less painful for the patient and easier for both the radiologist and surgeon (30,31). 
However, failures in the placement of the radioactive tracer have been described, and this 
technique can be complicated by intraductal injections resulting in widespread dispersal 
of the isotope (31,32). An attractive alternative to guide the excision is intraoperative 
ultrasonography. This method is technically feasible, patient comfortable and enables 
the surgeon to excise the nonpalpable tumour under direct vision. Intra-operative 
ultrasonography can show some impalpable lesions that are not visible by mammography 
and can be helpful in assessing the margins after the excision. Many studies have shown 
that of all intra-operative imaging modalities the ultrasonography is the most accurate 
(29,33-39). Rahusen et al. conducted a randomized controlled trial and reported 89% (24/27) 
tumour-free resection margins by ultrasound-guided surgery as compared to 55% (12/22) 
by wire-guided surgery (29). Snider and Morrison obtained 82% (18/22) clear resection 
margins by ultrasound-guided surgery, as well as a smaller resection volume with respect 
to wire-guided surgery (62,2 cm3 and 81,1 cm3, respectively) (39). Only one report, by 
Moore et al. studied the use of intra-operative ultrasonography for palpable breast cancer 
and compared this to no imaging technique. A significant reduction in the incidence of 
margin involvement (3.5% and 29%, respectively) and a smaller mean resection volume 
(104 cm3 and 114 cm3, respectively) were reported (36).
Recently, oncoplastic strategies have been introduced to improve cosmetic outcomes 
after BCS. Oncoplastic techniques permit a wide local resection of the tumour and 
tend to optimise the cosmetic outcomes via breast reshaping, volume displacement or 
contra-lateral surgery. Although oncoplastic surgery receives a large amount of attention, 
large prospective studies are lacking. As a consequence, there are no data on longer 
term follow-up, and it is still unclear which groups might benefit most from these 
strategies. A large drawback is that positive margins after the initial excision often result 
in a subsequent mastectomy. Moreover, oncoplastic surgery is time-consuming, and the 
questions concerning the boost field remain unanswered (40-43).
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Before introducing oncoplastic procedures, the evaluation of strategies for image-guided 
surgery must be studied further. Continuous visualisation of the tumour during the 
surgery for monitoring and guiding of the excision can be helpful in obtaining the 
greatest degree of surgical accuracy. Based on earlier studies and our own experience with 
US-guided surgery for nonpalpable breast cancer, we propose the use of ultrasonography 
for accurate intra-operative assessment of palpable breast tumours as well. A prospective 
randomised controlled clinical trial will be undertaken in our region to assess the 
surgical accuracy of intra-operative ultrasound guidance for palpable tumours and its 
effects on the cosmetic outcomes and patient satisfaction. 
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CHAPTER 3
A comparison of three methods for 
nonpalpable breast cancer excision 
A retrospective multicentre study
N.M.A. Krekel, B.M. Zonderhuis, H.B.A.C. Stockmann, W.H. Schreurs, H. van der Veen, 
E.S.M. de Lange de Klerk, S. Meijer, M.P. van den Tol.
European Journal of Surgical Oncology 2011 Feb;37(2):109-15.
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ABSTRACT
Aims To evaluate the efficacy of three methods of breast-conserving 
surgery (BCS) for nonpalpable breast cancer in obtaining adequate 
resection margins and resection volumes.
Materials and methods A total of 201 consecutive patients undergoing 
BCS for nonpalpable invasive breast cancer between January 2006 and 
2009 in four affiliated institutions were retrospectively analysed. 
Patients with pre-operatively diagnosed primary or associated ductal 
carcinoma in situ (DCIS), multifocal disease, or a history of breast 
surgery or neo-adjuvant treatment were excluded from the study. 
The resections were guided by wire localisation (WL), ultrasound 
(US), or radio-guided occult lesion localisation (ROLL). The pathology 
reports were reviewed to determine oncological margin status, as 
well as tumour and surgical specimen sizes. The optimal resection 
volume (ORV), defined as the spherical tumour volume with an added 
1.0-cm margin, and the total resection volume (TRV), defined as the 
corresponding ellipsoid, were calculated. By dividing the TRV by the 
ORV, a calculated resection ratio (CRR) was determined to indicate the 
excess tissue resection.
Results Of all 201 excisions, 117 (58%) were guided by WL, 52 (26%) by US, and 
32 (16%) by ROLL. The rate of focally positive and positive margins for invasive 
carcinoma was significantly lower in the US group (N = 2 (3.7%)) compared to the 
WL (N = 25 (21.3%)) and ROLL (N = 8 (25%)) groups (p = 0.023). The median CRRs 
were 3.2 (US), 2.8 (WL) and 3.8 (ROLL) (WL versus ROLL, p < 0.05), representing a 
median excess tissue resection of 3.1 times the optimal resection volume.
Conclusion US-guided BCS for nonpalpable invasive breast cancer was more 
accurate than WL- and ROLL-guided surgery because it optimised the surgeon’s 
ability to obtain adequate margins. The excision volumes were large in all 
excision groups, especially in the ROLL group.
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INTRODUCTION
Breast-conserving surgery (BCS) with adjuvant radiotherapy has become the local 
treatment of choice for early-stage breast cancer. In recent years, advances in early 
diagnosis have been achieved by widespread screening mammography, better imaging 
techniques, improved patient awareness and breast self-examination. As a consequence, 
the rate of BCS procedures for early-stage, nonpalpable lesions has increased. [1-3]
For these nonpalpable lesions, intra-operative guidance of the excision is indispensable 
and continues to develop. Wire localisation (WL) is still considered the gold standard 
for intra-operative tumour localisation. The WL procedure is technically demanding 
and depends on both the wire placement by the radiologist and on the experience 
and three-dimensional orientation abilities of the surgeon. The insertion of the 
wire can be uncomfortable for the patient; also, there is a risk of wire transaction, 
dislocation, or migration. [4-6] Intra-operative ultrasonography (US) was introduced in 
1988 as a method of excising a tumour under direct visualisation. There is no need for 
additional interventions before surgery, but a possible restriction is the arrangement 
of a radiologist’s presence in the operating theatre. In contrast to ductal carcinoma in 
situ (DCIS), most invasive lesions are echogenic. In situ lesions are mostly visualised 
by mammographically observable microcalcifications. [5-12] Recently, the radio-guided 
occult lesion localisation (ROLL) technique has emerged. In this procedure, a radioactive 
pharmaceutical is injected into the tumour pre-operatively, and a gamma probe is used 
to guide the surgical resection. Although the ROLL technique seems promising, failures 
in the placement of the radioactive tracer and widespread dispersal of the isotope have 
been described. [13,14]
In daily practice, the main goal of BCS is to achieve tumour-free resection margins and 
thus prevent local recurrence. However, the cosmetic outcome is receiving increasing 
attention because of its strong relation to the patient’s well-being. [15,16] A number of 
studies have shown that the cosmetic outcomes following BCS are unacceptable in up 
to 40% of patients. Resection of a large volume of breast tissue often proves to be the key 
determinant of these poor cosmetic outcomes; specifically, a lump size exceeding 50 to 
85 cm3 results in a significantly higher rate of cosmetic failures. [17-21] 
The aim of this study was to evaluate the efficacy of the three most commonly used 
methods of BCS for nonpalpable invasive breast cancer in obtaining adequate resection 
margins and volumes of resection. The excess breast tissue resection was determined 
using the calculated resection ratio (CRR), representing a comparison of the total 
resection volume (TRV) to the optimal resection volume (ORV).
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PAT IENTS AND METHODS
Patient selection
All consecutive patients undergoing BCS for nonpalpable breast cancer in four affiliated 
hospitals over a three-year period were identified retrospectively (January 2006–January 
2009). The pathology reports were reviewed for patients with invasive breast carcinoma as 
identified in a surgical specimen. Breast cancer had been diagnosed pre-operatively with 
mammography, US, and occasionally MRI, followed by image-guided core needle biopsy 
or cytological puncture. Patients with pre-operatively diagnosed primary or associated 
DCIS, multifocal disease, a history of neo-adjuvant therapy or previous surgical treatment 
or radiation therapy of the affected breast were excluded from the study.
Excision methods
The method of tumour excision was reported for all included patients. The three methods 
that were evaluated were the WL, the US guidance and ROLL techniques. In the WL 
procedure, a guide wire had been placed under mammographic or US guidance before 
surgery, and the tumour had been excised by using the wire for localisation. After 
excision, the specimen had been sent to the radiology department for radiography 
to check the completeness of the excision. In the US-guided excision, repeated intra-
operative imaging with the US probe performed by a radiologist had guided the 
procedure and enabled the surgeon to maintain an appropriate surgical margin 
around the malignant tumour. Immediately after specimen removal, the radiologist 
had checked the completeness of the specimen ex vivo with US. In the ROLL technique, 
99mTc-labelled serum albumin particles had been injected into the tumour prior to the 
surgical procedure under mammographic or US guidance. A gamma probe had been 
used to locate the tumour and guide the excision. After excision, the gamma probe had 
been used to search the resection bed for residual areas of high radioactivity. All surgical 
procedures had been performed by dedicated breast surgeons or by closely supervised 
residents. The method utilised had been selected according to the surgeon’s preference 
and the logistical feasibilities of the institution. In each institution, WL, US guidance or 
ROLL had been performed. However, when the lesions had not been reliably identifiable 
by US or when ROLL could not be performed, WL had been used as an alternative. 
Tumour characteristics and margin status
The dimensions (in cm) of the surgical specimens, the tumour stage (T1a–T2) and the 
diameters of the tumours (in cm) as given in the final report were recorded. The following 
tumour histopathological subtypes were identified: invasive ductal carcinoma, invasive 
lobular carcinoma, and other types of invasive carcinoma. The presence and amount 
of tumour-associated DCIS, as found unexpectedly by the pathologist in the surgical 
specimen, were calculated and categorised. The oncological margin status was reported 
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and defined as negative, focally positive, or positive for either invasive or in situ cancer 
according to the World Health Organisation (WHO) classification for breast cancer and 
the Dutch national guidelines. The presence of an additional intraductal component had 
not been expected by the surgeon. Therefore, the main outcome of resection margins 
was calculated for invasive carcinoma only. An outcome on the associated DCIS-involved 
resection margins was considered separately. 
Calculations of the volumes and the calculated resection ratios
Both the tumour diameter and the three dimensions of the surgical specimen were used 
to calculate the ORVs and TRVs. The tumour was defined as a sphere (Fig. 1.a.). An ORV 
was calculated for each tumour as the spherical tumour volume plus a 1.0-cm margin of 
healthy breast tissue, calculated by the formula 4/3π(r+1.0 cm) 3. The TRV was assumed 
to be ellipsoid and was calculated by the formula 4/3π(a·b·c) (Fig. 1.b.). If additional 
tissue was excised during the initial surgery, the final TRV comprised the sum of the 
resection volumes. CRR was defined to determine the amount of excess breast tissue 
resected and was calculated by dividing TRV by ORV (CRR=TRV/ORV). In other words, in 
a perfect excision, in which TRV is equal to ORV, CRR is 1.0. If TRV is twice the size of 
ORV, CRR is 2.0. 
Figure 1. Mathematical calculation of the optimal resection volume (ORV) (1.a) and the total resection 
volume (TRV) (1.b) 
 
The tumour was defined as a sphere, and the tumour volume was calculated by the formula 4/3πr3. r 
represents the radius, which is equal to one half of the diameter measured by the pathologist. An ORV was 
calculated for each tumour. ORV was defined as the spherical tumour volume with an added 1.0-cm margin 
of healthy breast tissue, calculated by the formula 4/3π(r+1.0cm)3. 
 
TRV represents the volume of the surgical specimen. TRV was assumed to be ellipsoid in shape and was 
calculated using the three dimensions of the surgical specimen (in cm) measured by the pathologist. The 
formula applied to calculate TRV was 4/3π(a·b·c), with a, b, and c representing one half of each of the three 
dimensions of the surgical specimen.
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Statistical analyses
The data were analysed using the Statistical Package for the Social Sciences (SPSS 
statistical software, Version 15.0; SPSS, Inc., Chicago, IL, USA). The medians were 
calculated. Groups were compared using one-way analysis of variance and the chi-
square, Mann-Whitney or Fisher’s exact test where appropriate. Univariate analysis was 
performed to calculate the relationships of the risk factors (tumour size, unexpected 
tumour-associated DCIS (absent, minor, major), histopathological tumour type, excision 
method, and institution) with margin positivity. A multivariate model was used to 
evaluate the influence of the excision method on margin status. The results are presented 
with the corresponding p-values, and differences were considered significant at p < 0.05. 
RESULTS
Patient and tumour characteristics
Two hundred and one patients who had been treated for nonpalpable invasive T1–2N0–1 
breast carcinoma were identified; surgery was guided by WL in 117 patients (58.2%), by 
intra-operative US in 52 patients (25.9%), and by ROLL in 32 patients (15.9%). For patient 
and tumour characteristics, see Table 1. Seventy-five specimens (47.2%) presented with 
a tumour-associated DCIS component, as found unexpectedly by the pathologist. Most 
in situ lesions presented inside or within several millimetres surrounding the invasive 
tumour. There were no differences in patient age, tumour type, presence and amount 
of tumour-associated DCIS, tumour diameter, or tumour stage amongst the different 
excision groups (all p > 0.05).
Margin status
Table 2 shows the margin statuses for the total group and for the various methods of 
tumour excision. The tumours were grossly removed with adequately negative surgical 
margins. The differences amongst the three groups with regard to the margin status of 
invasive carcinoma were highly significant; focally positive or positive margins presented 
in 25 WL-guided tumours (21.4%) and in 8 ROLL-guided tumours (25%), whereas in the US-
guided group, 2 tumours (3.8%) were focally positive (p = 0.023). The unexpected presence 
of tumour-associated DCIS resulted in an extra 15 resection margins (7.5%) that involved 
DCIS. The differences in margin status amongst the three excision groups still supported 
the use of US-guided excisions but did not reach significance (p = 0.3). Univariate and 
multivariate analysis showed that the excision method, the institution, and the presence 
of unexpected tumour-associated DCIS significantly influenced oncological margin status 
(p = 0.009, p = 0.006 and p = 0.002, respectively).
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Table 1. Patient and tumour characteristics
Excision method WL
N=117
US
N=52
ROLL
N=32 
Total 
N=201
Age (median yrs) (range) 61.5 (33–77) 58.6 (42–82) 60.3 (39–79) 60.1 (33–82)
Histology (N) (%)
Invasive ductal 104 (88.9) 46 (88.5%) 24 (75.0%) 174 (86.6%)
Invasive lobular 9 (7.7%) 4 (7.7%) 6 (18.8%) 19 (9.4%)
Others 4 (3.4%) 2 (3.8%) 2 (6.2%) 8 (4.0%)
Tumour diameter 
(median) (cm) (range)
1.10 (0.30–4.00) 1.20 (0.30–3.50) 1.15 (0.30–3.50)
1.20 
(0.30–4.00)
Stage (pT) (N) (%)
T1a 4 (3.4%) 2 (3.8%) 2 (6.2%) 8 (4.0%)
T1b 38 (32.5%) 16 (30.8%) 11 (34.4%) 65 (32.3%)
T1c 63 (53.8%) 19 (36.5%) 16 (50.0%) 98 (48.8%)
T2 12 (10.3%) 15 (28.9%) 3 (9.4%) 30 (14.9%)
Associated DCIS (N) (%)
Minor 41 (35.0%) 24 (46.2%) 9 (28.1%) 74 (36.8%)
Major 12 (10.3%) 6 (11.5%) 3 (9.4%) 21 (10.4%)
Distribution of age, tumour type, tumour diameter, tumour stage, and the presence and amount of tumour-
associated DCIS in the WL, US and ROLL groups. The presence of tumour-associated DCIS, as found unexpectedly 
by the pathologist in the surgical specimen, was categorised. Minor associated DCIS represents DCIS inside or 
within several millimetres surrounding the invasive tumour; major associated DCIS represents an extended DCIS 
component surrounding the invasive tumour. There were no differences in patient age, tumour type, tumour 
diameter, tumour stage, or amount of associated DCIS amongst the different excision groups (all p > 0.05).
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Table 2. Margin status for the various methods of tumour excision.
Excision method
WL
N = 117
US
N = 52 
ROLL
N = 32 
Total 
N = 201
Margin status for invasive 
carcinoma
Negative 92 (78.6 %) 50 (96.2%)* 24 (75.0%) 166 (82.6%)
Focally 
positive
17 (14.5%) 2 (3.8%) 6 (18.8%) 25 (12.4%)
Positive 8 (6.9%) 0 (0.0%) 2 (6.2 %) 10 (5.0%)
Margin status for 
invasive carcinoma 
plus unexpected  DCIS 
component
Negative 86 (73.5%) 43 (82.7%)** 22 (68.7%) 151 (75.1%)
Focally 
positive
20 (17.1%) 4 (7.7%) 6 (18.8%) 30 (14.9%)
Positive 11 (9.4%) 5 (9.6%) 4 (12.5%) 20 (10.0%)
* p = 0.023 (negative margins between US and WL or ROLL); Fisher’s exact test.
** p = 0.3 (negative margins between US and WL or ROLL); Fisher’s exact test.
A “negative” margin status represents clear margins; “focally positive” represents focally tumour- involved (or 
“close”) margins; and “positive” represents tumour-involved margins. 
Resection volumes and calculated resection ratios 
The median ORVs, TRVs, and CRRs for the total group and for the various methods of 
tumour excision are stated in Table 3. Median CRR was 3.1. There was no evidence of 
any differences in median ORV or TRV amongst the different excision groups (p > 0.05). 
However, median CRR was significantly higher in the ROLL group compared to the WL 
group (3.8 and 2.8, respectively; p < 0.05). 
DISCUSSION
Margin status
This study of the methods of BCS for nonpalpable breast cancer clearly demonstrates 
that, of the three methods applied, US-guided surgery resulted in lower positive margin 
rates on final pathology, particularly for invasive carcinoma. Favourable oncological 
margin status is the primary goal for both the surgeon and the patient; tumour-positive 
margins are associated with an increased risk of locoregional recurrence, signifying the 
need for a second surgery to obtain definite clear pathological margins (via re-excision or 
even mastectomy); focally positive margins require either additional surgery or external
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Table 3. The optimal resection volumes (ORVs), the total resection volumes (TRVs), 
and the calculated resection
Excision 
method
WL
N = 117 
US
N = 52 
ROLL
N = 32 
p-Value
Total 
N = 201 
ORV 
(median) 
(cm3) 
(range)
16.60 
(6.37–113.10)
17.16 
(6.37–87.11)
16.38 
(6.37–87.11)
0.05*
17.16 
(6.37–113.10)
TRV
(median) 
(cm3) 
(range)
54.89 
(3.93–381.70)
71.08 
(20.94–383.86)
61.79 
(6.28–321.62)
0.16*
60.75 
(3.93–383.86)
CRR TRV/ORV 2.8 (0.3–29.9) 3.2 (0.4–18.1) 3.8 (0.3–14.7) 0.55* 0.043** 3.1 (0.3–29.9)
ratios (CRRs) for the various methods of tumour excision. 
* One-way analysis of variance; **Mann-Whitney test between WL and ROLL
ORVs (cm3) were calculated by adding a chosen 1.0-cm tumour-free margin to the tumour volumes, as calculated 
by using the diameters given in the pathology report; TRVs (cm3) were calculated using the three dimensions of 
the surgical specimen given in the pathology report; CRRs were calculated by dividing TRVs by ORVs.
beam radiotherapy, with a directed boost to the tumour bed. [22-24] Both options are 
psychologically stressful to the patient, reduce the patient’s well-being, and increase 
hospital costs. Moreover, when additional tissue is removed or boost irradiation is 
administered, the cosmetic result is worsened. 
Nearly half of all tumours presented with pre-operatively missed tumour-associated DCIS. 
This high rate of tumour-associated in situ structures corresponds well with previously 
reported data. [11] The unexpected ductal carcinomas resulted in only 7.5% DCIS-involved 
margins, while the invasive tumour was adequately removed. The surgeons in all three 
excision groups were unaware of the presence of an associated DCIS component. For this 
reason, they could not have anticipated a larger excision. In our opinion, the possible 
presence of tumour-associated DCIS does not justify excessively large resections in daily 
practice to prevent unexpected DCIS-involved margins. 
In the present study, the institution significantly influenced margin positivity. This was 
probably caused by the strong relationship between the institution and the selected 
excision method. Previous studies show that tumour type (lobular carcinomas) and 
tumour size (large tumours) are typically associated with margin positivity as well. [21] 
The small sample sizes may explain why the present study failed to show a relationship. 
Surprisingly, about 15% of all tumours were sized 2 cm or larger. In general, nonpalpable 
tumours are smaller. The nonpalpability of these relatively large tumours might be 
caused by their deep localisation in a large breast. 
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Resection volumes and calculated resection ratios 
As previously stated, the volume of resected breast tissue is the main determinant of 
cosmetic outcome. In our series, the relative excision volumes were large, especially in 
the ROLL group. In fact, with a median CRR of 3.1, the volumes were over three times as 
large as they should be. In the ROLL group, the excision volumes were nearly four times 
too large. In a recent study, we showed that in daily practice, an unnecessarily large 
amount of adjacent healthy breast tissue is often excised along with both palpable and 
nonpalpable tumours. There was also a marked difference in the depths of the margins 
around the cancer, with very generous margins on some sides and a very narrow margin 
on one side. Furthermore, despite the large excision volumes, clear margins were not 
assured. A remarkable finding of that previous study was that the rate of positive margins 
was higher for the palpable tumours than for the nonpalpable tumours. This might be 
caused by the lack of intra-operative visualisation for the excision of palpable tumours. 
[21] The large excision volumes in both the previous and the present study might be 
explained by the surgeons’ primary focus on obtaining tumour-free resection margins. 
The sparing of breast tissue was probably only a secondary aim and, therefore, was 
somewhat neglected.
Limitations of the study 
To calculate the optimal excision volumes, optimal resection margins of 1.0 cm were 
arbitrarily chosen. Although local recurrence and overall survival have proven to be 
unrelated to a tumour-free resection margin wider than 1 mm, surgeons should aim 
for a 1.0-cm margin because this is technically feasible. [22,23] The formula for the 
prediction of the optimal excision volumes and the specimen volumes was based on 
the assumptions that tumours are spheres and specimens are ellipsoids. In actuality, 
they may vary in shape. However, these assumptions permitted easy calculation from 
the measurements of the pathology reports. 
Primary DCIS was not taken into account in this retrospective study. In situ cancer 
often escapes detection by US. This type of pathology is typically nonpalpable and 
noncontiguous in nature, and it contains calcifications that are not easily visualised 
by US. Therefore, the results of this study are only applicable for primary invasive 
carcinomas. [10,11,25,26] 
The main limitations of this multicentre study are that the total sample size was 
relatively small and the numbers of patients in the various excision groups were not 
well balanced. The group of ROLL patients, in particular, was limited. The ROLL procedure 
is relatively new, and due to the learning curve the results from ROLL might be biased. 
Future studies may clarify whether ROLL is amenable to improvement.
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Intra-operative ultrasonography
Despite these limitations, previous prospective studies support our observations on the 
efficacy of intra-operative US guidance and the rates of tumour-involved margins. In 
1988, Schwartz and colleagues first reported the successful intra-operative use of US 
as an alternative to WL, and many reports followed. [5-12] Harlow et al. achieved an 
impressive overall success rate of 97% (65/67) of pathologically negative margins by US-
guided lumpectomy. [7] In 2002, Rahusen and colleagues reported the superiority of US 
guidance as compared to WL with respect to tumour-free resection margins (89% (24/27) 
and 55% (12/22), respectively). [5] In 2007, Haid and coworkers demonstrated the efficacy 
of US-guided surgery in the hands of the surgeon, with 81% (242/299) negative margins 
in the US-group compared to 62% (38/61) in the WL group. [11] Studies comparing WL 
with ROLL reported similar clinical efficacies for both procedures, but these studies are 
not conclusive. [13,27,28] 
On the basis of the present study and earlier studies, it can be theorised that the use 
of intra-operative US will offer several potential benefits for the patient desiring BCS. 
Most importantly, continuous intra-operative tumour visualisation with US results in 
the highest margin clearance compared to WL and ROLL. This is probably attributable 
to the direct real-time visualisation of all six margin depths. This advantage of using 
intra-operative US to visualise close margins or additional suspicious tissue permits 
the immediate removal of potentially malignant satellite lesions and adequate margin 
clearance. After excision, the specimen is scanned ex vivo by US to assess the completeness 
of the resection. The improved margin clearance as achieved by US guidance will lessen 
the need for re-excisions due to positive margins, decrease the frequency and expense 
of additional surgical interventions and improve cosmetic results. Moreover, because 
US enables the surgeon to optimally position the incision on the breast and to focus 
on delineating a margin around a breast tumour, US-guided surgery may reduce the 
unnecessary sacrifice of healthy breast tissue, thereby improving cosmetic outcomes 
further. US is a widely available and feasible tool, and it is the most comfortable and least 
traumatic option for the patient because there is no need for additional interventions, 
such as the placement of a wire or injection of  material. This allows the surgeon flexibility 
in scheduling patients. A potential disadvantage of intra-operative US is that the presence 
of a dedicated radiologist in the operating theatre is required. However, because US is 
clearly better for the patient, this cannot be considered a restriction. Studies using intra-
operative US for breast surgery have shown that, after a certain learning period, surgeons 
became confident in interpreting US images and recording them themselves. In the future, 
after adequate training of the surgeons, the radiologist’s presence will no longer be 
required for a successful procedure in simple cases. [7,11] In general, over 95% of invasive 
breast cancers and all palpable breast lesions are easily visualised on US. [10,25,26,29] For 
palpable breast cancer, US guidance might thus result in higher efficacy than palpation-
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guided surgery. It might provide the surgeon with more precision in localising tumours 
than palpation alone. To our knowledge, only one study has compared US-guided surgery 
with surgery without an imaging technique for palpable invasive ductal breast cancer. 
Margin status (96.3% (26/27) and 83.3% (20/24) negative margins) and the amount of breast 
tissue excised (104 cm3 and 114 cm3) were both improved with US. [12] 
CONCLUSION
The present study clearly shows that intra-operative guidance by US is the most efficient 
method of obtaining tumour-free margins in patients undergoing BCS for nonpalpable 
breast cancer. We propose the use of US for the accurate intra-operative assessment of 
all echogenic breast tumours because it is perfectly suited for detecting nonpalpable 
tumours intra-operatively and for outlining palpable lesions. A prospective randomised 
controlled clinical trial will be undertaken in our region to assess the surgical accuracy 
of intra-operative US guidance for palpable tumours and its effects on cosmetic outcomes 
and patient satisfaction. The results are expected in July 2011. 
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Is breast specimen shrinkage really 
a problem in breast-conserving 
surgery?
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ABSTRACT
Aim Breast-conserving surgery (BCS) currently focuses on improving margin 
clearance and excision volume, the main pathology report parameters for 
oncological and cosmetic outcomes. In this prospective multicentre study, 
discrepancies in surgical and pathological estimates of breast specimen sizes 
were quantitatively evaluated, including the influence of formalin fixation.
Methods This study included 68 breast specimens of consecutive patients 
undergoing BCS for breast cancer in three affiliated hospitals between November 
2010 to May 2011. Specimens were weighed immediately after excision. Specimen 
volumes were calculated from the length, width, and height. Actual specimen 
volumes were measured using volume displacement. Specimens were weighed 
once again after arrival at the pathology department, and volumes recalculated. 
The smallest pre- and post-fixation distances to the tumour-free margin were 
compared. 
Results The mean surgical specimen weight was 47.7 grams and was 
approximately similar to the actual specimen volume of 49.8 cm3. The weights 
of specimens immediately following surgery and on pathological appraisal were 
equal (p=0.94). The calculated volumes differed significantly from the actual 
specimen volumes (p>0.05). The mean distance to the closest tumour-free 
margin, 0.35 cm, was not altered by formalin fixation (p=0.1).
Conclusions We found no evidence to suggest that surgical breast specimens 
shrink in the period between the surgical procedure and pathological 
examination, or following formalin fixation. The pathological appraisal of 
specimen margins and volumes are not affected by changes in specimen size. As 
calculations of specimen volumes are unreliable, the use of water displacement 
or specimen weight is recommended for accurate volume measurement. 
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INTRODUCTION
Breast-conserving surgery (BCS) is now accepted as the treatment of choice for early-stage 
breast cancer, for which it has been proven to be equally viable as mastectomy.[1,2] The 
goal of tumour excision using BCS is to achieve tumour-free resection margins, while 
sacrificing as little healthy breast tissue as possible. The status of margins is directly 
associated with the rate of local recurrence, and additional boost radiation, re-excision 
or even mastectomy is indicated in cases with tumour-positive margins.[3-6] Removal 
of a large volume of breast tissue is the key determinant of a poor cosmetic outcome, 
particularly following repeat re-excision and boost radiation.[7-10] Consequently, the 
current focus in BCS is on improving the outcomes of both margin clearance and excision 
volume as defined by the pathology report, and this is reflected in the current breast 
cancer guidelines.[11-14] 
Two previous reports have suggested that a physical deformation of the breast specimen 
occurs in the period between the surgical procedure and the pathological examination. 
These reports described decreases in specimen height and volume including the distance 
to the closest tumour-free resection margin, particularly following the use of chemical 
fixation.[15,16] It was speculated that this “flattening” or “shrinkage” phenomenon may 
interfere with the accuracy of the final margin assessment, resulting in a spuriously 
positive classification due to a narrowing or disappearance of the margins surrounding 
the tumour. This could lead to an additional, and unnecessary, surgical procedure, 
while clear resection margins were actually obtained at the time of the original surgical 
excision. Moreover, these specimen changes will affect the pathological evaluation of 
the resection volume, leading to the reporting of volumes smaller than those at the 
moment of original excision. In practice, the results of these previous studies have not 
been widely accepted by physicians and despite the potentially crucial role of breast 
specimen shrinkage in determining the success of BCS, data on both the amount of 
breast specimen shrinkage and on the role of formalin fixation remain sparse. 
As the accurate assessment of both surgical margins and resection volumes by the 
pathologist are vital to the success of BCS, this study prospectively evaluated all 
discrepancies between the reported sizes of surgical and pathological breast specimens. 
Changes in specimens in the period from excision to pathological evaluation were 
recorded, taking special note of the influence of formalin fixation.
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MATER IALS AND METHODS
Patient selection
This study included 68 breast specimens from patients undergoing BCS for palpable 
invasive T1-2 N0-1 breast cancer at a University Medical Centre and two affiliated hospitals 
between November 2010 to May 2011. Patients were excluded if they had multifocal 
disease or if they had undergone pre-operative chemotherapy or radiotherapy.
Intra-operative specimen measurements
The specimen was weighed immediately after excision, and the length, width, and 
height of each specimen were measured using a millimetre ruler. A “cubical specimen 
volume” was calculated by multiplying measurements of the length, width, and height. 
An “ellipsoid specimen volume” was calculated using the formula 4/3π (length · width 
· height). The “actual specimen volume” was then measured using water displacement. 
This technique is considered the “gold standard” for volume measurement.[17] 
In two hospitals, the fresh specimen arrived at the pathology department prior to 
immersion in formalin; in one hospital, the specimen was preserved in formalin during 
transportation due to the location of the pathology department at another institution. 
Specimen radiography was not performed. 
Pathological specimen measurements
The final evaluation of the surgical specimens was done by the pathologists. The time 
between the surgical and pathological measurements was recorded. A pathologist 
weighed the specimen, measured the three dimensions of the specimen, and a “cubical 
specimen volume” and an “ellipsoid specimen volume” were recalculated. The pathology 
department did not use the volume displacement method to measure the “actual 
specimen volume”. The specimen was dried with a tissue, inked, flecked in acid, dried 
once again, and then wrapped in aluminium foil and refrigerated at a temperature of 
–20 degrees Celsius, followed by sectioning into 4-mm slices. The tumour diameter and 
the smallest distance between the tumour edge and the inked specimen surface were 
then measured. The unfixed specimens were fixed overnight in buffered formalin (4%). 
The tumour diameter and the distance between the tumour edge and the closest inked 
specimen surface, macro- and microscopically, were again measured by a pathologist. 
Margins were categorised as negative (no tumour at the surgical resection margin), focally 
positive (an area of ≤4 mm with tumour at the surgical resection margin), or positive 
(grossly discernible tumour >4 mm at the surgical resection margin).[3,18,19] Finally, 
tumour characteristics were recorded. 
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Statistical Analysis 
The data were analysed using the Statistical Package for the Social Sciences (SPSS 
statistical software, Version 15.0; SPSS, Inc., Chicago, IL, USA). The surgical and 
pathological weight, volume, and height (the smallest dimension of the surgical 
specimen), and the disparity between the fixed and non-fixed specimens, and between 
the pre-and post-fixation tumour diameter and closest free margin were compared using 
paired t test analysis. Linear regression analysis was used to assess the surgical weight 
and volume data. Scatterplots were generated from surgical and pathological weight, 
from volume, and from pre- and post fixation measurements. Differences were considered 
significant when p<0.05.
RESULTS
Patient and tumour characteristics
A total of 68 lumpectomy specimens were examined. The mean age of the study patients 
was 54 (range, 34-87 years). Thirty-five tumours (51.5%) were staged T1. Sixty (88.2%) 
tumours were classified as invasive ductal carcinomas. Three patients (4.4%) presented 
with an invasive lobular carcinoma and 5 patients (7.4%) had other types of carcinoma. An 
extensive tumour-associated ductal carcinoma in situ (DCIS) was present in 4 cases (5.9%). 
Specimen measurements 
The mean actual specimen volume was 49.8 cm3 (range, 7-150 cm3), and the mean 
specimen weight was 47.7 grams (range, 6-138 grams). Interestingly, a comparison between 
the actual specimen volume and the surgical specimen weight revealed that these were 
broadly similar (Volume = 7.236 + 0.935 · weight [grams] cm3).
From the data in Table 1, it is apparent that there was no significant change in weight 
between the surgical and pathological measurements (p=0.94), while the calculated 
volumes and height of specimens actually increased (all, p<0.05). However, both the 
cubical and the ellipsoid specimen volumes clearly differed from the actual specimen 
volume (mean differences -22.09, and 12.16; 95% CI=-64.50 – 5.55, and -3.71 – 22.62; both, 
p<0.05, respectively). 
The weights, volumes or heights of the surgical specimens were not significantly 
influenced by either preservation of the specimen in formalin for transportation (N=19), 
nor the time between the surgical and pathological measurements (mean 3:48 hrs (range, 
0:15-7:15 hrs; both, p>0.05). 
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Table 1  Specimen measurements
Surgeon Pathologist Mean difference
Actual specimen volume, 
cm3 (mean; range) 
49.8 (7-150) --- ---
Weight, grams (mean; 
range)
47.7 (6-138) 47.7 (6-135)
-0.05
p=0.94
95% CI=-1.25 – 1.16
Cubical specimen 
volume, cm3 (mean; 
range)
71.9 (2-392) 99.6 (18-252)
-27.72
p=0.03
95% CI=-51.87 – -3.62
Ellipsoid specimen 
volume, cm3 (mean; 
range)
37.6 (1-205) 51.9 (10-132)
-14
p=0.03
95% CI=-26.87 – -1.66
Height, cm (mean; range) 2.3 (1-4) 2.7 (1.5–4.5)
-0.38
p=0.01
95% CI=-0.66 – -0.09
CI, confidence interval
The final pathological evaluation concluded that 60 invasive carcinomas (88.2%) were 
excised with tumour-free resection margins. Three specimens (4.4%) showed focally 
positive margins, and 5 specimens (7.4%) showed tumour-positive margins. The mean 
tumour diameter pre-fixation was 1.93 cm (range, 0.5-4.1 cm), and the mean breadth of 
the narrowest tumour-free margin was 0.35 cm (range, 0.1–1.0 cm). The tumour diameter 
measured by the pathologist increased in specimens following the use of fixative (N=49; 
p=0.01), but this did not result in changes in the tumour-free resection margin (p=0.1), 
Table 2.
Table 2 Pre-and post-fixation measurements
Pre-fixation Post-fixation Mean difference
Tumour diameter, 
cm (mean; range) 
1.93 0.5–4.1 2.08 0.0–4.5
-0.15 
p=0.01
95% CI=-0.27 – -0.04
Closest free margin,  
cm (mean; range)
0.35 0.0–1.2 0.30 0.0–1.0
0.05 
p=0.1
95% CI=-0.01 – 0.11
CI, confidence interval
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DISCUSSION
With the increasing use of BCS in the treatment of breast cancer, the success of the 
surgery is more dependent than ever on accurate examination of margin status and 
resection volume. The status of the surgical margins predicts both local recurrence rates 
and further postoperative non-adjuvant treatment necessities, while excision volume has 
a major impact on the cosmetic result of surgery. In general, a pathology report details 
both the final margin status, and the length, width and height of the specimen used 
to calculate the specimen volume.[11-14] It has been speculated that the pathological 
evaluation of the success of BCS may be influenced by specimen handling, leading to 
considerable changes in specimen volume and shape. This may result in the reporting of 
smaller volumes than the real volumes at the time of excision. More importantly, these 
significant differences in surgical and pathological specimens may lead to an incorrect 
assessment of margin clearance, possibly resulting in additional unnecessary treatment.
[15,16] However, to our knowledge, these theories are based on only two studies. In 2001, 
Graham et al. described specimen changes in 100 breast biopsies for nonpalpable breast 
lesions. A 30% loss of specimen volume, and a 54% loss of specimen height were seen, 
as measured prior to fixation and after specimen compression for radiography. Even 
in the absence of specimen compression, there was still a 41% loss of specimen height.
[15] In 2006, Yeap et al. described the pre- and post-fixation changes in the mastectomy 
and lumpectomy specimens of 50 consecutive patients. The distance to the closest 
surgical margin decreased 3.5 mm (34%) on average, while the tumour itself did not 
shrink substantially (a reduction of 1.86 mm; 4.5%).[16] In contrast, our series has clearly 
shown that breast specimens do not shrink in the period between surgical excision 
and pathological evaluation. Although the “gold standard” for volume measurement, 
the water displacement method, was used only once, a comparison between the actual 
volume and the specimen weight revealed that these measurements were comparable.
[17] As specimen weight did not change in the period between surgical and pathological 
evaluation, it can be safely concluded that the specimen volume remained constant. 
Furthermore, our study produced no evidence suggesting that the use of formalin 
significantly influenced specimen volumes, nor that it affected the measured distance 
to the closest tumour-free resection margin. Shrinkage of tissue during processing still 
remains a source of controversy. An illustration of the current confusion is that some 
studies reported that the use of formalin for preservation was reported to further increase 
the flattening and shrinkage of excised specimens.[20-22] However, others stated that 
average specimen size remained unchanged or even re-expanded slightly upon formalin 
fixation.[23-25]
The apparently contradictory increases in calculated specimen volume and specimen 
height in our series should be interpreted with caution, as this was probably caused by 
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the approximate and relatively inaccurate measurements of length, width, and height. 
In addition, although the ellipsoid formula was more accurate than the cubical formula, 
the influence of specimen shape on the calculation of specimen volume means that 
the use of any mathematical formula is essentially “random”, and should therefore be 
discouraged. The reported specimen weight is an acceptable alternative for the ideal 
volume measurement, and it is therefore recommended that pathologists always record 
the weight of the specimen. 
In the light of previous data, the lack of shrinkage in our series was unexpected. In 
breast carcinomas, the margin is generally composed of a normal cuff of fatty breast 
tissue, and it has been suggested that tissue shrinkage may be due to dehydration of 
this fat margin, particularly when using a fixative.[26] A possible explanation for the 
lack of shrinkage in our series might be the fact that, in contrast to previous studies, 
only palpable carcinomas were included. The solid and concrete palpable masses are 
probably less susceptible to shrinkage than the soft, fatty nonpalpable carcinomas. An 
alternative explanation might be the complete immersion of the specimen in water. This 
may have prevented dehydration, although the longer-term use of water for specimen 
preservation should be avoided to prevent specimen degradation. However, the concept 
of specimen shrinkage is clearly contradicted by our data, as we show that surgical breast 
specimens do not shrink in the period between the surgical procedure and pathological 
examination, and the use of formalin fixation does not lead to shrinkage significant 
enough to influence adequate margin assessment.
CONCLUSIONS
It can be safely concluded that the pathological reporting of outcomes of the margin 
status and resection volume are not affected by changes in original specimen size 
or shape, and are therefore reliable for oncological decision-making. Calculation of 
the specimen volume is unreliable, and should be discouraged. The use of the water 
displacement method for accurate volume measurement is recommended, but failing 
this, measuring specimen weight is an acceptable alternative. Pathologists should be 
encouraged to always measure and record specimen weight.
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TAKE -HOME MESSAGES
-  The current focus in breast-conserving surgery is on improving the outcome of both 
margin clearance and excision volume as defined by the pathology report.
-  It has been suggested that a physical deformation of the breast specimen occurs in the 
period between the surgical procedure and the pathological examination, or following 
formalin fixation, but data on this important topic remain sparse.
-  Surgical breast specimens do not shrink in the period between the surgical procedure 
and pathological examination, or following formalin fixation, and therefore do not 
influence oncological decision-making.
-  As calculations of specimen volumes are unreliable, the use of water displacement 
or the more readily available specimen weight is recommended for accurate volume 
measurement.
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CHAPTER 5
Study protocol Ultrasound-guided 
breast-sparing surgery to improve 
cosmetic outcomes and quality of life
A prospective multicentre randomised 
controlled clinical trial comparing ultrasound-
guided surgery to traditional palpation-guided 
surgery 
(COBALT trial)
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ABSTRACT
Background: Breast-conserving surgery for breast cancer was developed as a 
method to preserve healthy breast tissue, thereby improving cosmetic outcomes. 
Thus far, the primary aim of breast-conserving surgery has been the achievement 
of tumour-free resection margins and prevention of local recurrence, whereas 
the cosmetic outcome has been considered less important. Large studies 
have reported poor cosmetic outcomes in 20-40% of patients after breast-
conserving surgery, with the volume of the resected breast tissue being the 
major determinant. There is clear evidence for the efficacy of ultrasonography 
in the resection of nonpalpable tumours. Surgical resection of palpable breast 
cancer is performed with guidance by intra-operative palpation. These palpation-
guided excisions often result in an unnecessarily wide resection of adjacent 
healthy breast tissue, while the rate of tumour-involved resection margins is still 
high. It is hypothesized that the use of intra-operative ultrasonography in the 
excision of palpable breast cancer will improve the ability to spare healthy breast 
tissue while maintaining or even improving the oncological margin status. The 
aim of this study is to compare ultrasound-guided surgery for palpable breast 
cancer with the standard palpation-guided surgery in terms of the extent of 
healthy breast tissue resection, the percentage of tumour-free margins, cosmetic 
outcomes and quality of life.
Methods / design: In this prospective multicentre randomised controlled clinical 
trial, 120 women who have been diagnosed with palpable early-stage (T1-2N0-1) 
primary invasive breast cancer and deemed suitable for breast-conserving 
surgery will be randomised between ultrasound-guided surgery and palpation-
guided surgery. With this sample size, an expected 20% reduction of resected 
breast tissue and an 18% difference in tumour-free margins can be detected with 
a power of 80%. Secondary endpoints include cosmetic outcomes and quality of 
life. The rationale, study design and planned analyses are described.
Conclusion: The COBALT trial is a prospective, multicentre, randomised 
controlled study to assess the efficacy of ultrasound-guided breast-conserving 
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surgery in patients with palpable early-stage primary invasive breast cancer 
in terms of the sparing of breast tissue, oncological margin status, cosmetic 
outcomes and quality of life.
Trial Registration Number: NTR2579
BACKGROUND
Breast cancer is the most common cancer among women in the western world. It affects 
women of all ages and the lifetime risk of developing invasive breast cancer is 12-13%. 
The 5-year disease-free survival rate for node-negative breast cancer, however, is excellent 
(98%). Breast cancer surgery has changed dramatically over the past few decades. Breast-
conserving therapy (BCT) was introduced in the 1970s and refers to the surgical removal 
of the breast tumour in all cases followed by radiotherapy to eradicate residual tumour 
cells. The introduction of the sentinel node procedure for nodal staging has avoided 
the morbidity of axillary lymph node dissection in the majority of patients. Several 
trials demonstrated comparable results with regard to disease-free and overall survival 
between mastectomy and BCT combined with radiotherapy, and the latter has become 
the standard of care for early-stage breast cancer. According to national guidelines, 75% of 
breast cancer patients are suitable for BCT. The main advantage of BCT over mastectomy 
is preservation of the breast with improved cosmetic outcomes. [1-5]
Breast cancer and its treatment have many adverse side-effects, which may be both 
physical and psychological. Psychological distress is common in the breast cancer 
population and affects approximately 30% of patients. Fear of disease recurrence, 
concerns about future health and interruption of life plans often lead to anxiety and 
depression.
The cosmetic result is also a major determinant of psychological distress. Cosmetic 
outcome of the breast has a large impact on body image, and studies have shown that 
women with poor cosmetic outcomes as determined by pronounced breast asymmetry 
and skin alterations are impaired in their self-esteem, feelings of sexuality and quality 
of life. Furthermore, these women are more likely to feel stigmatised and have more 
symptoms of depression. Focusing on the best achievable cosmetic result will lead to a 
decrease in psychological distress. [6-9]
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Although BCT is considered the least invasive surgical method for treatment of breast 
cancer, cosmetic outcomes vary widely. Studies have reported satisfactory cosmetic results 
in only 60-80% of patients, with cosmetic failure rates up to 40%. Factors determining 
cosmetic outcome after BCT include the volume of resected breast tissue, the amount of 
radiotherapy, the site of the tumour in the breast, the type of incision and postoperative 
complications such as wound infection. Overall, a large volume of resected breast tissue 
is the major determinant of a poor cosmetic outcome. Regardless of the size of the breast, 
excision volumes exceeding 85 cm3 result in a 50% rate of cosmetic failures, whereas 
smaller excision volumes result in only a 22% rate of cosmetic failures. Therefore, surgeons 
should excise the tumour with only a small volume of surrounding breast tissue. [10-15]
As a practical and reasonable guideline during surgery, the aim is to achieve a safe and 
cosmetically acceptable resection margin of 5-10 mm. It should be noted that the size 
of the tumour-free resection margin (>1 mm) is unrelated to local recurrence or overall 
survival. Higher risks of local recurrence have been shown only with evident involvement 
of the tumour on the inked resection margins. Therefore, there is no need to excise a 
tumour with a large volume of adjacent breast tissue. This is also stated by the Dutch 
national guidelines. Accurate excision leads to a smaller and more precise volume of 
surrounding breast tissue removal without compromising the minimal tumour-free 
margin. [16-19]
In daily practice, the succes of the removal of palpable breast cancer is based on pre-
operative imaging techniques and the experience of the surgeon. The surgeon is guided 
by intra-operative palpation without objective imaging during the surgery. The primary 
aim of the procedure is to achieve tumour-free resection margins and to prevent local 
recurrence; a secondary aim is a satisfactory cosmetic outcome. Avoiding inadequate 
resection margins and subsequent re-excision results in an unnecessarily wide resection 
of adjacent healthy breast tissue. Indeed, our recent large retrospective multicentre 
study demonstrated that during routine breast-conserving surgery, an excessive volume 
of breast tissue is excised in the majority of patients. The study participants (n=726) 
underwent breast-conserving surgery in four hospitals in our region for invasive breast 
cancer in three consecutive years. The volumes of the excised specimens were calculated 
using histopathological reports. It was shown that in 33.6% (244/726) of the patients, 
the excised tissue volume exceeded 85 cm3, i.e., deteriorating the cosmetic outcome. In 
this group, 98.8% (241/244) had presented with an excision that exceeded the optimal 
resection volume (= the tumour volume plus a 1 cm margin of tumour-free breast tissue). 
(Figure 1.a., see Appendices) In fact, in 54.9% (134/244) of these patients the tumour 
stage was T1 and a maximum resection volume of 33.51 cm3 would have been sufficient 
(optimal resection volume for a tumour size of 2 cm and an added 1 cm margin of 
healthy breast tissue). Also, in most cases presenting with a tumour-free margin, the 
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malignant lesion was located eccentrically in the excision volume, close to the nearest 
margin (Figure 1.b., see Appendices). Remarkably, the rate of focally positive or positive 
margins was higher for the palpable tumours than for the nonpalpable tumours (22.5% 
and 17.4%, respectively; P=0.13). [20] This might be caused by the lack of three-dimensional 
orientation with intra-operative visualisation in the excision of palpable tumours.
An easily available and feasible method to improve the amount of healthy breast tissue 
spared while ensuring tumour-free resection margins is intra-operative ultrasonography 
(US). US-guided surgery (USS) enables the surgeon to visualise the tumour during 
excision. Earlier studies have clearly shown the efficacy of USS for nonpalpable tumours. 
Rahusen et al. reported that USS, in which an experienced radiologist perfomed US, is 
superior to wire-guided surgery with respect to tumour-free resection margins (89% 
and 55% of cases, respectively). Snider et al. also showed an excellent rate of tumour-
free resection margins using USS (82%) with a smaller volume of healthy breast tissue 
resection compared to wire-guided surgery (62.2 cm3 and 81.1 cm3, respectively). [21-26] 
Our retrospective multicentre study showed that USS for nonpalpable invasive breast 
cancer was more accurate than wire-localisation and Radio Occult Lesion Localisation 
(ROLL)-guided surgery because it optimised the surgeon’s ability to obtain adequate 
margins (3.7%, 21.3%, and 25% tumour-involved margins, respectively, (P<0.05). Intra-
operative ultrasonography for nonpalpable tumours results in a dramatically lower 
rate of tumour-involved resection margins than palpation-guided surgery for palpable 
tumours (3.7% and 22.5%, respectively, (P<0.05); unpublished data). [27] To the best of our 
knowledge, only one study, by Moore et al., has evaluated the use of USS for treatment 
of palpable invasive ductal breast cancer. One group of patients received USS, and the 
other group underwent surgery without an imaging technique. The breast tissue spared 
and margin status were both improved with US. [28]
In general, all palpable breast masses are visible by US. Given that the efficacy of USS 
has already been shown for nonpalpable tumours, we hypothesise that USS will also be 
useful for palpable tumours with regard to improving the amount of healthy breast tissue 
spared, cosmetic outcomes and quality of life while still maintaining or even increasing 
tumour-free resection margins.
METHODS /DESIGN
Design 
This study will be a multicentre prospective randomised clinical trial. Eligible patients will 
be randomised for either ultrasound-guided surgery (USS) or palpation-guided surgery (PGS).
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Subjects and patient selection
One hundred and twenty patients will be recruited over a period of six months at a 
university medical center and several medium to large hospitals in the Netherlands. All 
women aged 25-75 yrs who are diagnosed with palpable early-stage (T1-2N0-1) invasive 
breast cancer in the trial centres will be invited to participate in this study. Breast 
cancer will be diagnosed with physical examination, mammography (2R) and US, and 
occasionally MRI of the breast and axilla. The diagnosis of invasive (ductal or lobular) 
breast cancer will be established with image-guided core needle biopsy or cytological 
puncture. All patients will be discussed in a multidisciplinary team, and suitable for BCT 
according to national guidelines. Participants will not have a history of prior mammary 
surgery of the affected breast, radiation therapy or neo-adjuvant therapy. Participants 
will have ASA Classification I–III and will be well-informed having signed an informed 
consent form. 
Full ethical approval is obtained for this study from the Investigational Review Board of 
the VU University Medical Centre, including the Medical Ethical Review Board.
Study procedures
Pre-operative Prior to surgery, patients will be informed about this trial by both written 
and oral explanations. Informed consent will be obtained. Subsequently, the patients 
will complete the quality of life questionnaire, EORTC QLQ-C30/-BR23. The principal 
investigator will randomly assign the participants to either of the two treatment 
modalities by using a digital randomisation program. Group I will undergo PGS and 
group II USS. Stratification by institute will be performed to ensure balanced allocation 
between the two treatment modalities in each institution. 
Surgery Surgery will be performed under general anaesthesia by dedicated oncological 
breast surgeons or by surgical residents under their close supervision. The surgery will 
start with the axillary procedure. In clinically node-negative patients surgery of the 
axilla consists of a single sentinel node procedure. For the sentinel node procedure, 
a triple method will be used, consisting of combined lymphoscintigraphy (Tc99m 
colloidal albumin [Nanocoll®]), Patent Blue V® (Guerbet, Aulnay-Sous Bois, France) dye 
injection, and gamma probe detection.[2] In some institutions, the sentinel node is 
sent for frozen section study, and if metastases are diagnosed, axillary lymph node 
dissection is performed during the same procedure. Node-positive patients who are 
pre-operatively confirmed by US-guided cytological puncture will undergo an axillary 
lymph node dissection. Axillary lymph node dissection is a routine procedure, consisting 
of a classic level I and II dissection. After the axillary procedure, surgery of the breast is 
performed. The aim in both the USS-group and the PGS-group will be to obtain a rim of 
1 cm of healthy adjacent breast tissue around the malignant breast lesion. 
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Palpation-guided surgery In the PGS group, tumour excision will be guided by the 
palpation of the surgeon in the standard manner. The index finger will be used to 
palpate the mass, retract it and guide the dissection. In this procedure, the adequacy 
of the resection is based on the experience of the surgeon without objective imaging 
during surgery. 
Ultrasound-guided surgery In the USS group, tumour excision will be performed by 
the surgeon with US guidance in collaboration with an experienced radiologist. Prior 
to surgery, the surgeon will carry out an US of the lesion under direct supervision 
of the radiologist. During the surgery, the radiologist will be present either in the 
operating theatre or in the radiology department. The surgical procedure will start with 
the standard sentinel node procedure, after which the US-guided lumpectomy will be 
performed. USS will be performed using a THI 14-MHz US probe (Toshiba Viamo portable 
ultrasound system, Japan). The probe is coupled to a mobile US unit and covered with a 
sterile sheath that enables it to be used in the surgical wound. The lesion will be carefully 
localised in the breast by palpation and US imaging (Figure 2). The localisation of the 
lesion will be compared to the pre-operative images. The breast tissue will be positioned 
in such a way that the lesion is located as close to the skin surface as possible, and the 
breast will be fixed in that position throughout the procedure by hand or using tape. 
The tumour size, lesion-to-skin distance and lesion-to-fascia distance will be measured 
in millimetres by US. The localisation of the tumour will be precisely marked on the 
skin (Figure 3, see Appendices), and the incision will be made. After the incision, the 
skin over the lesion will be dissected from the subcutaneous tissue, and the US probe 
Figure 2 Ultrasound image view on the screen. The tumour size, lesion-to-skin distance and lesion-to-fascia 
distance will be measured in millimetres.
Proefschrift_Nicole_v17.indd   75 04-12-12   15:25
76
will be positioned in the wound to reassess the position of the lesion. Also, the index 
finger will be used to palpate the mass, retract it and guide the dissection. Dissection 
is continued posteriorly in the plane between the breast and the pectoral fascia. To 
achieve adequate margins, US will be applied repeatedly in the wound from different 
angles while continuously monitoring the location and depth of the tumour (Figure 4 
and 5, see Appendices). Subsequently, a spherical lump of breast tissue will be excised. 
It is recommended to place a “pool suture” around the tumour under US guidance to 
facilitate the excision. After completion of the excision, the specimen will be scanned 
ex vivo by US to assess the completeness of the excision (Figure 6, see Appendices).
The orientation of the specimen will be preserved with marking sutures such that 
positive resection margins can be identified and re-excised if necessary. Haemostasis 
will be obtained, and drains will not be used. If requested, titanium clips will be placed in 
each quadrant to guide radiotherapy. Subcutaneous tissue will be closed with dissolvable 
stitches, and the skin will be closed with stitches or staples.
Outcome parameters 
Perioperative parameters The experience of the surgical residents, complications, the 
duration of procedure (i.e. time from the incision to wound closure; time needed for the 
axillary surgery is excluded) and costs of the procedure are registered.
After excision the volume of the specimen will be measured in the operating room by 
fluid displacement. The specimen will be submerged in an Erlenmeyer flask filled with 
normal saline at 37oC. The volume of fluid displaced equals the volume of the specimen. 
If re-excision is performed during the surgery, the volume of the reexcised specimen 
will be calculated separately and subsequently added to the originally excised specimen.
Pathology This study would not influence current pathological examination.
After the placement of wire markers on the fresh specimen, the specimen is sent together 
with the sentinel node immediately to the pathologist. The pathological examination 
of the surgical specimen and sentinel node is as follows: The three dimensions of the 
surgical specimen are measured macroscopically. Specimens will be carefully inked 
and cut in 4-mm slices. Subsequently, the tumour diameter, the site of the tumour in 
the surgical specimen, the margin status and the smallest distance to the tumour-free 
resection margin will be measured (mm). The margin status and the smallest distance 
to the tumour-free resection margin will be measured more precisely using microscopy 
(mm), and finally, tumour characteristics (e.g. tumour differentiation, receptor status) will 
be recorded. The three dimensions of the sentinel node are measured macroscopically. 
Lymph nodes measuring <5mm are examined in toto, nodes measuring > 5mm are cut. 
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Microscopically the presence and size of metastasis are defined (mm).
Calculations
The ratio of the resected volume to the optimal resected volume can be calculated from 
the diameter of the tumour and the three dimensions of the specimen. 
Three assumptions are made:  
1) the tumour is spherical (using the radius (= ½ diameter),  
2) in an optimal resection volume, a margin of 1 cm is excised around the tumour and  
3) the excised specimen is ellipsoid.
The volume of the excised specimen will be measured during surgery by fluid 
displacement and the histopathological ellipsoid calculation will serve as a control. 
- The volume of the tumour will be calculated by 4/3πr 3. 
-  The optimal volume required for excision will be calculated by adding a resection 
margin of 1 cm to the lesion radius and converting this value into a spherical 
volume using the formula 4/3π(r+1cm) 3. 
-  The volume of the surgical specimen will be calculated using the formula 4/3πa·b·c 
(with a, b and c as given in the pathology report). The specimen volume will be 
compared with the optimal excision volume, resulting in a ratio (Figure 7). [29] 
Postoperative This study would not influence current postoperative treatment.
Figure 7. Comparing the specimen volume with the optimal excision volume
The current postoperative treatment is as follows: Within two weeks after surgery, 
patients visit the outpatient clinic. Pathological results and further treatment (with 
multidisciplinary approach) are explained in detail. Complications are registered and 
treated, with special attention given to wound healing. Approximately six weeks after 
surgery, all patients receive radiotherapy of the affected breast. Patients younger than 
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50 years old are treated with whole-breast irradiation (50 Gy in 25 fractions) including a 
simultaneously integrated boost (SIB), for a total dose of 68,75 Gy. Patients over 50 years 
old receive 40 Gy in 15 fractions with a SIB, for a total dose of 50,25 Gy. Radiotherapy 
strategies may vary slightly according to institutional guidelines. If necessary, a medical 
oncologist is consulted for the administration of systemic therapy. Adjuvant therapy 
is administered according to national guidelines. When multiple axillary lymph node 
metastases are diagnosed, patients will receive adjuvant therapy prior to radiotherapy.
Cosmetic Analysis 
During the follow-up visits three and six months after surgery, the cosmetic outcome 
will be evaluated. Standard 4-point view digital photographs, including the suprasternal 
notch, will be taken. These photographs will be scored by a panel consisting of six persons 
(including both professionals and non-professionals). The items scored will be the overall 
result, the appearance of the surgical scar, breast size, breast shape, nipple position and 
the shape of areola. The treated breast will be compared to the untreated breast, using 
the 4-point Lickert scale. Objective cosmetic analysis will be performed with the Breast 
Retraction Assessment (BRA) or comparable objective software. BRA values are calculated 
using measurements from the frontal view photographs and quantity the amount of 
retraction of the treated breast compared to the healthy contralateral breast by measuring 
nipple displacement. A large BRA value corresponds to increased asymmetry between 
the breasts and to poor cosmetic results (Figure 8). Subsequently, the patients’ opinions 
concerning cosmetic outcome will be assessed using patient self-evaluation. Long-term 
follow-up (3 yrs) will probably be studied in a future research project.
Figure 8. Breast Retraction Assessment
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Quality of Life questionnaire 
The EORTC QLQ-C30/-BR23 questionnaire will be completed by the patient prior to surgery 
and during follow-up visits three and six months after surgery. Using a personalised 
interview three and six months after surgery, patients’ feelings concerning the cosmetic 
results of their breasts will be assessed more specifically. Results will be analysed over time.
Follow-up  
Oncological follow-up will continue according to national guidelines (every three months 
for the first two years). One year after surgery, follow-up will include no study issues. If the 
results of this study are promising, long-term results will be analysed (3 yrs of follow-up).
Sample size calculation
The sample size was calculated based on the primary endpoint: volume of resected breast 
tissue. Previous studies have shown that excision volumes exceeding 85 cm3 result in 
significantly higher cosmetic failure rates. In our recent retrospective multicentre study it 
was found that in 33.9% (244/726) of the patients the excision volumes exceeded 85 cm3. In 
98.8% (241/244) of these patients, the CRR was >1.0, implying that excess tissue was excised. 
[20] It can therefore be concluded that, in 33.2% (241/726) of all patients, excessive tissue 
resection resulted in impairment of the cosmetic outcome. Assuming that this excessive 
resection can be avoided with US-guided surgery, it is expected that only 10% of women will 
have excessive breast tissue resection (a ratio of >1.0) that results in a worse cosmetic outcome 
(resection volume >85 cm3). Therefore, we assume a difference in resected volume of 22.3% 
in favour of the US group. With a statistical power of 80% to detect this 22.3% improvement 
as significant (P<0.05), we will require 57 patients in the palpation group and 57 patients in 
the US group. The margin status is currently involved in 22.5% of palpable breast tumour 
excisions. To improve this rate to 5%, we will require 60 patients in the palpation group and 
60 patients in the US group. Therefore, the target sample size will be 120 patients.
Timeline
The inclusion period will run from October 2010 to July 2011. The EORTC QLQ-C30/-BR23 
questionnaire will be completed by the patient prior to surgery. Surgery will be scheduled 
1-2 weeks after diagnosis. During a follow-up visit to the outpatient clinic, usually 1-2 
weeks after discharge, complications will be recorded and treated. Three and six months 
after surgery, information will be collected from each patient concerning the cosmetic 
outcome and quality of life, and photographs will be taken. Patients can withdraw from 
the study at any time during the study period.
Statistical analysis
Descriptive statistical methods will be applied. Statistical software (i.e. SPSS 15.0.) will be 
used for analysis. The 95% confidence intervals of the differences between the two groups 
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will be calculated. The Chi-square test will be used for comparisons of dichotomous variables. 
The Students’ t-test will be used, where appropriate, for comparisons of continuous variables. 
The Fisher’s exact test will be performed where applicable. Multiple regression analysis 
will be used for comparisons of independent variables. The patient, tumour and treatment 
related differences will be calculated for the two treatment strategies. 
An interim analysis will be performed after the inclusion of 60 patients (30 patients in 
each group). The final data analysis will be performed after the surgeries of the total of 
all 120 patients are completed. Definitive results are expected in December 2011.
DISCUSSION
The goals of breast-conserving surgery are to obtain adequate margins and good cosmetic 
results. Both goals are poorly defined, and there is no universal acceptable standard. 
According to Dutch national guidelines, a negative margin is defined as a margin of ≥1 
mm of normal tissue intervening between the tumour and the edge of the specimen. 
Resections are described as focally involved when cancer cells invade the resection margin 
in a maximum of two microscopic slides or when margins include <1mm of normal 
tissue. The margins are described as involved or positive when microscopic cancer cells 
are situated on the inked resection border. It has been well-established that the status 
of the margin affects the local recurrence rate. Therefore, re-excision is indicated for 
involved margins. Vrieling et al. showed that patients with focally involved margins 
have lower rates of recurrence when treated with a higher radiation boost dose, equal 
to patients with adequate margins. Therefore, a higher boost dose is given to patients 
with focally involved margins without further surgery. This has been confirmed by 
national guidelines. [15-19]
To analyse cosmetic outcomes, frequently used subjective methods are patient self-
evaluation and panel evaluation. Patient self-evaluation is a valuable method as the 
patient’s opinion is of great importance; however, patients tend to report consistently 
better scores than professionals. Panel-evaluation, consisting of a panel of six professionals 
and non-professionals, has proven to be the most reliable subjective method. The panel 
evaluates 4-point view pictures of the breasts. [8,13] Breast Retraction Assessment (BRA) is 
a well-validated and frequently used objective method to evaluate breast asymmetry. The 
BRA is reliable and minimally time-consuming; however, it is only correlated moderately 
for tumours located in the lower quadrant, and skin changes (e.g. disturbing scars or 
telangiectasias) are not taken into account. In the framework of the EORTC trial, Vrieling 
et al. compared these different methods of cosmetic outcome assessment. The BRA is 
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recommended for comparing the cosmetic outcomes between two different approaches 
to BCT and for analysing cosmetic changes over time. The panel evaluation gives the best 
measure of the overall cosmetic result. Therefore, in order to assess cosmetic outcomes, 
the most appropriate method is to combine the panel evaluation and the BRA into an 
overall score. Patient self-evaluation is necessary with regard to quality of life. [30,31]
The excision of nonpalpable breast cancer can be performed with guidance from 
several tools. The wire-localisation (WL) is still the gold standard. The WL procedure 
is technically demanding and depends on both the wire placement by the radiologist 
and on the experience and three-dimensional orientation of the surgeon. The insertion 
of the wire can be uncomfortable for the patient; Furthermore, there is a risk of wire 
migration between the time of insertion and the beginning of the surgery. Other less 
frequently used techniques are emerging, including the use of radioactive seed implants, 
an electrosurgical loop device and Radio-guided Occult Lesion Localisation (ROLL), which 
uses a radioactive pharmaceutical that is injected into the tumour pre-operatively. A 
gamma probe is used to guide the surgical resection. A drawback is that these guidance 
tools are invasive. Currently, these techniques are being validated. [32-34] Intra-operative 
ultrasonography (US) was introduced in 1988 as an easily available and patient-
comfortable method of excising a tumour under direct vision. Using intra-operative US, 
surgeons can localise and guide the excision of non-palpable lesions, without the need 
for additional interventions before surgery. After specimen removal, the US is valuable to 
confirm excision and check margin clearance before wound closure. However, a possible 
restriction is the arrangement of a radiologist’s presence in the operating theatre. In our 
multicentre study wire-localisation (WL), ROLL and USS were retrospectively compared. 
USS was clearly the most effective method for the excision of nonpalpable tumours. 
[27] Moreover, a number of studies such as Rahusen et al. and Snider et al. have clearly 
demonstrated that intra-operative US guidance has considerable advantages over wire-
guided excision, including reduced pre-operative stress and discomfort for patients and 
decreased operating room time. Most importantly, intra-operative US guidance resulted 
in improved resection margins and smaller excision volumes. 
High-frequency US shows most lesions, and in general, all palpable breast lesions are 
visible with ultrasonography (US). Therefore, intra-operative US is applicable in the 
majority of women with a palpable breast cancer. [21-26,28,33]
Intra-operative ultrasonography will contribute to improved cosmetic outcomes by: 
1. Smaller volumes of resected breast tissue 
2.  Improvement of margin status 
- avoiding a higher boost dose for focally involved margins 
- avoiding re-excision or even mastectomy for involved margins
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Approximately 9000 out of 13000 breast cancer patients are diagnosed with a palpable 
breast cancer in the Netherlands each year, and around 5000 patients undergo breast-
conserving surgery for a palpable breast cancer. An improvement of cosmetic outcomes 
in an estimated n=1115 (22.3%) of all patients treated with breast-conserving surgery can 
be achieved by USS. Also, an estimated n=875 (17.5%) less operations will be necessary 
after treatment by US-guided surgery (A re-operation costs about € 7 000,-, so eventually € 6 125 000, - might be saved by this method each year).
CONCLUSION
In conclusion, this randomised controlled trial aims to demonstrate the superiority of 
USS versus PGS for the treatment of patients with palpable breast cancer in terms of the 
sparing of breast tissue, oncological margin status, cosmetic outcomes and quality of life.
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CHAPTER 6
Optimising surgical accuracy in 
palpable breast cancer with intra-
operative breast ultrasound - 
feasibility and surgeons’ learning 
curve
N. M. A. Krekel, A. M. F. Lopes Cardozo, S. Muller, E. Bergers, S. Meijer, M. P. van den Tol.
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ABSTRACT
Aims: To evaluate if intra-operative guidance with ultrasonography (US) could 
improve surgical accuracy of palpable breast cancer excision, and to evaluate the 
performance of surgeons during training for US-guided excision. 
Materials and methods: Thirty female patients undergoing breast-conserving 
surgery for palpable T1-T2 invasive breast cancer were recruited. Three 
individual breast surgeons, assisted by US, targeted and excised the tumours. 
The main objective was to obtain adequate resection margins with optimal 
resection volumes. The specimen volume, tumour diameter and histological 
margin status were recorded. The specimen volume was divided by the optimal 
resection volume, defined as the spherical tumour volume plus a 1.0-cm margin. 
The resulting calculated resection ratio (CRR) indicated the amount of excess 
tissue resected. 
Results: All tumours were correctly identified during surgery, 29 of 30 tumours 
(96.7%) were removed with adequately negative margins, and one tumour was 
removed with focally positive margins. The median CRR was 1.0 (range, 0.4 – 2.8), 
implying optimal excision volume. For all breast surgeons, CRR improved during 
the training period. By the 8th procedure, all surgeons showed proficiency in 
performing intra-operative breast US.
Conclusion: Surgeons can easily learn the skills needed to perform intra-
operative US for palpable breast tumour excision. The technique is non-invasive, 
simple, safe and effective for obtaining adequate resection margins. Within 
the first two cases, resections reached optimal volumes, thereby, presumably 
resulting in improved cosmetic outcomes. In a multicentre, randomised, clinical 
trial, intra-operative US guidance for palpable breast tumours will be evaluated 
for oncological ánd cosmetic outcomes.
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INTRODUCTION
The surgical treatment of breast cancer has undergone considerable evolution over the 
past decades. Breast-conserving surgery (BCS) has been accepted as an equally viable 
option as mastectomy for the management of early-stage breast cancer, and the sentinel 
node procedure has replaced axillary dissection in the majority of patients. [1,2] The 
current focus is on improving the surgical accuracy of BCS, which includes a higher rate 
of margin clearance with smaller excision volume, thereby improving patient satisfaction 
and cosmetic outcome. [3-8] To this end, advances have been made in image-guided 
breast surgery for nonpalpable breast cancer, and several studies have shown that the 
use of ultrasonography (US) for intra-operative tumour localisation results in the most 
accurate surgical excision. [9-14] 
In daily practice, the excision of palpable breast cancer is guided by palpation. The 
adequacy of this procedure is based on pre-operative imaging techniques and the 
experience and tactile abilities of the surgeon. However, palpation of the tumour mass 
during this “blind” procedure can be problematic, especially in dense breasts. Indeed, 
in our previous retrospective study, 22.5% of all palpation-guided tumour-excisions 
presented with tumour-involved surgical margins. [5] Other studies have also reported 
a high incidence of positive margins after initial excision, ranging from 20 to 60%. [15-17] 
Moreover, it has been shown that many surgeons tend to overexcise volumes of normal 
tissue in an effort to obtain adequate margins. Actually, it was shown that the median 
excision volume of all palpation-guided tumour excisions is over two times to large. [5] 
Intra-operative guidance with US may therefore improve surgical accuracy of palpable 
breast cancer excision as well, being helpful for intra-operative tumour localisation, 
orientation, direction of planes of excision, and assessment of surgical margins. 
In the hospital setting, US generally is performed by a radiologist. However, problems 
can arise in the planning and arrangement of a radiologist’s presence in the operating 
theatre. Therefore, surgeons have become interested in performing intra-operative US 
themselves. Unfortunately, most surgeons have little experience with US, and a major 
obstacle to the use of US among surgeons is the difficulty in learning how to use it.
Preceding a randomised, controlled trial, a hands-on training period was initiated for 
surgeons to perform US-guided BCS for palpable breast cancer. [18] The main objectives 
were to obtain adequate, clear resection margins and remove as little healthy breast 
tissue as possible. In this article, we present the surgical accuracy of the procedure, as 
well as the practice-based learning experience, its difficulties, and the potential pitfalls 
that could suggest strategies for the training and improvement of the US procedure. 
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PAT IENTS AND METHODS
Patient selection
Between May 1, 2010, and September 25, 2010, 30 female patients were recruited for 
this study. All women were evaluated in the outpatient clinic, and the formal workup 
included physical examination, diagnostic breast and axilla US, mammography, and 
fine-needle aspiration or core biopsy. Patients were chosen for this study when they had 
a palpable, US-visible, biopsy-supported, invasive carcinoma of the breast, stage T1 or T2. 
Patients with pre-operatively diagnosed primary or associated DCIS, multifocal disease, 
a history of neo-adjuvant therapy or previous surgical treatment or radiotherapy of the 
affected breast were excluded. Research Ethics Board approval was obtained from all 
hospitals. Informed consent was obtained from all patients.
Surgeons
Three dedicated breast surgeons participated in this training period. Procedures on 
patients 1 through 10 were performed by breast surgeon I, who had several years 
experience in radiologist-assisted US–guided excision of nonpalpable breast tumours. 
Breast surgeons II and III had no prior experience with intra-operative breast US. 
Procedures on patients 11 through 20 were performed by surgeon II, and procedures on 
patients 21 through 30 were performed by surgeon III. Surgeon I closely supervised all 
surgical procedures. 
Prior to surgery
A close working relationship with the radiology department was required to ensure 
appropriate patient selection and evaluation for this clinical training phase. The surgeons 
carried out US under the direct supervision of a breast radiologist. The localisation of 
the carcinoma, the margins (defined as regular or irregular), the size (length, width, 
and anterior-posterior diameter), and the distances to the skin and to the fascia were 
documented.
Surgical procedure
Surgeons used a 14-MHz US probe connected to a portable US system (Toshiba Viamo 
portable ultrasound system, Japan). The probe was covered with a sterile glove and 
plastic sheath filled with sterile acoustic gel. The patient was positioned supine with the 
ipsilateral arm raised beside the head. The surgeon carefully localised the tumour in the 
breast by palpation and US imaging. To visualise the tumour at its largest diameter, the 
US probe was moved in short, strokelike motions, perpendicular to the long axis of the 
transducer. The breast tissue was positioned in such a way that the lesion was located as 
close to the skin surface as possible. The breast was fixed in that position throughout the 
procedure by hand or with tape. The tumour diameter (transverse versus vertical), the 
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lesion-to-skin distance and the lesion-to-fascia distance were measured in millimeters, and 
compared to the digital pre-operative US images, which could be retrieved on the same 
US system at any time. Thereafter, the tumour was positioned on the lateral borders of 
the screen to precisely mark the tumour margins on the skin. This process was repeated 
in the cranial-caudal plane. The skin marks were connected and used to determine the 
incision line (Figure 1, see Appendices). After making the incision, the skin over the lesion 
was dissected from the subcutaneous tissue, with the goal of obtaining an “optimal” 
1-cm margin of healthy breast tissue around the tumour. The extent of dissection was 
determined using the skin marks and the US, which further assisted the surgeon with 
the excision. To achieve adequate margins (Figure 2, see Appendices), US was applied 
repeatedly in or around the wound from different angles while continuously monitoring 
the location and depth of the tumour and ensuring the maintenance of adequate 
resection margins. Right-angle scanning allowed the surgeon to modify the dissection 
if the margins seemed too close to the lesion. The plane of dissection was determined by 
the presence of air between the specimen and normal breast tissue, which was clearly 
visible on the US image, thereby ensuring that the tumour remained surrounded by an 
appropriate margin of normal breast tissue (Figure 3, see Appendices). The adequacy of 
the deep margin between the breast and the pectoral fascia was determined by placing 
the US transducer perpendicular to the tumour and parallel to the chest wall. Finally, 
a spherical lump of breast tissue was excised. Cavity shavings were not performed; 
specimen radiography was not used. After excision, the specimen was examined with 
US ex vivo to determine whether the tumour was completely excised (Figure 4, see 
Appendices). If the margin appeared inadequate, additional breast parenchyma could 
be excised at that site. The specimen was oriented by marking sutures such that positive 
resection margins could be identified and re-excised if necessary. 
Data 
Preoperative data included patient age, tumour localisation, tumour stage, and tumour 
type. The duration of the excision (i.e., time from the mammary incision to wound 
closure), US-findings, and difficulties or pitfalls encountered during the surgical 
procedure were reported. After tumour excision, the specimen was weighed, and the 
volume was measured by using fluid displacement, which is considered the “gold 
standard” for volume measurement. [19] The tumour diameter, histological resection 
margin status, and length of the smallest clear margin were recorded from the pathology 
reports. Margins were categorised as negative (no tumour at the surgical resection 
margin), focally positive (an area of ≤ 4 mm with tumour at the surgical resection 
margin), or positive (grossly discernible tumour > 4 mm at the surgical resection margin). 
[20-22] In cases with positive margins, re-excision or even mastectomy would be indicated, 
while focally positive margins would require either additional surgery or external beam 
radiotherapy with a directed boost to the tumour bed.
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The calculated resection ratio
To determine the excess tissue resection, the calculated resection ratio (CRR) was defined, 
whereby the specimen volume was compared to the “optimal” specimen volume. 
The optimal specimen volume was defined as the spherical tumour volume plus an 
arbitrarily chosen “optimal” 1-cm tumour-free resection margin. The tumour diameter 
was used to calculate the optimal specimen volume for each tumour using the following 
mathematical formula: 4/3π(r+1.0 cm)3. The CRR was calculated by dividing the specimen 
volume by the optimal specimen volume. In other words, in a perfect excision, the 
specimen volume would be equal to the optimal specimen volume, and the CRR would 
be 1.0. If the specimen volume is twice the size of the optimal specimen volume, then 
the CRR would be 2.0. [5,12]
Data analysis
All data were analysed by using the Statistical Package for the Social Sciences (SPSS 
statistical software, Version 15.0; SPSS, Inc., Chicago, IL, USA). Scatterplots were generated 
from time points versus the excision volume and CRR. Scatterplots were explored to 
see whether linear regression analysis was a valid method. Spearman’s correlation 
coefficients of time points versus the excision volume and CRR were applied. 
RESULTS
Patient and tumour characteristics (Table 1)
A total of 30 female patients were included in this study. The mean patient age was 53 
(range, 33-79) years. Fifteen tumours (50.0%) were localised in the left breast. Twenty-eight 
of 30 (93.3%) tumours were invasive ductal carcinomas, which frequently presented with 
a minimal additional intraductal component (50.0%). An extensive tumour-associated 
ductal carcinoma in situ (DCIS) was unexpectedly present in two cases (6.7%).
Intra-operative findings
All tumours were readily identified by US during the surgery. Most invasive ductal 
carcinomas were characterised by heterogeneous areas of low echogenicity, and showed 
posterior shadowing that was adequately recognised before and during surgery. Although 
most tumours were well defined with regular margins (Figure 5.a), some tumours 
presented features that were less easily identified by US: irregularly demarcated 
margins, angular margins, or hypoechoic spiculations. One tumour presented with a 
well-recognised hematoma, and in two cases a well defined cyst was located near the 
tumour (Figure 5.b).
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Table 1 Patient and tumour characteristics
Tumour localisation No. of patients %
Upper outer quadrant 15 50.0
Upper inner quadrant 4 13.3
Lower outer quadrant 5 16.7
Lower inner quadrant 2 6.7 
Central 4 13.3 
Mean tumour diameter in cm (range) 2.1 (0.8-4.0)
Tumour stage No. of patients %
T1 14 46.7
T2 16 53.3
Tumour type No. of patients %
Invasive ductal carcinoma 11 36.7
Invasive ductal carcinoma with DCIS 17 56.7
Invasive papillary carcinoma 1 3.3
Invasive adenosquamous carcinoma 1 3.3
Axillary surgery No. of patients %
Sentinel lymph node biopsy 24 80.0
Axillary lymph node dissection 6 20.0
 
Intra-operative re-excision was not performed. The average duration of the procedure 
ranged from 5 to 26 minutes, with a mean duration of 14 minutes. It must be noted 
that the additional time needed for US -imaging prior to the incision and for specimen 
scanning after the excision (estimated, up to 5 minutes) was not included in the reported 
procedure duration.
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Figure 5.a.  US image of a palpable malignant tumour in the upper inner quadrant of the right breast shows 
a well-defined hypoechoic mass (A), lobulated margins (B), and duct extension (C). Histologic findings were 
mixed infiltrating ductal carcinoma and ductal carcinoma in situ (DCIS); tumour diameter 2.30 cm. The 
tumour was excised with adequately negative resection margins, and the length of the smallest tumour-free 
margin was 0.4 cm. The specimen volume was 40 cm3, and the CRR was 1.01.
Figure 5.b.  US image of a palpable malignant tumour in the lower outer quadrant of the left breast shows a 
heterogeneous hypoechoic texture (A), irregular, indistinct, and angular margins (B), hypoechoic spiculations 
(C), and a small cyst (D). Histologic findings were mixed infiltrating ductal carcinoma and ductal carcinoma 
in situ (DCIS); tumour diameter 1.50 cm. The tumour was excised with adequately negative resection 
margins, and the length of the smallest tumour-free margin was 0.3 cm. The specimen volume was 25 cm3, 
and the CRR was 0.5.
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Postoperative findings
Twenty-nine tumours (96.7%) were removed with adequate, tumour-free surgical margins. 
The median smallest margin length of uninvolved breast tissue was 0.3 (range, 0.1–1.0) 
cm. In one patient, a 24-mm highly spiculated infiltrating ductal carcinoma was excised 
with focally invasive margin involvement; unexpectedly, several foci of DCIS were found 
as well, presenting 1-mm inferior to the inked margins. Because of intraductal disease, 
a re-excision was performed with a negative histologic finding. 
The median specimen weight and volume were 30.5 (range, 12.0–138.0) grams, and 29.0 
(10.0–130.0) cm3, respectively. The median CRR was 1.0 (range, 0.4–2.8). Table 2 describes 
the results on the margin statuses, resection volumes, and CRRs for the individual 
surgeons. There were no significant differences between the performances for the 
individual surgeons (P > 0.05). Figure 6 shows the improvement of excision volume and 
CRR over time for each of the breast surgeons. In the beginning of the training period, 
the surgeons tended to overexcise the tumour. However, the volumes and CRRs became 
smaller after several surgical procedures, resulting in overall optimal-volume resections. 
Spearman’s correlation coefficients of time points versus excision volumes and CRRs 
were not significant (P > 0.05). Within eight procedures, all breast surgeons achieved 
a level of competency and confidence such that they could readily incorporate the US 
techniques in the operating theatre. Post-operative complications within 30 days that 
required intervention were not reported.
Table 2 Results for margin clearance, excision volumes and CRR for surgeons I, II, and III
Surgeon I Surgeon II Surgeon III Total
Tumour-free resection 
margins (N, (%))
10 (100.0) 9 (90.0) 10 (100.0) 29 (97.7)
Weight (grams) (median, 
(range))
31.0 
(16.0 – 94.0)
34.5 
(12.0 – 75.0)
27.0 
(12.0 – 138.0)
30.5 
(12.0 – 138.0)
Excision volume
(cm3) (median, (range)) 
34.0 
(15.0 – 100.0)
34.0 
(10.0 – 75.0)
25.0 
(10.0 - 130.0)
29.0 
(10.0 – 130.0) 
CRR 
(median, (range))
1.0 
(0.5 – 1.6)
0.8 
(0.4 – 2.2)
1.1 
(0.4 – 2.8)
1.0 
(0.4 – 2.8)
CRR  Calculated Resection Ratio, indicating the excess tissue resection
Difficulties and pitfalls
Initially, the most difficult part of the procedure was to translate the US image to the 
tumour position in the breast. According to the procedure, the US probe is placed 
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perpendicular to the tumour position, and one must be careful to continue dissection 
in that direction. Also, the breast tissue should continuously be fixed in one position 
by hand or with tape, particularly when tumours are located in the outer quadrant. 
Most importantly, experience is required to identify poorly defined, irregular or angular 
tumour margins and inconspicuous spiculations. Moreover, unexpected additional 
intraductal disease can often not be detected by US. [10,23-25] 
One technical pitfall was that the US-cover sheath should perfectly fit around the US 
probe, because the interference of air within a large sheath may cause an indistinct US 
image. Furthermore, the 7-cm probe was too large to be placed within some wounds. 
The overlying skin had to be repositioned over the tumour, or the transducer had to be 
manipulated to guide the excision. Visibility markedly improved by using normal saline 
within the wound, thereby eliminating disturbing air artifacts.
 
Figure 6. Learning curves of excision volume and CRR over time for each of the breast surgeons
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DISCUSSION
Margin status
BCS has gained wide acceptance as the treatment of choice for breast cancer. So far, 
surgeons have striven to ensure a complete excision of the carcinoma; tumour-positive 
margins are associated with an increased risk of locoregional recurrence, thus requiring 
re-intervention. [15,20-22] In this hands-on training period of surgeon-performed intra-
operative US for palpable invasive breast cancer, free margins were obtained in all the 
patients but one. In retrospect, these inadequate resection margins could probably not 
have been avoided, with or without US; the tumour had infiltrating spiculations that 
were nonpalpable and not clearly visible with US. Moreover, this tumour unexpectedly 
presented with extensive DCIS.
Approximately half of all tumours presented with pre-operatively missed DCIS, which 
corresponds well with previously reported data. [5,10,12] Still, only one specimen showed 
surgical margins with DCIS. Therefore, the possible presence of tumour-associated DCIS 
does not justify excessively large resections to prevent intraductal margin involvement 
in daily practice, and will therefore not have implications for the use of intra-operative 
US. Previous studies have reported a high incidence of positive margins after initial 
palpation-guided excision, ranging from 20-60%. [5,15-17] Therefore, US-guided surgery 
seems promising for obtaining adequate, clear resection margins.
Resection volumes and calculated resection ratio’s
BCS should be an oncologically effective, as well as cosmetically acceptable treatment. 
The cosmetic outcome after BCS is strongly related to the patient’s well-being. [3,6] 
However, a number of studies have shown that the cosmetic results following BCS are 
unacceptable in as many as 40% of patients. Resection of a large volume of breast tissue is 
the key determinant. Specifically, a lump size exceeding 85 cm3 results in a significantly 
higher rate of cosmetic failures. [4,7,8] A practical guideline during surgery is to achieve 
a safe and cosmetically acceptable resection margin of 5-10 mm. [15,20,22] 
In the present study, the median resection volume was 29.0 cm3. The excision volumes 
exceeded 85 cm3 in four patients (13.3%), of whom three were treated early in the 
experience of surgeon III. The fourth patient presented with a cyst near the tumour, 
which also required excision and resulted in a large excision volume and CRR. The 
median CRR in the training period was 1.0, which implies that the median specimen 
volume was equal to the optimal specimen volume. Our previous study showed that the 
median CRR of all palpation-guided tumour excisions was 2.2. [5] Therefore, the results 
of this learning period seem promising for obtaining adequate tissue volumes as well.
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Learning curve
US-guided BCS is a rather new technique for surgeons, who require a combination of 
knowledge and judgment of US images, and must be able to translate the US images 
into the technical ability of tumour excision. Performance during the training phase 
varied among surgeons. Breast surgeon I showed the fastest progress, probably because 
of a higher level of US expertise. Surgeons II and III, who had little experience with US, 
initially felt uncomfortable in switching off their tactile perceptions to rely on the US 
images. Indeed, one difficulty in learning US-guided BCS is that tactile perception is 
limited. Tactile abilities instead must be turned into visible judgments and translated 
from the US screen into a three-dimensional orientation inside the breast. Still, the 
surgeons easily familiarised themselves with the technique and rapidly mastered basic 
US skills. One should be aware that the surgeons were not required to distinguish benign 
from malignant lesions; the surgeons’ aims were to target the breast tumour intra-
operatively with US and to excise with precision by delineating the breast volume. 
The benefits of intra-operative US-guided breast tumour localisation and excision have 
been consistently reported; US is accurate, simple, not time-consuming, and comfortable 
for the patient, and it carries a minimal risk of procedure-related complications. [9-14] 
The increasingly more important role of breast US in the intra-operative evaluation of 
breast cancer calls for efforts from surgeons to perform US-guided breast procedures, 
particularly in settings where dedicated radiologists are not readily available at all times. 
Although doubts have been addressed regarding the ability of surgeons to perform breast 
US, previous studies have shown a high accuracy of breast US performed by surgeons. 
[10,11,26-29] These findings support the conclusion that, with appropriate instruction 
and experience, breast surgeons can attain a level of competency that will enable them 
to perform US-guided BCS for palpable, and probably even impalpable, breast cancer.
Limitations of the study
Several limitations to this study need to be acknowledged. Although the surgeons 
performed well, there were only 3 subjects, and one of them had previously participated 
in radiologist-performed US-guided excisions. Additionally, none of the patients had 
presented with invasive lobular carcinoma. It may be more difficult to define margins of 
lobular breast cancer, and further work is required to evaluate the efficacy of US-guided 
excision of palpable lobular carcinomas. To calculate the optimal excision volumes, 
optimal resection margins of 1.0 cm were arbitrarily chosen. Although local recurrence 
and overall survival have proven to be unrelated to a tumour-free resection margin 
wider than 1 mm, a 1.0 cm margin is technically more feasible. [15,20-22] Moreover, to 
allow easy calculations, the formulas for the prediction of these volumes were based on 
the assumption that tumours are spherical, while in actuality, they may vary in shape. 
Furthermore, the exact data on the time needed for US-imaging prior to the incision and 
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for specimen scanning after the excision are failing, and future studies should analyse 
the time of the whole procedure. Lastly, this study was not controlled, and there was 
no evaluation of cosmetic outcome. The results of the multicentre, randomised clinical 
trial on US guided surgery for palpable breast cancer are, therefore, awaited.
CONCLUSIONS
It seems highly beneficial for surgeons to learn the skills needed to perform US-guided 
excision of palpable breast tumours. Intra-operative US allows real-time localisation 
of the breast carcinoma and subsequent planning of surgical margins, thereby 
presumably resulting in a more accurate tumour excision. The described technique is 
easy, straightforward, noninvasive, and not time consuming, and it may be learned in 
a relatively short time. In a multicentre, randomised, clinical trial, intra-operative US 
guidance for palpable breast tumours will be evaluated for margin clearance, excision 
volume, CRR, cosmetic outcomes and quality of life. The results will be compared with 
traditional palpation-guided surgery (Trial Registration Number: NTR2579). [18]
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CHAPTER 7
Intraoperative ultrasound guidance 
for palpable breast cancer excision: 
results of a multicentre, parallel 
group randomised controlled trial. 
(COBALT)
N. M. A. Krekel, M.H. Haloua, A. M. F. Lopes Cardozo, R.H. de Wit, A.M. Bosch, 
L.M. de Widt-Levert, S. Muller, H. van der Veen, E. Bergers, E.S.M. de Lange de Klerk, 
S. Meijer, M. P. van den Tol.
The Lancet Oncology, Published online ahead of print, December 4th, 2012
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ABSTRACT
Background: Breast-conserving surgery for palpable breast cancer is associated 
with both tumour-involved margins in up to 41% of cases and with excessively 
large excision volumes. Ultrasound-guided surgery has the potential to resolve 
both problems, thereby improving surgical accuracy for palpable breast cancer. 
We aimed to compare ultrasound-guided surgery with the standard for palpable 
breast cancer, palpation-guided surgery in terms of margin status and extent of 
healthy breast tissue resection.
Methods: In this comparative, parallel group randomised clinical trial, patients 
with palpable T1-T2 invasive breast cancer were recruited between October 2010 
and closing of the trial in March 2012 in 6 medical centres in the Netherlands. 
Participants were randomly assigned (1:1) by computer-generated random 
sequence via a web system, and stratified by study centre, to either ultrasound-
guided surgery or palpation-guided surgery. Patients and investigators were not 
masked to treatment assignment. The primary outcomes were surgical margin 
involvement (classified as tumour-free, focally positive, or positive), and excess 
healthy tissue resection which was defined by a calculated resection ratio (CRR) 
(derived from excision volumes and tumour diameters). Data was analysed on 
an intention to treat basis. This trial is registered at TrialRegister.nl, NTR2579.
Findings: A total of 134 patients were randomly assigned to ultrasound-guided 
surgery (n = 65) or palpation-guided surgery (n=69). A dramatic difference in 
margin involvement was seen with 2 (3%) of the 65 patients had tumour-involved 
margins in the ultrasound-guided surgery group compared to 12 (17%) of the 69 
patients in the palpation-guided surgery group (difference 14%, 95% CI 4 – 25, 
p=0·0093). Ultrasound-guided surgery also resulted in reduced excision volumes, 
38 vs. 58 cc (difference 20 cc, 95% CI 7 - 31) and reduced CRR , 1·0 vs. 1·7 (difference 
0·7, 95% CI 0·4 – 1·0), compared with palpation-guided surgery (both, p<0·002).
Interpretation: By allowing continuous intraoperative tumour visualisation, 
ultrasound-guided surgery can significantly lower the high rate of tumour-
involved resection margins following palpable breast cancer excision, thus 
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reducing the need for additional interventions, including re-excision, 
mastectomy and radiotherapy boost. In addition, through the achievement of 
optimal resection volumes, ultrasound-guided surgery significantly reduces 
unnecessary healthy breast tissue resection and may therefore contribute to 
improved cosmetic results and quality of life of breast cancer patients.
Funding: The randomised controlled trial was supported by the Dutch Pink 
Ribbon Foundation, Osinga-Kluis Foundation and Toshiba Medical Systems.
INTRODUCTION
Breast-conserving surgery (BCS) has gained wide acceptance as the treatment of choice 
for early-stage breast cancer. Over the past decades, advances in early diagnosis have been 
achieved through greater patient awareness, widespread screening mammography and 
improved imaging techniques. This has resulted in an increase in the rate of BCS and 
these procedures can now be safely offered to the majority of breast cancer patients.1-3 
One of the primary goals of BCS is to obtain tumour-free resection margins. Margins 
positive or focally positive for tumour cells are associated with an increased risk of local 
recurrence, and in case of tumour-positive margins, re-excision or even mastectomy are 
often required to achieve definite, clear margins. In cases of focally positive margins, 
either a second surgery or additional boost radiotherapy should be considered.4-7 These 
additional treatments increase patient stress and have a major impact on the final 
appearance of the breast. An important secondary goal of BCS is the achievement of a 
satisfactory cosmetic outcome. The cosmetic outcome of BCS has received increasing 
attention in recent years due to the close relationship with patient well-being and quality 
of life.8,9 The key factor in a poor cosmetic result following BCS is the volume of breast 
tissue resected, which means that a surgeons should aim for a complete excision of the 
carcinoma, while sacrificing as little healthy breast tissue as possible.10,11
In practice, the excision of a palpable breast carcinoma is guided by pre-operative 
diagnostic images and the intraoperative tactile skills of the surgeon. The somewhat 
‘blind’ approach of using palpation-guided surgery is known to be highly inaccurate, 
with studies worldwide reporting positive resection margins in up to 41% of patients.7,12-14 
Moreover, a surgeon tends to overexcise normal breast tissue in an effort to attain 
negative margins, resulting in needlessly large excision volumes.11,13 
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High-frequency real-time ultrasonography was introduced in the 1970’s and the 
technology has steadily improved, resulting in increased sensitivity, greater portability 
and the availability of ultrasonography in the operating theatre. In recent years, 
ultrasonography has emerged as an effective guidance tool during surgery and 
ultrasound-guided surgery has been introduced into breast cancer surgery as a method 
of excising nonpalpable breast cancer. An extensive body of literature has accumulated 
showing the manifold benefits of ultrasound-guided surgery over needle localisation 
for nonpalpable breast cancer excision, including improved margin clearance, fewer 
re-excision procedures, smaller excision volumes, and better lumpectomy specificity.15-19 
In light of the advantages when applied to nonpalpable masses, ultrasound-guided 
surgery for palpable breast cancer should similarly decrease margin positivity and 
excision volumes. Nevertheless, reports on the application of ultrasonography in palpable 
breast cancer excision are limited, with only a single report describing the prospective 
comparison of the outcomes of ultrasound-guided surgery with palpation-guided surgery 
in palpable invasive ductal carcinomas and showing a significant improvement of margin 
status in patients who underwent ultrasound-guided surgery.20 
The present study was designed as a randomised, controlled trial and aimed to compare 
the effectiveness of ultrasound-guided surgery in palpable invasive breast cancer with 
standard palpation-guided surgery, including the main outcomes of incidence of tumour-
involved margins and extent of healthy breast tissue resection.21
METHODS
Study Design, Randomisation and Masking
The COBALT study was a prospective, multicentre, comparative, two-arm, parallel 
randomised clinical trial undertaken in 6 hospitals in the Netherlands from October 
2010 to March 2012. A computer-generated randomisation was used by the principal 
investigators at the coordinating centre to assign patients equally to the study arms. 
Randomisation was stratified for each study centre. All patients and investigators were 
aware of study group assignments. The participating breast surgeons had all participated 
in an ultrasonography training program outside of the trial, as previously described.22 
The same breast surgeons performed both ultrasound-guided surgery and palpation-
guided surgery, without the presence of a dedicated radiologist in the operating theatre.
This study was conducted in accordance with the principles of the declaration of 
Helsinki, the guidelines for Good Clinical Practice and the CONSORT statement.23 The 
study protocol was approved by the central and local independent medical ethics review 
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boards of the participating hospitals, and the trial was registered under NTR2579 (COBALT 
study). Protocol details have been published previously.21 All patients provided written 
informed consent.
Participants
Patients were eligible to participate if diagnosed with a palpable early-stage (T1-2N0-1) 
invasive breast cancer and scheduled to undergo BCS. Breast cancer was diagnosed by 
physical examination, mammography, ultrasonography of the breast and axilla followed 
by cytological puncture or image-guided core needle biopsy. Magnetic Resonance 
Imaging (MRI) was rarely used in this study. Patients with preoperatively diagnosed 
ductal carcinoma in situ (DCIS), multifocal disease, a history of neo-adjuvant therapy, 
previous surgical treatment or radiation therapy of the affected breast were excluded 
from the study. It should be stressed that patients with invasive carcinoma with limited 
or extensive DCIS as postoperatively diagnosed by the pathologist (i.e. unexpected 
additional DCIS) were not excluded. 
Interventions
Patients were assigned to undergo either ultrasound-guided surgery or palpation-guided 
surgery. The aim in both ultrasound-guided surgery and palpation-guided surgery was 
to achieve complete tumour removal with grossly healthy tissue margins of up to 1 
cm. Ultrasound-guided surgery was performed using a THI 14-MHz ultrasonography 
probe (Toshiba Viamo portable ultrasound system, Japan), allowing continuous tumour 
visualisation during the surgical procedure. The method of ultrasound-guided surgery 
has been described previously.22 Briefly, the surgeon localised the tumour in the breast 
by palpation and ultrasonography imaging, and compared images with the digital pre-
operative ultrasonography images. The surgeon measured the tumour diameter, the 
lesion-to-skin distance and the lesion-to-fascia distance, in millimeters, and marked 
the tumour margins on the skin. These markings were used to determine the incision 
line and the extent of dissection. Dissection was further assisted by placing the 
ultrasonography repeatedly in or around the wound at different angles, continuously 
visualising the tumour margins, thereby checking the attainment of adequate resection 
margins. During the ultrasound-guided surgery surgeons did not guide their surgery by 
palpation; they merely focused on ultrasound images. Following excision, the specimen 
was scanned with ultrasonography ex vivo so that additional tissue could be excised if 
the tumour excision appeared incomplete.
palpation-guided surgery was guided by palpation in the standard manner and the fingers 
were used to palpate the tumour, retract it and guide the dissection. The adequacy of 
the resection using this approach relied on the experience and tactile abilities of the 
surgeon, and did not make use of objective imaging during the surgery.
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The orientation of the specimen was preserved with marking sutures, such that 
positive resection margins could be identified and re-excised if necessary. In neither 
of the treatment modalities were frozen section analysis, cavity shavings or specimen 
radiography performed. Axillary surgery was performed in the same surgical session, 
according to international guidelines.24,25 All cases were pre-and postoperatively reviewed 
by a multidisciplinary team, and adjuvant radiotherapy or systemic therapy was 
administered according to institutional and national guidelines. 
Study Outcomes
The first coprimary outcome was a composite of margin status and the requirements 
for additional treatment interventions. The method of pathological examination was 
standardised, according to Dutch national guidelines. Margins were categorised as 
negative, focally positive, or positive (respectively, no ink on any tumour cells, an area 
with a diameter of ≤ 4 mm with tumour, grossly discernible tumour at the inked edge 
of the specimen) in accordance with Dutch national guidelines.26 The second coprimary 
outcome was excess volume resection. A calculated resection ratio (CRR) was introduced, 
whereby the volume of the fresh specimen was measured in the operating theatre by 
fluid displacement and divided by the ‘optimal specimen volume’, defined prior to this 
study as the spherical tumour volume plus an arbitrarily chosen ‘optimal’ tumour-
free resection margin of 1 cm.13,26,27 Secondary outcomes were excision time, defined 
as the time from the first mammary incision to wound closure (in minutes), and post-
operative complications requiring intervention. Cosmetic outcomes, quality of life and 
local recurrence rates were evaluated following surgery, and will be evaluated at least 
at 3, 6 12, 24, and 36 months.
Statistical Analysis
A sample size of 120 patients gives a power of 80% to detect a 17·5% reduction in tumour-
involved margins, thereby reducing the rate of tumour-involved margin from 22·5% to 
5%. Secondly, worldwide literature and our previous retrospective multicentre study 
showed that excision volumes exceeding 85cc result in poor cosmetic outcome in 33% 
of patients. We assumed a 23% reduction in cases with excess tissue resection (from 
33% to 10%). A statistical power of 80% to detect this 23% improvement would require 
57 patients in each group. Anticipating a 10% exclusion rate, at least 132 patients would 
need to be initially recruited, and trial end was anticipated when at least 132 patients 
were recruited.13,21
All analyses were performed with Statistical Package for the Social Sciences (SPSS 
statistical software, Version 15.0; SPSS, Inc., Chicago, IL, USA) and Confidence Interval 
Analysis for Windows, which goes with the book Statistics with Confidence 2nd (Eds: 
Altman, Machin, Bryant and Gardner). Values were expressed as mean and range, and 
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percentages were given where appropriate. The two intervention groups were generally 
compared using an independent samples T-test, a Chi-square or an exact test for nominal 
data. Stratified analysis was performed post-hoc for margin status using Cochran’s test 
for conditional independence. Post-hoc stepwise linear regression analysis was applied 
for analysis of resection of excess healthy tissue resection controlled for centre and 
surgeons. The results are presented with the corresponding P values and differences 
were considered significant at P<0·05. 
This trial is registered at TrialRegister.nl, NTR2579.
Details of Funding
The Dutch Pink Ribbon Foundation provided funding for this trial, and for future related 
studies. The Osinga-Kluis Foundation provided funding for a Toshiba Viamo portable 
ultrasound system. Toshiba Medical Systems Corporation provided two extra Viamo 
portable ultrasound systems for use during the study period. The study sponsors were not 
involved in the study design, collection, analysis or interpretation of data, in the writing 
of the report, or in the decision to submit the paper for publication. All researchers were 
independent of the funders. N.M.A. Krekel, M.H. Haloua, S. Meijer and M.P. van den Tol 
had complete access to the data and were responsible for the decision to submit the 
manuscript.
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RESULTS
Patient and tumour characteristics
A total of 142 patients were enrolled from 6 hospitals in the Netherlands from October 
4th 2010 to March 22nd 2012.. Of these, 6 were excluded due to either multifocal disease 
(n=3), neo-adjuvant chemotherapy (n=2), or the absence of invasive carcinoma (n=1). Two 
patients refused to participate despite having previously given informed consent (Fig 1). 
The remaining 134 patients were randomly assigned to undergo either ultrasound-guided 
surgery (n = 65) or palpation-guided surgery (n = 69). There was no bias due to unequal 
weighting of the numbers of each procedure conducted by each surgeon. The patient 
and tumour characteristics in both study groups were comparable (Table 1), with a mean 
age of 56 years, 80 (61%) of the 132 tumours located in the upper outer quadrant, and 
a mean tumour size of 2·0 cm. All palpable invasive carcinomas were visible with the 
ultrasound-system. The majority of patients presented with invasive ductal carcinoma. 
Tumour-associated unexpected ductal carcinoma in situ (DCIS) diagnosed at pathological 
examination of the specimen was present in 84 (64%) of 132 cases. Minor lesions of 
additional DCIS inside or within several millimetres of the invasive tumour were found 
by the pathologist in 73 (55%) of the 132 specimens. In 12 (9%) of the 132 specimens a 
more extensive additional DCIS component was identified in the surgical specimen by 
the pathologist. 
Margin status
Analysis of resection margins showed a  reduced rate of invasive tumour-involvement 
when using intraoperative ultrasonography, with tumour-free margins in 63 (97%) of the 
65 patients who underwnt ultrasound-guided surgery, compared with 57 (83%) of the 69 
patients in the palpation-guided surgery group (difference 14%, 95% CI 4 – 25, p=0·0093) 
(Table 2). The mean size of the smallest tumour-free margin was 0·3 cm with ultrasound-
guided surgery, against 0·4 cm with palpation-guided surgery (range 0·1–1·0 cm, p=0·31). 
Margins were neither involved with invasive carcinoma nor unexpected additional DCIS 
in 58 (89%) of the 65 patients who underwent ultrasound-guided surgery, compared with 
50 (72%) of the patients of the palpation-guided surgery group (difference 17%, 95% CI 3 – 
30 p=0·031). Stratified analysis on margin involvement showed significant improvement 
with ultrasound-guided surgery independent of surgeons’ performance, or study centre. 
In all cases, the initial ultrasound-guided surgery excision appeared complete by using 
ultrasonography ex vivo, thus did not result in additional tissue resection. 
The improvement of margin status with ultrasound-guided surgery also resulted in 
less additional treatment in the ultrasound-guided surgery group (difference 17%, 95% 
CI 3 – 30, p=0·015, Table 2). Additional boost radiotherapy was considered sufficient for 
6 ultrasound-guided surgery patients and a re-excision was required in only 1 patient 
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Table 1. Patient and tumour characteristics
USS (n = 65) PGS (n = 69)
Age (years)* 54 (38-78) 57 (40-78)
BMI (kg/m2)* 26 (19-41) 27 (20-48)
Bra cup size* C (A-G) C (A-E)
Location carcinoma
Upper outer quadrant (%) 32 (49) 48 (70)
Upper inner quadrant (%) 12 (18) 7 (10)
Lower outer quadrant (%) 16 (25) 9 (13)
Lower inner quadrant (%) 5 (8) 5 (7)
Tumour size (cm)^ (range) 2.0 (0·6 – 4·1) 2.0 (0·5-4·5)
Tumour stage
T1 36 (55) 35 (50)
T2 29 (44) 34 (49)
Type carcinoma
Invasive ductal carcinoma (%) 61 (94) 62 (90)
Invasive lobular carcinoma (%) 1 (1) 4 (6)
Other (%) 3 (5) 3 (4)
Aditional DCIS
Limited (%) 38 (59) 35 (50)
Extensive (%) 5 (8) 7 (10)
Axillary surgery 
Sentinel lymph node only (%) 50 (77) 58 (84)
Axillary dissection (%) 15 (23) 11 (16)
 
PGS, palpation-guided surgery; USS, ultrasound-guided surgery; *, mean (range); BMI, body mass index.
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Table 2. Margin status
Margin status USS (n = 65) PGS (n = 69)
Invasive carcinoma 
Negative (%) 63 (97) 57 (83)
Positive (%) 0 (0) 5 (7)
Focally positive (%) 2 (3) 7 (10)
Invasive carcinoma and/or unexpected additional DCIS 
Negative (%) 58 (89) 50 (72)
Positive (%) 2 (3) 9 (13)
Focally positive (%) 5 (8) 10 (15)
Additional treatment 7 (11) 19 (27)
Radiotherapy boost (%) 6 (9) 11 (16)
Re-excision (%) 1 (2) 3 (4)
Mastectomy (%) 0 (0) 5 (7)
PGS; palpation-guided surgery; USS, ultrasound-guided surgery.
due to the presence of extensive DCIS at the surgical margin. In the palpation-guided surgery 
group, 11 patients received additional boost radiotherapy, 3 patients underwent a re-excision 
and 5 patients underwent a mastectomy (in 3 cases because of massively tumour-involved 
margins following first excision and in 2 cases due to margin-positivity following re-excision).
Excess healthy tissue resection
Both specimen weight and volume were significantly lower with ultrasound-guided 
surgery than with palpation-guided surgery (Table 3). The ultrasound-guided surgery 
group showed a mean CRR of 1·0, whereas the mean CRR with palpation-guided surgery 
was 1·7 (difference 0·7, 95% CI 0·4 – 1·0, p=0·0001), indicating that while ultrasound-
guided surgery facilitates optimal volume resection, palpation-guided surgery leads to 
unnecessarily large resections. A CRR>2·0 was seen in only 5% (n=3) of the ultrasound-
guided surgery group, compared with 30% (n=20) of the palpation-guided surgery group 
(P<0·00014). Patients undergoing ultrasound-guided surgery showed 45% (n=29) of CRR>1·0,
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Fig.1 CONSORT diagram for the trial. 
PGS, palpation-guided surgery; USS, ultrasound-guided surgery
compared with 67% (n=46) with palpation-guided surgery (P=0·015). For all patients with 
positive or focally-positive margins, the mean resection volume was 53cc, and the mean 
CRR was 1·3. Linear regression analysis of excess tissue resection for different surgeons 
and centres still showed significant improvement of specimen volumes with ultrasound-
guided surgery. (5 missing values for excision volume and CRR: 1 ultrasound-guided 
surgery, 4 palpation-guided surgery)
Operative time and complications (Table 4)
Although excision time was equal between the two groups, an additional 5 minutes 
operative time were needed in the ultrasound-guided surgery group for ultrasound-
handling prior to and following the operative procedure (1 minute for sterile covering 
of the ultrasonography probe, 2-3 minutes for tumour-localisation and skin markings, 
and 1 minute for a specimen check) (difference 3 minutes, 95% CI 1 – 6, p=0·0066). 
Complications requiring intervention were infrequent and were distributed equally 
between the two groups. Cosmetic results, quality of life and local recurrence rates are 
the subjects of an ongoing evaluation, and the first results are expected in 2013.
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Table 3. Post-operative surgical measurements 
USS (n = 65) PGS (n = 69)
Difference 
(USS-PGS)
95% CI p value
Specimen weight 
(grams)* 
38 (6-138) 52 (2-156) -14 4 – 24 0·008
Specimen 
volume (cc)*
38 (7-135) 58 (10-200) -19 7 – 31 0·002
CRR^ 1.0 (0.4-2.6) 1.7 (0.3-5.4) -0·7 0·4 – 1·0 0·001
PGS, palpation-guided surgery; USS, ultrasound-guided surgery; CRR, calculated resection ratio; *, mean (range). 
 
Table 4. Operative time and complications
USS (n = 65) PGS (n = 69)
Difference 
(USS-PGS)
95% CI p value
Duration excision 
(minutes)* 
14 (6-30) 15 (2-40) -1 -2 – 4 0·38
Operative time 
(minutes) *
19 (11-35) 15 (2-40) 4 1 - 6 0·0066
Complications 4 (6) 3 (4) 1 -6 – 1·5 0·35**
Wound infection (%) 1 (2) 3 (4) -2 -5 – 11
Hematoma (%) 1 (2) 0 (0·0) 1 -4 – 8
PGS, palpation-guided surgery; USS, ultrasound-guided surgery; *, mean (range).
** p-value calculated with the use of  fisher exact-test on wound infection and hematoma crosstabulation.
DISCUSSION
Primary outcomes
The results of this multicentre, randomised controlled trial unequivocally demonstrate 
that the intra-operative use of ultrasonography significantly improves the surgical 
accuracy of palpable breast cancer excision. The rate of adequate, clear resection margins 
was exceptionally high when using ultrasound-guided surgery with tumour-free resection 
margins in over 95% of cases, almost 15% higher than with palpation-guided surgery. 
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In our study, the improved margin clearance achievable through ultrasound guidance 
lowered the rate for both additional boost radiotherapy and re-operation, thus potentially 
avoiding adverse effects on cosmesis, psychological distress and health costs. Moreover, 
ultrasound-guided surgery resulted in significantly lower excision volumes and less 
resection of healthy breast tissue, and in contrast to the excessive specimen volumes 
seen in the group that underwent palpation-guided surgery, ultrasound-guided surgery 
achieved near optimal resection volumes. It is reasonable to assume that this reduction 
in excision volumes will translate to improved cosmetic outcomes, and thereby improved 
patient satisfaction and quality of life. These data are expected in the near future. 
The dramatic improvements in surgical accuracy obtained with ultrasound-guided 
surgery are made tangible by the fact that despite the small excision volumes in the 
ultrasound-guided surgery group, the rate of tumour-free margins was high, even in 
cases with additional in situ carcinoma. DCIS is mostly located in or around the invasive 
tumour, and although the surgeons were unaware of the presence of a tumour-associated 
intraductal component - being nonpalpable and mostly invisible with ultrasonography- 
the accuracy of ultrasound-guided surgery in the localisation of the central point of the 
tumour allowed additional complete resection of DCIS. 
Additional post-hoc analyses of different surgeons and centres on margin status, excess 
healthy tissue resection and operative time showed no statistical differences, implying 
there was no difference in performance among surgeons and centres.
The benefits of an ultrasonography-based procedure over palpation-based approaches 
are clear. The only assistance during palpation-guided surgery derives from the 
surgeons’ tactile skills and pre-operative imaging. Physical examination during these 
‘blind’ palpation-guided procedures may not accurately delineate the extent of the 
breast cancer, particularly in patients with dense breasts, a palpable hematoma (from 
percutaneous biopsy) or an adjacent, palpable cyst. Furthermore, the interpretation 
of the pre-operative images in terms of the full extent and precise location of the 
carcinoma is often problematic, and patient positioning in both mammography and 
MRI (although MRI was rarely used in this study) differ considerably from that in the 
operating theatre. ultrasonography is free of all these problems. Ultrasound-guided 
surgery enables the surgeon to localise and measure the tumour precisely, to optimally 
position the incision on the breast, and to operate under direct vision. This allows the 
surgeon to reorientate intraoperatively, while continuously monitoring the attainment 
of tumour-free resection margins and avoiding unnecessary sacrifice of healthy breast 
tissue. Following the procedure, the completeness of tumour excision can be checked 
once again with ultrasonography and additional tissue can be excised if necessary.
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The benefits of intraoperative ultrasonography for nonpalpable breast cancer excision 
have been consistently demonstrated; ultrasound-guided surgery is practical, simple, time-
efficient, comfortable for the patient due to the lack of additional interventions, and it 
carries a minimal risk of procedure-related complications. In addition and most importantly, 
ultrasound-guided surgery is highly accurate in nonpalpable breast cancer and even in DCIS 
by using an appropriate marker, showing impressive overall success rates of between 81%-
97% negative margins.16,17,19,28,29  It is therefore remarkable that ultrasound-guided surgery has 
not been widely integrated into daily surgical practice and that wire-localisation remains 
the method of choice for intraoperative guidance for nonpalpable carcinomas. Possible 
explanations may be the surgeons’ lack of experience with ultrasonography and the fact 
that dedicated radiologists are not readily available at all times.
In contrast to nonpalpable carcinomas, few studies have reported the use of ultrasound-
guided surgery in palpable breast cancer. In 2001, Moore et al. were spurred to prospectively 
evaluate ultrasound-guided surgery due to the poor results obtained with palpation-guided 
surgery. Comparing 27 patients undergoing ultrasound-guided surgery for palpable invasive 
ductal breast cancer with 24 undergoing palpation-guided surgery, the results were striking; 
only 3% tumour-margin positivity was found in the ultrasound-guided surgery group, 
compared to 29% for the palpation-guided surgery group (p<0·05).20 More recently, two smaller 
retrospective studies supported the high rates of tumour-free resections margins as obtained 
with ultrasound-guided surgery, however, these authors described the use of ultrasonography 
mainly prior to incision as a method to mark the tumour extent onto the skin.  30,31
In contrast to intraoperative ultrasound-guidance, some authors describe techniques 
and devices for ex vivo specimen margin assessment following tumour excision to 
perform immediate re-excision if necessary. These techniques do not guide the surgeon 
through surgery. As described by Olsha et al. and Eichler et al., this approach resulted in 
tumour-free margins in 95% and 96% of patients, respectively.32,33 Using radiofrequency 
spectroscopy technique, the MarginProbe has recently been recommended as a device to 
ex vivo detect the presence of invasive carcinomas and even DCIS at the surgical specimen 
margins.34 The results of a clinical study showed the necessity of an intraoperative 
re-excision in 41% of cases, resulting in less secondary surgical interventions.35 The 
performance of the MarginProbe seems promising, in particular for the detection of 
DCIS which is generally ultrasonography-invisible.35,36
Our study clearly shows that intraoperative ultrasonography can significantly improve 
surgeon performance and we now strongly recommend that surgeons gain personal 
competence in the use of ultrasonography, thus avoiding the need for a radiologist and, 
most importantly, improving hand-eye coordination by single-individual performance of 
ultrasound-guided surgery. In our opinion and experience surgeons can learn the skills 
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needed to perform ultrasound-guided surgery in a relative short training period of up 
to 8 procedures. Furthermore, an ultrasound device should be available in the operating 
room, and in most clinics is already present for other procedures. Despite the greater 
use of resources, analysis showed that ultrasound-guided surgery is cost-saving due to 
an improved surgical accuracy with lower costs for additional treatment..16,22,37
This study also has a number of limitations. As study centres did not collect a screening 
log, both the total number of patients screened and deemed eligible and the reasons for 
exclusion were not fully recorded. Further, it should be noted that the definition of a 
negative resection margin remains a subject of debate, and there is still no worldwide 
consensus of what constitutes a positive or negative margin. In this trial, the Dutch 
national guidelines were applied, which state that margins are involved only when 
tumour is present at the inked margin.26 Morrow et al. suggested to end the discussion 
on margin width, as margin width is not related to higher local recurrence rates and 
negative margins should therefore be considered as margins without residual tumour 
(NSABP definition).38
It is well known that the excision of invasive lobular cancer can be complicated by 
indistinct tumour margins or inconspicuous spiculations, generally resulting in high 
rates of tumour-involved margins.13,39 As lobular carcinomas are often poorly visible 
with ultrasonography, the advantage of using ultrasound-guided surgery in lobular 
carcinomas seems limited. Only five patients with invasive lobular carcinoma have 
been included in this study, and drawing any conclusions on this subject is impossible. 
Further research should specifically evaluate the efficacy of ultrasound-guided surgery 
for lobular invasive cancer.
In conclusion, this multicentre, randomised study showed that ultrasound-guided surgery 
for palpable, invasive (ductal) carcinomas facilitates a higher rate of margin clearance 
with fewer additional treatment interventions following first excision. Ultrasound-guided 
surgery also leads to lower levels of excess tissue resection. Study follow-up will focus 
on comparisons of ultrasound-guided surgery- and palpation-guided surgery-related 
cosmetic outcomes, quality of life and local recurrence rates, with improvements with 
ultrasound-guided surgery in all areas anticipated. 
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ABSTRACT
Background: Early-stage palpable breast cancer is most commonly treated with 
palpation-guided breast-conserving surgery (PGS). Ultrasound-guided surgery 
(USS) has recently been proven to result in a significant reduction of tumour-
involved surgical margins, and thereby less re-excisions. The objective of this 
economic evaluation alongside a randomised trial was to evaluate the costs 
and benefits of USS compared to PGS, for patients with palpable invasive breast 
cancer.
Methods: Eligible patients from 6 institutions, with a palpable T1-T2 invasive 
breast cancer, were randomly allocated to PGS (n=69) or USS (n=65). The hospital 
perspective was used in the cost-benefit analysis. On the cost side of the analysis, 
resource use related to baseline treatment was taken into account and on the 
benefit side, resource use related to re-treatments was included. Differences 
in costs and benefits between the two groups were calculated. The return 
on investment was calculated by dividing the difference in benefits by the 
difference in costs. Finally, we explored the relation of cost-benefit of USS versus 
PGS and the number of patients operated on in a hospital using one US system.
Results: On the cost side, the difference in costs per patient was €193 (95% CI €153-€233) with higher costs in the USS group resulting from the use of the US 
system.  On the benefit side, the difference in costs per patient was -€349 (95% 
CI -€591 to -€103) with higher costs in the PGS group due to a larger number of 
re-treatments. In total, the sum of the cost-benefit difference amounted to a cost 
decrease of -€154 (95% CI -€388 to €81) in the USS group compared to the PGS 
group. The return on investment was 1.80 (95% CI 0.64 to 3.01). Above a threshold 
of 30 patients, use of a US system in BCS is cost-saving compared to PGS.
Conclusion: USS is both highly effective and cost-saving. USS dramatically 
reduces the rate of tumour-involved margins and thereby reduces the costs of 
re-treatment.
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INTRODUCTION
Breast cancer remains the most common cancer among women in the Western world 
and approximately 1 in 8 women will be diagnosed with breast cancer during the 
course of their lifetime, resulting in 13.000 new breast cancer cases in the Netherlands 
each year. Approaches to the surgery of breast cancer have changed dramatically over 
the past decades and the emergence of breast-conserving surgery (BCS) now allows 
the preservation of the breast without compromising oncological outcomes. The 
introduction of widespread mammographic screening, better imaging techniques, 
improved patient awareness and breast self-examination have all contributed to an 
increase in early diagnoses and accordingly, in the number of BCS procedures. Around 
75% of all breast cancer patients are eligible for BCS and BCS is now accepted as the 
treatment of choice for early-stage breast cancer.1,2
Palpable breast carcinoma is present in approximately 3 out of 4 patients and excision 
is normally guided by palpation. The success of palpation-guided surgery (PGS), i.e. 
achieving adequate tumour-free resection margins while sparing healthy breast 
tissue, depends on pre-operative imaging techniques and the experience and tactile 
abilities of the surgeon. 3-9 The somewhat ‘blind’ approach of PGS is known to be highly 
inaccurate, with studies worldwide reporting up to 25% positive resection margins 
and excessively large excision volumes.10-13 Ultrasound-guided surgery (USS) allows for 
continuous localisation of the breast carcinoma during the surgical procedure and 
results in significantly improved surgical accuracy of palpable breast cancer excision, 
with high rates of tumour-free resection margins (>96%) while also achieving optimal 
resection volumes. (Krekel 2012) Consequently, USS requires less additional treatment 
(either boost radiotherapy, re-excision or mastectomy) to obtain definite, clear margins, 
while the reduction in excision volumes and additional treatments will presumably 
result in an improved cosmetic outcome, patient satisfaction and quality of life. 
From a clinical viewpoint, all surgeons should be encouraged to perform USS. However, 
a major obstacle to the use of USS is the additional expenditure required, particularly 
the costs associated with purchasing a high-end US machine, and the costs of the extra 
operative time needed for USS. On the other hand, the improved margin clearances 
as obtained with USS eliminate the expenses associated with subsequent treatment 
for tumour-involved margins. The aim of this cost-benefit analysis, alongside our 
randomized controlled clinical trial (RCT), was therefore to weigh the additional costs 
of USS compared to PGS against the benefits of USS in terms of reduced re-treatment 
costs.
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METHODS
The study protocol was approved by the central and local independent medical ethics 
review boards of the participating hospitals, and the trial was registered under NTR2579. 
Protocol details and an evaluation of the clinical outcomes of this trial have been 
published previously.14(Krekel 2012)
Participants
Patients were eligible to participate if diagnosed with a palpable early-stage (T1-2N0-1) 
invasive breast cancer and scheduled to undergo BCS. Patients with pre-operatively 
diagnosed primary ductal carcinoma in situ (DCIS), multifocal disease, a history of neo-
adjuvant therapy, previous surgical treatment or radiation therapy of the affected breast 
were excluded from the study.
Treatment
Patients were randomised to undergo either USS or PGS. The aim in both groups was to 
achieve complete tumour removal, with healthy tissue margins of up to 1cm. USS was 
performed using a THI 14-MHz US probe (Toshiba Viamo portable ultrasound system, 
Japan). The probe was covered with a sterile glove and a plastic sheath filled with sterile 
acoustic gel. The method of USS has been described previously.15 Briefly, the surgeon 
carefully localised the tumour in the breast by palpation and US imaging. The tumour 
was then excised under continuous US imaging and control. Following excision, the 
specimen was scanned with US ex vivo to determine complete tumour excision.
PGS was guided by palpation by the surgeon in the standard manner. The fingers were 
used to palpate the mass, retract it and guide the dissection, without the use of imaging 
modalities.
In neither treatment modality were frozen section analysis, cavity shavings or specimen 
radiography performed. Axillary surgery was performed in the same surgical session, 
following international guidelines.16,17
Health outcomes
The main outcomes were margin status and the requirements for additional treatment 
interventions. Margins were categorized as negative, focally positive, or positive in 
accordance with the World Health Organization (WHO) classification. For tumour-positive 
or focally-positive margins, radiotherapy boost rates, re-excision lumpectomy rates and 
mastectomy rates were recorded.
Other outcomes included excess volume resection. A calculated resection ratio (CRR) 
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was introduced, whereby the specimen volume - measured by fluid displacement - was 
divided by the ‘optimal specimen volume’, defined as the spherical tumour volume plus 
an arbitrarily chosen ‘optimal’ tumour-free resection margin of 1 cm.10,15,18 Operative time 
(minutes) was recorded for both surgical methods.
Cost-benefit analysis
The hospital perspective was used in this cost-benefit analysis and as such, only hospital 
costs related to breast cancer were included. Since we were interested in differences 
in costs and benefits between the two groups rather than absolute costs and benefits, 
only those resource use items were included for which a difference between the groups 
was expected or considered possible. Dutch standard costs were used to value most 
resource items.19 Additional resource prices were provided by the information and cost 
management department of the VU University Medical centre Amsterdam, Netherlands 
(VUMc).
Relevant costs (Table 1)
The cost side: baseline treatment
Costs concerned resource use related to the index operation. Resource items included 
for the cost side of the analysis were use of the US system and operative time. Costs of 
complications were not included, because no differences were expected between the 
groups.
The costs for operative time were calculated by multiplying individual operative times 
(in hours) by a cost price per hour. Operative time was measured on an individual level 
and defined as the time from incision to wound closure. The extra time for the pre- and 
post-surgical use of the US system (5 minutes) was added to the US group. The cost price 
per hour included operating room time and salary for operating room personnel (two 
nurses, one breast surgeon, one intern and an anaesthesiologist), with the prices for 
separate items provided by the VUmc. The total cost of one hour operative time was €1020 or €17 per minute. 
The average cost per patient of using the US system was estimated to be €127. This price 
was derived as follows; although various US systems are available, ranging in price from €28,950 to €58,500, excluding VAT, a high-end €58,500 US system was used in this study 
and these costs were applied in the analysis. With an estimated 7-year durability of the 
US system, the US costs were €8,357 per year. A mean of 68 patients with palpable breast 
cancer are expected to be operated on with a US system per year in each hospital in the 
Netherlands, leading to an estimated €8,357/68, or €123,- per patient. In addition, a 
sterile small T-shaped latex-free probe cover with gel was used during each procedure, 
at a cost of €4.
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Table 1. Relevant costs
Price of ultrasound machine €58.500
Probe cover per unit €4
Price of ultrasound pp.* €127
OR-price per minute €17
Boost price per fraction €180
Total costs radiotherapy boost** €900
Outpatient clinic visit €87
Hospital stay per day €365
Pathological evaluation €465
Re-excision €1.217
Total costs re-excision*** €3.034
Mastectomy €1.823
Total costs mastectomy**** €3.105
US = Ultrasound
* Based on an assumed number of 68 patients per hospital per year and a 7-year use of the ultrasound system. 
(€58,500/(7*68)). Includes an additional €4 is for the ultrasound probe cover.
** Includes 5 additional fractions of radiotherapy. 
*** Includes a 1-day hospital stay, one additional outpatient clinic visit, radiotherapy boost, and pathology.
**** Includes 2-day hospital stay, one additional outpatient clinic visit, and pathology.
The benefit side: additional radiotherapy boost and surgery
Benefits included resource use related to the number of re-operations (either re-excision 
or mastectomy), pathology investigations of re-excisions and mastectomies, hospital 
days, number of visits to the outpatient clinic and number of additional radiotherapy 
boosts were included.  
According to the 2012 Dutch national guidelines for radiotherapy, all patients younger 
than 50 years and patients older than 50 years with involved margins, DCIS and 
angioinvasion receive boost radiotherapy (21 fractions of 2.2 Gy with an integrated boost 
on the tumour bed of 2.67 or 2.85 Gy). Women older than 50 years and without margin 
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involvement receive 16 fractions of 2.67 Gy. In cases with margin involvement and a 
patient age above 50 years (excluding patients undergoing mastectomy), 5 additional 
fractions of radiotherapy are required at a total cost of €900.
The cost of a re-operation was calculated using prices for surgery based on hospital 
costs, the costs of the pathology evaluation, a one-day hospital stay and an additional 
outpatient visit one week following surgery. With additional radiotherapy, the total cost 
of a re-excision was estimated at €3034.
For mastectomy, a two-day hospital stay and one additional outpatient visit is required 
in addition to the surgery and the pathological evaluation. No additional radiotherapy 
boost is administered following mastectomy. The total costs for a mastectomy amounted 
to €3105.
Pathology costs included histopathology and quantitative analysis of the surgical 
specimen.
Statistical Analysis
The statistical analysis of the clinical outcomes of USS and PGS was reported previously. 
(Krekel 2012) As cost data is typically skewed, confidence intervals for cost differences 
cannot be estimated with conventional methods that assume normality. We therefore 
applied bias-corrected accelerated bootstrapping techniques, i.e. 2000 samples of the 
same size as the original dataset were sampled with replacement from the data.20-22 These 
resamples were used to estimate 95% confidence intervals for the differences in costs and 
benefits between the two groups. The results were represented in a cost-benefit plane. For 
the cost-benefit analysis, the difference in baseline costs was compared to the difference 
in retreatment costs between the two groups. Total cost-savings or cost-expenditures were 
calculated by summing the differences in costs and benefits. The return on investment 
was calculated by dividing the difference in benefits by the difference in costs. Finally, the 
results were extrapolated to other hospitals with differing numbers of annually-treated 
patients from the number included in this trial. Independent of the number of patients 
per year, each hospital requires one US system in order to perform USS and as such, the 
average cost of USS per patient depends on the total number of patients treated per year. 
We explored the relation between the return on investment and the total cost-savings or 
cost-expenditure on the one hand, and the number of patients treated per year on the 
other hand, by varying the cost price of use of the US system per patient.
Statistical Analysis was performed with Statistical Package for the Social Sciences (SPSS 
statistical software, Version 15.0; SPSS, Inc., Chicago, IL, USA) and Stata SE 12.
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RESULTS
Patients
From October 2010 through March 2011, a total of 142 patients were enrolled from 
6 hospitals in the Netherlands. Of these, 8 were excluded for various reasons. The 
remaining 134 patients were randomly assigned to undergo either USS (n=65) or PGS 
(n=69). The patient and tumour characteristics of the patients in the two study groups 
were comparable. Full details of patient characteristics are available in the clinical papers. 
(Krekel 2012)
Health effects
Margin involvement and additional treatment
Analysis of resection margins showed a reduction in invasive tumour-involvement when 
using intraoperative US, with tumour-free margins in 96.9% of all USS, compared with 
82.6% in PGS (P<0.01). Margins were tumour-free for invasive carcinoma and unexpected 
additional DCIS in 89.2% of USS, compared with 72.5% of PGS cases (P<0.04). 
The improvement of margin status with USS resulted in less additional treatments 
in the USS group (P<0.04). Only 1 USS needed a re-excision and no mastectomies were 
required in the USS group. Additional boost radiotherapy was considered sufficient for 
an additional 6 patients. In the PGS group, 3 patients underwent a re-excision, 5 patients 
underwent a mastectomy and 11 patients received additional boost radiotherapy. (Table 2)
Table 2. Additional treatment
USS (n = 65) PGS (n = 69) P
Total 7 (10.8) 19 (27.5) 0.015
Mastectomy (%) 0 (0.0) 5 (7.2)
Re-excision (%) 1 (1.5) 3 (4.3)
Radiotherapy boost (%) 6 (9.2) 11 (15.9)
PGS; palpation-guided surgery; USS, ultrasound-guided surgery.
Operative time
Although the mean excision time was equal for both USS and PGS (respectively 13 minutes 
[range, 6-30] and 14 minutes [range, 2-40]) (P>0.05), an additional 5 minutes were needed 
for US handling prior to and following the operative procedure (1 minute for sterile 
covering of the US probe, 2-3 minutes for tumour-localisation and skin markings, and 
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1 minute for a specimen check). For this reason, 5 minutes were added to the operative 
time of patients in the USS group €85 additional operative time costs for USS). 
Cost-Benefit analysis
The 2000 bootstrap estimates of the difference in costs and benefits between the USS and 
PGS groups are shown in a cost-benefit plane in Figure 1. Cost differences are depicted 
on the y-axis and benefits on the x-axis. Note that the x-axis is inverted to show negative 
differences, i.e. cost savings, on the right. On the cost side, the difference in costs per 
patient was €193 (95% CI €153 to €233) with higher costs in the USS group. On the 
benefit side, the difference in costs per patient was €-349 (95% CI €-591 to €-103) with 
higher costs in the PGS group due to a larger number of re-treatments. In total, the sum 
of the differences in costs and benefits amounted to cost-savings of €-154 (95% CI €-388 
to €81) in the USS group compared to the PGS group. The return on investment was 1.80 
(95% CI 0.64 to 3.01), which means that on average 1.8 times more benefits than costs 
are obtained in the USS group compared to the PGS group. Note that the confidence 
interval is very broad, which is caused by the large variability in costs in the two groups.
Extrapolation of the results to other hospitals
In this trial, the average cost price for the US system per patient was €127. In Table 3, 
the average cost price is shown for a total of 50, 100, 150 or 200 patients treated per year 
using one USS system. For each of these cost prices, the average return on investment 
is shown and the 95% confidence interval. Above 150 patients per year, the return on 
investment is higher than 2.79 and statistically significant.  
Table 3. Return on investment
Number of patients 
receiving USS
US system costs per 
patient (€)
Average return on 
investment
95% Confidence 
Interval
50 171 1.46 0.51 – 2.46
68 127 1.80 0.64 – 3.01
100 88 2.27 0.81 – 3.82
150 60 2.79 0.99 – 4.74
200 46 3.15 1.13 – 5.46
USS: ultrasound-guided surgery; US: ultrasound
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Figure 1. Cost benefit plane.
Figure 2. Total cost-savings (minus [costs+benefits]) per volume of patients treated, using one US system 
relative to PGS (including 95% confidence intervals estimated by bootstrapping).
 
Figure 2 shows the cost-savings (minus (costs + benefits)) of USS relative to PGS for the 
total patient volume that is treated using one US system. With patient volumes below 
30 the cost-savings are negative, indicating that use of the US system amounts to cost 
expenditure. Above 30 patients, use of the USS system leads to cost savings. These savings 
increase linearly with patient volume, reaching €47,000 when 200 patients per year 
are treated using USS-BCS. Note that the 95% confidence intervals are broad, due to the 
large individual variability in costs. The lower limit of the cost-savings is positive (i.e. 
cost-saving) for patient volumes above 200.
Proefschrift_Nicole_v17.indd   130 04-12-12   15:25
Ultrasound-guided surgery for palpable breast cancer is cost-saving
C
h
ap
te
r 
8
131
 
Figure 3. Mean cost-savings (minus [costs+benefits]) per patient treated, using one US system relative to PGS 
(including 95% confidence intervals estimated by bootstrapping). 
Figure 3 essentially shows the same results, but here the average cost per patient is 
depicted on the y-axis. It is interesting to see that whereas total cost savings increase as 
the patient volume increases, the average cost-saving per patient reaches an asymptote 
of around €240 for patient volumes above 150.
Extrapolation to the Dutch patient population
Patient volumes in the Netherlands 
Approximately 13,000 patients are diagnosed in the Netherlands with breast cancer 
each year, of whom 9,000 undergo BCS. Of the breast tumours approximately 75% are 
palpable, thus 6,750 breast cancer patients are suitable for ultrasound-guided excision. 
Approximately 100 hospitals perform breast cancer surgery, thus 68 patients per hospital 
per year could benefit from USS. This means that total healthcare costs for BCT in the 
Netherlands could be decreased by €1,001,655 per year through the use of USS. Greater 
cost-savings might be achieved through the concentration of healthcare, when fewer 
hospitals operate on higher volumes of patients with palpable breast cancer.
DISCUSSION
Breast-conserving therapy (BCT) has gained wide acceptance as the treatment of choice 
for early-stage breast cancer. The surgical accuracy of palpable breast cancer excision is 
significantly improved by the use of USS, as shown by both exceptionally high rates of 
tumour-free resection margins and optimal resection. Resulting in a lower number of 
re-excisions, mastectomies and additional radiotherapy boosts. Consequently, the benefits 
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expressed in monetary units were significantly larger in the USS group than in the PGS 
group, with the re-treatment related healthcare costs €349 lower for USS than for PGS. 
On the other hand, costs related to the use of the US system during initial treatment were 
significantly higher in the USS group, but as this difference was only €193 the average 
return on investment was 1.8. Varying the number of patients per US system, and as 
such the US price per person, showed that for any number of patients above 30, use of 
a US system in BCS is cost-saving. As expected, with an increase in patient volume, total 
cost savings also increase but the average cost-savings per patient reaches an asymptote 
above a volume of 150 patients. An average clinic operating 68 patients per year would 
save around €10,000 annually.
It should be noted that although the benefits of intraoperative US over needle localization 
have been consistently demonstrated, USS for non-palpable breast cancer was not 
evaluated in this trial. USS may lead to even greater cost-savings when applied to non-
palpable breast cancer.
US-guided excision is a widely available and feasible tool. The technique is easy, 
straightforward, non-invasive, not time consuming, and it can be learned in a relatively 
short time.15 Furthermore, as USS does not require additional interventions, such as 
the placement of a wire or injection of material, it allows the surgeon flexibility in 
scheduling patients. Additionally, the US system could be used for surgical purposes 
other than breast surgery alone.
In general, new treatment options for breast cancer can be justified only if they result 
in increased survival rates or improved quality of life, at acceptable costs. Margins 
positive for tumour cells are associated with an increased risk of local recurrence with 
its influence on survival, thereby affecting the amount and type of additional treatments 
that patients receive.11,23,24 These additional treatments also increase patient stress and 
have a major impact on the final appearance of the breast. The volume of breast tissue 
resected is the key factor in a poor cosmetic result following BCS and is strongly related to 
patient well-being and quality of life.25-27 In addition to the reduction in excision volumes, 
USS has the potential to achieve improved cosmetic outcomes, patient satisfaction and 
quality of life by reducing additional treatment.4,8,28 Furthermore, as USS may lead 
to fewer patients demanding reconstructive surgery due to poor cosmetic outcome, 
additional cost-savings could be achieved in the long term. 
When presenting economic evaluations alongside randomized trials, it is customary 
to include results on health-related quality of life (HR-QOL).27,29 However, economic 
evaluations including HR-QOL evidence based on validated instruments are not yet 
available for BCT and although we have not included HR-QOL in this cost-benefit 
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evaluation, the randomized trial on which this evaluation is based has repeatedly 
measured both HR-QOL and cosmetic outcomes. These results are expected in 2014.
Relatively few cost- or cost-effectiveness analyses of BCS are currently available. A study of 
the costs of treating breast cancer in the United States indicated that BCS and mastectomy 
were equally expensive.30 Other available studies reported the cumulative medical costs 
over 5 years for patients receiving mastectomy or BCS combined with radiotherapy and 
showed higher costs in the mastectomy group due to higher complication rates, higher 
inpatient-care costs and late surgical breast reconstruction.31-33 Our study is the first to 
present a cost-benefit analysis comparing two different methods of BCS.
This study has a number of limitations. As it is difficult to include the latest patterns 
of practice in terms of adjuvant therapies, especially systemic therapies following BCS, 
only USS and PGS costs due to margin involvement in patients with T1-T2 palpable breast 
cancer were included.30 Furthermore, only USS costs for palpable breast cancer excisions 
were included, while additional cost-savings may be achieved when USS is also applied 
to nonpalpable breast cancer excision. Study follow-up will focus on comparisons of 
USS- and PGS-related cosmetic outcomes and quality of life.
CONCLUSIONS
USS increases the surgical accuracy of palpable breast cancer excision as shown by a 
higher rate of margin clearance resulting in a lower need for additional treatment 
interventions following excision and lower levels of excess tissue resection. Furthermore, 
this study shows that USS is cost-saving when applied to a minimum of 30 patients per 
hospital per year, due to less re-treatment interventions for tumour-positive resection 
margins. USS is hereby recommended as the preferred method of treatment for patients 
with palpable T1-T2 invasive breast cancer undergoing BCS.
Proefschrift_Nicole_v17.indd   133 04-12-12   15:25
134
REFERENCES
1.  Fisher B, Anderson S, Bryant J et al. Twenty-year 
follow-up of a randomized trial comparing total 
mastectomy, lumpectomy, and lumpectomy plus 
irradiation for the treatment of invasive breast 
cancer. N Engl J Med 2002; 347:1233-1241.
2.  Veronesi U, Banfi A, Salvadori B et al. Breast 
conservation is the treatment of choice in small 
breast cancer: long-term results of a randomized 
trial. Eur J Cancer 1990; 26:668-670.
3.  Al-Ghazal SK, Blamey RW, Stewart J et al. The 
cosmetic outcome in early breast cancer treated 
with breast conservation. Eur J Surg Oncol 1999; 
25:566-570.
4.  Cochrane RA, Valasiadou P, Wilson ARM et al. 
Cosmesis and satisfaction after breast-conserving 
surgery correlates with the percentage of breast 
volume excised. Br J Surg 2003; 90:1505-1509.
5.  Schnitt SJ, Abner A, Gelman R et al. The 
relationship between microscopic margins of 
resection and the risk of local recurrence in 
patients with breast cancer treated with breast-
conserving surgery and radiation therapy. Cancer 
1994; 74:1746-1751.
6.  Smitt MC, Nowels KW, Zdeblick MJ et al. The 
importance of the lumpectomy surgical margin 
status in long-term results of breast conservation. 
Cancer 1995; 76:259-267.
7.  Taylor ME, Perez CA, Halverson KJ et al. Factors 
influencing cosmetic results after conservation 
therapy for breast cancer. Int J Radiat Oncol Biol 
Phys 1995; 31:753-764.
8.  Vrieling C, Collette L, Fourquet A et al. The 
influence of patient, tumor and treatment factors 
on the cosmetic results after breast-conserving 
therapy in the EORTC ‘boost vs. no boost’ trial. 
Radiother Oncol 2000; 55:219-232.
9.  Waljee JF, Hu ES, Newman LA et al. Predictors 
of breast asymmetry after breast-conserving 
operation for breast cancer. J Am Coll Surg 2008; 
206:274-280.
10.  Krekel N.M.A., Zonderhuis B.M., Muller S. et al. 
Excessive resections in breast-conserving surgery: A 
retrospective multicentre study. Breast J 2011; 17(5).
11.  Park CC, Mitsumori M, Nixon A et al. Outcome at 8 
years after breast-conserving surgery and radiation 
therapy for invasive breast cancer: influence of 
margin status and systemic therapy on local 
recurrence. J Clin Oncol 2000; 18:1668-1675.
12.  Pleijhuis RG, Graaf land M, de Vries J et al. 
Obtaining adequate surgical margins in breast-
conserving therapy for patients with early-stage 
breast cancer: current modalities and future 
directions. Ann Surg Oncol 2009; 16:2717-2730.
13.  Waljee JF, Hu ES, Newman LA et al. Predictors of 
re-excision among women undergoing breast-
conserving surgery for cancer. Ann Surg Oncol 
2008; 15:1297-1303.
14.  Krekel N, Zonderhuis B, Schreurs H et al. 
Ultrasound-guided breast-sparing surgery to 
improve cosmetic outcomes and quality of life A 
prospective multicentre randomised controlled 
clinical trial comparing ultrasound-guided 
surgery to traditional palpation-guided surgery 
(COBALT trial). BMC Surg 2011; 11:8.
15.  Krekel NMA, Lopes Cardozo A.M.F., Muller S et al. 
Optimising surgical accuracy in palpable breast 
cancer with intra-operative breast ultrasound 
- feasibility and surgeons’ learning curve. Eur J 
Surg Oncol 2011; [ter perse].
16.  Borgstein PJ, Pijpers R, Comans EF et al. Sentinel 
lymph node biopsy in breast cancer: guidelines 
and pitfalls of lymphoscintigraphy and gamma 
probe detection. J Am Coll Surg 1998; 186:275-283.
17.  Giuliano AE, Hunt KK, Ballman KV et al. Axillary 
dissection vs no axillary dissection in women 
with invasive breast cancer and sentinel node 
metastasis: a randomized clinical trial. JAMA 2011; 
305:569-575.
18.  Krekel NMA, Zonderhuis BM, Stockmann HBAC et 
al. A comparison of three methods for nonpalpable 
breast cancer excision. Eur J Surg Oncol 2011; 
37:109-115.
19.  Hakkaart-van Roijen L, Tan S, Bouwmans C. 
Handleiding voor kostenonderzoek: Methoden 
en standaard kostprijzen voor economische 
evaluaties in de gezondheidszorg. [Dutch manual 
for costing in economic evaluations]. Internet 
2012; Available from: http://www.cvz.nl/binaries/
live/cvzinternet/hst_content/nl/documenten/losse-
publicaties/handleiding-kostenonderzoek-2010.
pdf.
20.  Barber JA, Thompson SG. Analysis of cost data 
in randomized trials: an application of the non-
parametric bootstrap. Stat Med 2000; 19:3219-3236.
21.  Briggs AH, Wonderling DE, Mooney CZ. Pulling 
cost-effectiveness analysis up by its bootstraps: a 
non-parametric approach to confidence interval 
estimation. Health Econ 1997; 6:327-340.
22.  Thompson SG, Barber JA. How should cost data 
in pragmatic randomised trials be analysed? BMJ 
2000; 320:1197-1200.
23.  Kaufmann M, Morrow M, von Minckwitz G et 
al. Locoregional treatment of primary breast 
cancer: consensus recommendations from an 
International Expert Panel. Cancer 2010; 116:1184-
1191.
24.  Singletary SE. Surgical margins in patients with 
early-stage breast cancer treated with breast 
conservation therapy. Am J Surg 2002; 184:383-393.
25.  Al-Ghazal SK, Fallowfield L, Blamey RW. Does 
cosmetic outcome from treatment of primary 
breast cancer influence psychosocial morbidity? 
Eur J Surg Oncol 1999; 25:571-573.
Proefschrift_Nicole_v17.indd   134 04-12-12   15:25
Ultrasound-guided surgery for palpable breast cancer is cost-saving
C
h
ap
te
r 
8
135
26.  Sneeuw KC, Aaronson NK, Yarnold JR et al. 
Cosmetic and functional outcomes of breast 
conserving treatment for early stage breast cancer. 
2. Relationship with psychosocial functioning. 
Radiother Oncol 1992; 25:160-166.
27.  Waljee JF, Hu ES, Ubel PA et al. Effect of esthetic 
outcome after breast-conserving surgery on 
psychosocial functioning and quality of life. J Clin 
Oncol 2008; 26:3331-3337.
28.  Olivotto IA, Rose MA, Osteen RT et al. Late 
cosmetic outcome after conservative surgery 
and radiotherapy: analysis of causes of cosmetic 
failure. Int J Radiat Oncol Biol Phys 1989; 17:747-
753.
29.  Norum J, Olsen JA, Wist EA. Lumpectomy or 
mastectomy? Is breast conserving surgery too 
expensive? Breast Cancer Res Treat 1997; 45:7-14.
30.  Campbell JD, Ramsey SD. The costs of treating 
breast cancer in the US: a synthesis of published 
evidence. Pharmacoeconomics 2009; 27:199-209.
31.  Barlow WE, Taplin SH, Yoshida CK et al. Cost 
comparison of mastectomy versus breast-
conserving therapy for early-stage breast cancer. 
J Natl Cancer Inst 2001; 93:447-455.
32.  Desch CE, Penberthy LT, Hillner BE et al. A 
sociodemographic and economic comparison 
of breast reconstruction, mastectomy, and 
conservative surgery. Surgery 1999; 125:441-447.
33.  Malin JL, Keeler E, Wang C et al. Using cost-
effectiveness analysis to define a breast cancer 
benefits package for the uninsured. Breast Cancer 
Res Treat 2002; 74:143-153.
Proefschrift_Nicole_v17.indd   135 04-12-12   15:25
Proefschrift_Nicole_v17.indd   136 04-12-12   15:25
CHAPTER 9
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MINI -ABSTRACT
This systematic review represents a broad summary of current evidence relating 
to oncoplastic breast conserving surgery. Nonetheless, evidence supporting these 
approaches is currently sparse and prospective randomised controlled trials or 
prospective multicenter studies are sorely needed in order to demonstrate both 
the safety and the necessity of such procedures.
BACKGROUND
History and description of oncoplastic surgery
Breast cancer is the most common form of cancer in women, with a worldwide estimated 
incidence of 1.38 million patients per year.1 Several trials have compared the efficacy 
of mastectomy to breast-conserving surgery (BCS) followed by eradication of residual 
tumour cells by radiotherapy (referred to as breast-conserving therapy [BCT]) and found 
that disease-free and overall survival are equivalent.  The latter approach has become 
the standard of care for early-stage breast cancer and under Dutch guidelines, 75% of 
breast cancer patients qualify for BCT. 2-6
The primary goal of tumour excision using BCS is to achieve tumour-free resection 
margins. Despite the best surgical efforts, tumour-involved surgical margins still occur 
in 20-40% of all tumour excisions, leading in many cases to additional boost radiation, 
re-excision or even mastectomy.7-10 Local recurrence rates range from 2% to 5%. 4,9,11-13 It 
should also be noted that a tumour-free resection margin of >1mm is unrelated to local 
recurrence or overall survival.7 Although an important secondary goal in BCS is to achieve 
a satisfactory cosmetic outcome, a factor crucial to patient satisfaction and quality of 
life, poor cosmetic outcomes are still observed in up to 40% of patients. 14-17
Many localised tumours can be successfully treated by standard lumpectomy, but some 
lesions are difficult to excise without the risk of cosmetic deformity and/or margin 
involvement. In some cases, cosmetically favourable results can be difficult to obtain 
and an example of this is in patients with large breast tumours in relation to breast 
size. Specialized approaches to resection with concomitant reconstruction have been 
developed over the past decades and are now referred to as oncoplastic breast surgery 
(OPBS). These new surgical approaches combine oncological resection with plastic 
surgery techniques in a single procedure. Advocates of oncoplastic surgery in breast 
cancer emphasize the freedom to perform wider tumour excisions, potentially reducing 
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margin involvement and thereby retreatment resulting in lower local recurrence rates, 
in combination with adjuvant therapies. Another advantage of OPBS is the possibility 
to allow the excision of larger tumours without compromising cosmetic outcome.
OPBS is based on two broad techniques; i) volume-displacement using (dermo)glandular 
transposition of breast tissue into the resection site; ii) volume replacement using 
autologous tissues to compensate the volume loss following tumour resection. Diverse 
oncoplastic techniques are practised under the umbrella of these two forms of oncoplastic 
surgery, but in all cases, the surgeon should prepare for postoperative tumour bed 
localisation by using clips to mark the tumour bed.
Volume displacement
Volume displacement is generally used to correct small or moderate defects following 
tumourectomy and these techniques reduce the risk of a localised defect through 
glandular or dermoglandular redistribution of breast tissue.
While a wide variety of oncoplastic volume displacement techniques have been described 
in the literature, the most frequently encountered techniques are the following.18-21
1. Glandular rotation is a method of parenchymal redistribution that can be used in almost 
every location in the breast in cases of tumourectomy without skin resection. The skin 
is undermined in order to mobilise the whole quadrant and the lateral glandular flaps 
of the defects can then easily be approximated for suturing into the defect.
2. Nipple-areolar complex elevation or centralisation can be used to correct the 
nipple asymmetry that may occur when the central volume of the breast needs to 
be mobilised towards the defect. The central portion of the breast is undermined, 
separating the nipple-areola complex from the underlying breast tissue, and then 
sutured into the defect.
3. The round block technique is often used in breasts with moderate ptosis or 
hypertrophy, with tumour localisation in the periareolar region. This technique 
involves drawing circles of two different diameters around the nipple and resecting 
the intervening skin. This allows good access to the tumour site and facilitates 
quadrant resection. Reshaping is achieved by partially dissecting breast tissue off 
the pectoralis muscle, while preserving the major perforating vessels in order to 
preserve vascularisation of the breast.
4. The radial technique can be used when the tumour is located in the medial or 
lateral quadrants. Skin resection is performed in a radial manner followed by a large 
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quadrantectomy until the deep pectoral plane is reached. Partial undermining of the 
skin allows glandular rotation into the defect. Nipple-areolar complex centralisation 
can prevent upward or median deviation of the nipple.
5. Oncoplastic mamma reduction is probably the oldest OPBS technique and is often 
used in patients with large breasts for whom smaller breasts are perceived as a 
positive outcome. This technique allows wide excisions and depending on the 
location of the tumour, a lower or upper pedicled flap is preferred, using the same 
technique in the opposite breast.
Volume replacement
Volume replacement corrects a defect by replacement of the patient’s own tissue 
from a distant site. Volume replacement techniques are mainly used when a large 
resection volumes is required in relatively small breasts. In such cases the defect 
cannot be corrected by volume displacement due to a lack of remaining breast tissue. 
Several different approaches to volume replacement have been described, including 
myocutaneous, myosubcutaneous and adipose flaps;
1. Latissimus dorsi myocutaneous flap (LD) is indicated in small-breasted women. This 
myocutaneous autologous reconstruction technique uses the latissimus dorsi muscle 
and overlying skin to replace areas of excised tissue volume. A skin island with 
underlying muscle is prepared and pivoted under the axilla whilst maintaining the 
blood supply of the flap.22
2. Latissimus dorsi myosubcutaneous flap or latissimus dorsi mini flap (LDm) is 
indicated in small-breasted women where the skin overlying the tumour can be 
preserved but where replacement of the excised tissue volume needs to take place 
to preserve symmetry and improve cosmetic results. The LDm technique is similar to 
the LD technique, except that the skin overlying the LD is not used in this particular 
reconstruction.23
3. Other more complex oncoplastic volume replacement techniques for partial 
breast reconstruction have been described, using free flap reconstruction and 
microvascular anastomosis. These techniques include the transverse rectus 
abdominus myocutaneous flap (TRAM), the deep internal epigastric perforator flap 
(DIEP), the superficial inferior epigastric artery flap (SIEA), the superior gluteal artery 
perforator flap (SGAP), and the omental flap. Further techniques can be found in 
oncoplastic and plastic surgery literature.
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How the intervention might work
Oncoplastic breast surgery should only be considered when an unfavourable cosmetic 
outcome is expected with standard BCS. The choice of the technique should rely on 
a well-defined algorithm that take into account the tumour size in relation to breast 
size, location of the tumour and minimal postoperative complications. The primary 
focus in breast cancer surgery should be the effective treatment of the breast cancer 
and the oncological outcome should always prevail over the desired cosmetic results. In 
Attainment of tumour-free resection margins in OPBS is more important than ever, as 
remodelling or direct reconstruction impedes re-excision in case with positive resection 
margins.
Aims of this Systematic Review
Oncoplastic surgery has rapidly gained acceptance and is now widely practiced.24 
An extensive body of literature has accumulated over the past decade, claiming that 
oncological, cosmetic and psychological benefits can be achieved through immediate 
oncoplastic reconstruction during BCS.25,26 A summary of the evidence from this literature 
could help clinicians and patients understand both oncological and cosmetic outcomes, 
and issues of morbidity and quality of life, thus allowing informed decisions on the 
most appropriate surgical technique for the treatment of a specific breast cancer case.
The primary objectives of this systematic review were to evaluate the oncological and 
cosmetic outcomes of OPBS. The secondary objectives were to assess morbidity, quality 
of life and applied algorithms.
METHODS
Relevant studies were identified using computerised bibliographic searches of MEDLINE, 
EMBASE, and the Cochrane database (November 2011) and supplemented by a manual 
search of reference lists and the review of “epub ahead of print” articles. A comprehensive 
search was performed using the following search terms: breast-conserving surgery, 
oncoplastic breast surgery, partial breast reconstruction, reduction mammoplasty, partial 
mastectomy, immediate reconstruction and cosmesis. Additional keywords and further 
logical combinations of these and related terms were used to maximise sensitivity. The 
search included all study designs.
The search was limited to articles published in English between 2000-2011 and involving 
women with breast cancer undergoing immediate reconstruction after breast conserving 
surgery. A manual cross-reference search of the bibliographies of relevant articles was 
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conducted to identify studies not found through the computerised search. Randomised 
controlled clinical trials (RCTs), prospective observational or comparative studies with an 
oncoplastic operated patient group greater than 25 individuals were considered. Articles 
describing appropriate and recognised OPBS techniques were included (either volume 
displacement or volume replacement). No other restrictions were applied on selection.
Data Extraction
Two review authors (MHK, NMAK) independently evaluated titles and abstracts to assess 
eligibility in terms of outcome measures and study design. The authors were blinded 
to each others’ results during the review process and findings were then compared. 
Articles for which agreement could not be reached were reassessed to achieve consensus. 
Four studies were reassessed due to differing evaluations of study design, and 3 of these 
articles were subsequently excluded from the review.
RESULTS
Literature Search (Figure 1.)
Titles and abstracts of 2090 citations were identified from the MEDLINE, EMBASE 
and Cochrane searches. Following appraisal of the inclusion criteria, 88 articles were 
identified for potential inclusion and reviewed in detail. A total of 76 articles were 
excluded, leaving 12 articles to form the basis of this systematic review. 
OPBS Methodological Characteristics (Table.1)
Study Design
No RCTs were identified during the selection process. As Veiga et al. used the same study 
population in articles from 2010 and 2011, we considered both articles as one study.27,28 
Of these 11 studies, 7 were prospective observational studies and 4 were prospective 
comparative studies. Three studies compared OPBS with BCT, and 1 study compared OPBS 
with reduction mammaplasty for macromasty. All the trials were single centre studies.
Study Population
All studies recruited patients from a single clinical institution and tended to towards 
small sample sizes. Four of the studies included less than 100 patients in the OPBS 
group and none of the remaining 7 studies exceeded 200 patients. A total of 998 patients 
were treated using OPBS techniques in these prospectively monitored studies and the 
predominant histotype was invasive ductal carcinoma. The mean or median tumour 
size ranged from 22mm to 34mm.
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Figure 1 Literature search
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Breast surgeons and plastic surgeons
The majority of the operations was performed by breast surgeons, only occasionally 
assisted by plastic surgeons. Surgery was conducted without the assistance of a plastic 
surgeon in 6 studies. The first 15 patients in the study by Clough et al. were operated 
on by both a breast surgeon and a plastic surgeon. Other studies noted that breast 
surgeons had received plastic surgery training. Rusby et al. even described using volume 
replacement techniques (in particular the LDm-technique) by a trained breast surgeon 
without the help of a plastic surgeon.
OPBS techniques applied and indications
A wide variety of OPBS techniques have been developed and over 10 different techniques were 
used in the reviewed studies. Overall, the most commonly employed were volume displacement 
techniques, in particular reduction mammoplasties and glandular rotation techniques.
Clough et al. used the reduction mammaplasty with superior pedicle technique (RMsp) in 
83% of the cases, followed by a concomitant contralateral mammaplasty in 88% of cases. 
Other techniques included posterior pedicle technique (3%), and the free nipple graft (6%).
Contralateral breast surgery was performed concomitantly by Rietjens et al. in all cases of 
their series.29 Kaur et al. performed an immediate contralateral reduction mammaplasty 
in 27 patients (90%) of the oncoplastic group. Other studies performed immediate 
contralateral symmetrisation in fewer cases.
None of the studies described whether concomitant contralateral breast surgery for 
symmetrisation was planned preoperatively or chosen for during the operation. In most 
cases, the choice for an OPBS technique was based purely on the location of the tumour 
as described in oncoplastic literature, without use of a validated algorithm.
Follow-Up
Mean or median follow-up ranged from 1 month to 74 months.
Oncological Outcomes (Table 2)
Margin Involvement
Any literature review of the oncological outcomes resulting from OPBS should consider 
the limitations of the reported studies. It is important to note that the accepted definition 
of tumour-free margins is at least a 1mm distance between the cut edge of the specimen 
and the outer limit of the tumour. Greater distances are not associated with lower local 
recurrence rates, despite the aim of OPBS to excise greater volumes of breast tissue even 
for smaller tumours.7,8,10 Few of the studies reviewed heeded the internationally accepted 
descriptions of free margins, close margins and focally involved margins. Moreover, many 
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were inconsistent in their reporting of tumour and specimen size, the rate of invasive 
tumours, and in particular, the oncoplastic technique employed.
In this review, we compared the 20% to 40% positive margin rate achieved with regular 
BCS to the margin involvement results of OPBS, using the margin involvement outcomes 
of 7 prospective studies in which they were described.29-35 These studies used varying 
definitions of close margins, but they were mostly defined as a 1mm or 2mm distance 
between the cut edge of the specimen and the outer limit of the tumour.
In summary, in these 7 OPBS studies 77% to 95% of all tumours were invasive breast 
cancers. Furthermore, the use of OPBS resulted in tumour-free margins in 78% to 93% 
of cases; close margins in 3% to 13% and positive margins in 0% to 10%, resulting in a 
need for mastectomy in 3% to 16% of all cases. Specimen weight range in these studies 
was wide, ranging from 157g to 948g.
Local Recurrence
A follow-up of at least 2 years was considered relevant for the assessment of local 
recurrence. Furthermore both patient and tumour characteristics should be described 
when reporting local recurrence, so that non-invasive tumours (benign or DCIS) and 
patients who previously underwent mastectomy can be excluded. Unfortunately, 
methodological problems are still hampering many reports.
Seven studies reported local tumour recurrence, with a mean or median follow-up 
ranging from 1 month to 74 months. Four of these studies described tumour recurrence 
with mean and median follow-up periods of >24 months. 29,30,33,36 These studies indicate 
that a mean or median follow-up of more than 24 months allows the identification 
of local recurrence at rates ranging from 0% to 7%. Although the follow-up varied 
considerably, ranging from 10 to 108 months, the number of patients with a minimum 
follow-up of at least 24 months was not described. Only Rusby and colleagues noted the 
exclusion of mastectomies from local recurrence rate calculations, although they did 
not mention the exclusion of non-invasive tumours when reporting local recurrence.33
Cosmetic Outcomes (Table 3)
The cosmetic outcomes of OPBS were adequately reported in only 4 studies, and while 3 
of these described the method of cosmetic evaluation, no uniform or validated method 
was used.30,36-38 Veiga et al. described the method of cosmetic outcome assessment but 
did not describe results numerically. 28 
Together, these four studies reported good cosmetic outcomes following OPBS in 84% to 
89% of patients. Nevertheless, there was wide variation in both the manner of assessment 
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Reference
No. of 
patients
Groups Histotype
Tumor size in mm
Weight
Margin involvement Metastasis Recurrence Mortality
Bong et al., 2010 167 OPBS
IDC=127
ILC=5
DCIS=33
MC=2
Invasive: 80.2%
< 2 cm = 74 (55.2%)
> 2 cm = 60 (44.8%)
Close or involved = 37/167 (22.2%)
Re-excision = 17 (10%)
Mastectomy = 11 (7%)
Radiotherapy = 3 (2%)
Plan to reoperate = 3 (2%)
ALN status reported NR
NR
Chan et al., 2010 162 OPBS
Invasive or in situ 
carcinoma
Median 25 (6-50)
30g (3-184g)
NR NR NR NR
Clough  
et al., 2003
101 OPBS
IDC=66
IDC+DCIS=18
ILC=9
DCIS=7
Paget=1
Invasive 94%
Mean 32 (10-70)
T class in table2
Free: 90 (89%)
Focal: 4 (4%)
Extensive: 3 (3%)
Unknown: 4 (4%)
Mastectomy = 6 (6%)
Boost = 5 (5%)
13 (13%)
5 year metastasis 
free survival 82.8% 
(72.5 – 93.2%)
5 year actuarial 
local recurrence 
9.4% (1.8-16.9%)
8 died 8%
5 year  overall 
survival 95.7 % 
(91 – 100%)
Giacalone et al., 
2010
1. 31
2. 43
1. OPBS
2. 
Quadrantectomy
1:
IDC=10
ILC= 1
DCIS=8
ILC+EIC=12
Invasive: 77%
2:
IDC= 19
ILC= 3
DCIS= 6
ILC+EIC= 15
Invasive: 86%
1:
5-20mm=20
20-30mm=8
30-40mm=1
>40mm=2
Specimen Volume: 190cc 
(32-945)
2:
5-20mm=25
20-30mm=14
30-40mm=3
>40mm=1
Specimen Volume: 99cc 
(12-463)
1:
Free: 24 (77%)
Close*: 4 (13%)
Positive: 3 (10%)
2:
Free: 29 (67%)
Close*: 7 (16.5%)
Positive: 7 (16.5%)
NR NR NR
Gulcelik  
et al., 2011
1. 101
2. 185
1. OPBS
2. Macromasty
NR
Stage I and II
Breast volumes described
1:
Positive: 6 (6%)
Re-excision = 3 (3%)
Mastectomy = 3 (3%)
NR NR NR
Kaur et al., 2005
1. 30
2. 30
1. OPBS
2. 
Quadrantectomy
NR only DCIS 
involvement
1: 
DCIS= 4 
2:
DCIS= 11
Tumour size was identical 
in both groups
1.
pTis: 4
pT1: 18
pT1: 2 (bifocal)
pT2: 6
1:
Free: 25 (83%)
Close*: 4 (13%)
Positive: 1 (3%)
2:
Free: 17 (57%)
Close*: 10 (33%)
Positive: 1 (3%)
Unknown: 2 (7%)
3 patients None NR
Table 2. Oncological outcomes.
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Reference
No. of 
patients
Groups Histotype
Tumor size in mm
Weight
Margin involvement Metastasis Recurrence Mortality
Bong et al., 2010 167 OPBS
IDC=127
ILC=5
DCIS=33
MC=2
Invasive: 80.2%
< 2 cm = 74 (55.2%)
> 2 cm = 60 (44.8%)
Close or involved = 37/167 (22.2%)
Re-excision = 17 (10%)
Mastectomy = 11 (7%)
Radiotherapy = 3 (2%)
Plan to reoperate = 3 (2%)
ALN status reported NR
NR
Chan et al., 2010 162 OPBS
Invasive or in situ 
carcinoma
Median 25 (6-50)
30g (3-184g)
NR NR NR NR
Clough  
et al., 2003
101 OPBS
IDC=66
IDC+DCIS=18
ILC=9
DCIS=7
Paget=1
Invasive 94%
Mean 32 (10-70)
T class in table2
Free: 90 (89%)
Focal: 4 (4%)
Extensive: 3 (3%)
Unknown: 4 (4%)
Mastectomy = 6 (6%)
Boost = 5 (5%)
13 (13%)
5 year metastasis 
free survival 82.8% 
(72.5 – 93.2%)
5 year actuarial 
local recurrence 
9.4% (1.8-16.9%)
8 died 8%
5 year  overall 
survival 95.7 % 
(91 – 100%)
Giacalone et al., 
2010
1. 31
2. 43
1. OPBS
2. 
Quadrantectomy
1:
IDC=10
ILC= 1
DCIS=8
ILC+EIC=12
Invasive: 77%
2:
IDC= 19
ILC= 3
DCIS= 6
ILC+EIC= 15
Invasive: 86%
1:
5-20mm=20
20-30mm=8
30-40mm=1
>40mm=2
Specimen Volume: 190cc 
(32-945)
2:
5-20mm=25
20-30mm=14
30-40mm=3
>40mm=1
Specimen Volume: 99cc 
(12-463)
1:
Free: 24 (77%)
Close*: 4 (13%)
Positive: 3 (10%)
2:
Free: 29 (67%)
Close*: 7 (16.5%)
Positive: 7 (16.5%)
NR NR NR
Gulcelik  
et al., 2011
1. 101
2. 185
1. OPBS
2. Macromasty
NR
Stage I and II
Breast volumes described
1:
Positive: 6 (6%)
Re-excision = 3 (3%)
Mastectomy = 3 (3%)
NR NR NR
Kaur et al., 2005
1. 30
2. 30
1. OPBS
2. 
Quadrantectomy
NR only DCIS 
involvement
1: 
DCIS= 4 
2:
DCIS= 11
Tumour size was identical 
in both groups
1.
pTis: 4
pT1: 18
pT1: 2 (bifocal)
pT2: 6
1:
Free: 25 (83%)
Close*: 4 (13%)
Positive: 1 (3%)
2:
Free: 17 (57%)
Close*: 10 (33%)
Positive: 1 (3%)
Unknown: 2 (7%)
3 patients None NR
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Reference
No. of 
patients
Groups Histotype
Tumor size in mm
Weight
Margin involvement Metastasis Recurrence Mortality
Meretoja et al., 
2010
90 OPBS
IDC=48
ILC=18
DCIS=7
Other type or 
mixed = 17
Invasive 92%
NR
Inadequate margin and required 
mastectomy: 11 (16%)
3 (3%)
No local or distant 
recurrences
One died (1%)
Rietjens  
et al., 2007
148 OPBS
DCIS = 11 (7%)
Invasive tumours= 
137 (93%)
1-10mm=18
11-20mm=65
21-30mm=42
>30mm=19
Mean 22mm
Negative: 135 (91%)
Close*: 5 (3%)
Focally involved with DCIS: 8 (5%) 2 
reoperations
Contralateral Br: 5 mastectomies due 
to new BrCa during FU
19 (13%) 5 (3%) 11 died (7%)
Rusby  
et al., 2008
110 OPBS
IDC=81
ILC=11
DCIS=6
Other type or 
mixed = 12
Invasive 95%
36/115 multifocal
Mean tumour size: 34 (SD 18)
Weight 157 (SD 87)
115 patients for frozen section:
Free: 107 (93%)
Close*: 3 (3%)
(2 reexcisions and 1 mastectomy)
Positive: 5 (5%)
(all mastectomies)
More patients 
alive with distant 
metastasis
1 (1%)
9 died of breast 
cancer (8%)
Veiga  
et al., 2010
1. 45
2. 42
1. OPBS
2. BCS
NR NR NR NR
1. local: 2 (2%)
2.NR
NR
Veiga  
et al., 2011
1. 45
2. 42
1. OPBS
2. BCS
NR
1. T1-T2: 41
T3: 4
2. T1-T2: 42
T3: 3
NR NR
1. local: 1 (1%)
2. NR1
NR
Yang et al., 2011 58
OPBS
NR
Invasive: 83%
Stage 0 n=10 (17%0
Stage I n=32 (55%)
Stage IIa n=10 (17%)
Stage IIb n=6 (10%)
84g (29-140g)
NR NR
No local 
recurrences
NR
OPBS: OncoPlastic Breast Surgery
BCS: Breast Conserving Surgery
DCIS: Ductal Carcinoma In Situ
IDC: Invasive Ductal Carcinoma
ILC: Invasive Lobular Carcinoma
AIDH: Atypical IntraDuctal Hyperplasia
EIC: Extensive Intraductal Component
MC: Mucinous Carcinoma
* Close margins were defined as those with tumour cells between the cut edge of the specimen and the outer 
   limit of the tumour ≤2mm
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Reference
No. of 
patients
Groups Histotype
Tumor size in mm
Weight
Margin involvement Metastasis Recurrence Mortality
Meretoja et al., 
2010
90 OPBS
IDC=48
ILC=18
DCIS=7
Other type or 
mixed = 17
Invasive 92%
NR
Inadequate margin and required 
mastectomy: 11 (16%)
3 (3%)
No local or distant 
recurrences
One died (1%)
Rietjens  
et al., 2007
148 OPBS
DCIS = 11 (7%)
Invasive tumours= 
137 (93%)
1-10mm=18
11-20mm=65
21-30mm=42
>30mm=19
Mean 22mm
Negative: 135 (91%)
Close*: 5 (3%)
Focally involved with DCIS: 8 (5%) 2 
reoperations
Contralateral Br: 5 mastectomies due 
to new BrCa during FU
19 (13%) 5 (3%) 11 died (7%)
Rusby  
et al., 2008
110 OPBS
IDC=81
ILC=11
DCIS=6
Other type or 
mixed = 12
Invasive 95%
36/115 multifocal
Mean tumour size: 34 (SD 18)
Weight 157 (SD 87)
115 patients for frozen section:
Free: 107 (93%)
Close*: 3 (3%)
(2 reexcisions and 1 mastectomy)
Positive: 5 (5%)
(all mastectomies)
More patients 
alive with distant 
metastasis
1 (1%)
9 died of breast 
cancer (8%)
Veiga  
et al., 2010
1. 45
2. 42
1. OPBS
2. BCS
NR NR NR NR
1. local: 2 (2%)
2.NR
NR
Veiga  
et al., 2011
1. 45
2. 42
1. OPBS
2. BCS
NR
1. T1-T2: 41
T3: 4
2. T1-T2: 42
T3: 3
NR NR
1. local: 1 (1%)
2. NR1
NR
Yang et al., 2011 58
OPBS
NR
Invasive: 83%
Stage 0 n=10 (17%0
Stage I n=32 (55%)
Stage IIa n=10 (17%)
Stage IIb n=6 (10%)
84g (29-140g)
NR NR
No local 
recurrences
NR
OPBS: OncoPlastic Breast Surgery
BCS: Breast Conserving Surgery
DCIS: Ductal Carcinoma In Situ
IDC: Invasive Ductal Carcinoma
ILC: Invasive Lobular Carcinoma
AIDH: Atypical IntraDuctal Hyperplasia
EIC: Extensive Intraductal Component
MC: Mucinous Carcinoma
* Close margins were defined as those with tumour cells between the cut edge of the specimen and the outer 
   limit of the tumour ≤2mm
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Table 3. Cosmetic outcomes, quality of life and patient satisfaction.
Reference Cosmetic Results Cosmetic Evaluation Method Quality of Life
Quality of Life Evaluation 
Method
Patient Satisfaction
Chan et al., 2010
Patients:
Nearly identical 40%
Slightly different 45%
Clearly different 14%
Distorted 1%
Surgeons:
Nearly identical 41%
Slightly different 48%
Clearly different 11%
Distorted 0%
4 item questionnaire:
1. Satisfaction with appearance
2. Comparison with untreated breast
3. Same treatment?
4. Further surgery or reshaping?
1-3 months after surgery, before 
chemotherapy and radiotherapy
NR NR 
60% very satisfied
34% satisfied
5% acceptable
1% dissatisfied
Satisfied when percentage 
of breast volume excised 
was <20%
Clough et al., 2003
Acceptable results (excellent, 
good or fair), 88% at 2 years
82% at 5 years
Patients who received preop 
RT vs postop RT, worse results 
(42.9% vs. 12.7%) p<.002
No table, no exact description. 
Score from 1-5 on 5 parameters:
1. Volumetric symmetry
2. Shape of breast mounds
3. Symmetry of NAC placement
4. Ipsilateral and contralateral scars
5. Post irradiation sequelae
3 people evaluating: a surgeon and 2 
nonmedical raters
Mastectomies were excluded.
NR NR NR
Meretoja et al., 2005
Acceptable cosmetic results 
84% of the time
NR NR NR NR
Veiga et al., 2010 and 
2011
Higher scores for the 
oncoplastic group than the 
BCT group
Photos preop, 6 months and 12 
months postop.  4 independent 
raters, modified Garbay criteria. 2 
breast surgeons, 2 plastic surgeons 
and didn’t participate in surgery.
Significantly higher scores in 
oncoplastic group 12 months 
postop regarding:
1. Health perception
2. Vitality
3. Social functioning
4. Role emotional
5. Mental health
Medical Outcomes Study 
36-item Short-Form Health 
Survey Questionnaire
NR
Rosenberg Self Esteem 
scale was used
Yang et al., 2011
Surgeon:
Excellent 31%
Good 52%
Fair 15%
Bad 2%
Patient:
Excellent 38%
Good 45%
Fair 15%
Bad 2%
At 12 months post operatively. 
Overall result evaluated
1. Global aspect, two breasts
2. Shape
3. Size
4. Scars
5. NAC position and shape
6. Breast symmetry
7. Post irradiation sequelae
Scale from excellent to bad (4-1)
Patient appraisal also recorded
NR NR NR
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Reference Cosmetic Results Cosmetic Evaluation Method Quality of Life
Quality of Life Evaluation 
Method
Patient Satisfaction
Chan et al., 2010
Patients:
Nearly identical 40%
Slightly different 45%
Clearly different 14%
Distorted 1%
Surgeons:
Nearly identical 41%
Slightly different 48%
Clearly different 11%
Distorted 0%
4 item questionnaire:
1. Satisfaction with appearance
2. Comparison with untreated breast
3. Same treatment?
4. Further surgery or reshaping?
1-3 months after surgery, before 
chemotherapy and radiotherapy
NR NR 
60% very satisfied
34% satisfied
5% acceptable
1% dissatisfied
Satisfied when percentage 
of breast volume excised 
was <20%
Clough et al., 2003
Acceptable results (excellent, 
good or fair), 88% at 2 years
82% at 5 years
Patients who received preop 
RT vs postop RT, worse results 
(42.9% vs. 12.7%) p<.002
No table, no exact description. 
Score from 1-5 on 5 parameters:
1. Volumetric symmetry
2. Shape of breast mounds
3. Symmetry of NAC placement
4. Ipsilateral and contralateral scars
5. Post irradiation sequelae
3 people evaluating: a surgeon and 2 
nonmedical raters
Mastectomies were excluded.
NR NR NR
Meretoja et al., 2005
Acceptable cosmetic results 
84% of the time
NR NR NR NR
Veiga et al., 2010 and 
2011
Higher scores for the 
oncoplastic group than the 
BCT group
Photos preop, 6 months and 12 
months postop.  4 independent 
raters, modified Garbay criteria. 2 
breast surgeons, 2 plastic surgeons 
and didn’t participate in surgery.
Significantly higher scores in 
oncoplastic group 12 months 
postop regarding:
1. Health perception
2. Vitality
3. Social functioning
4. Role emotional
5. Mental health
Medical Outcomes Study 
36-item Short-Form Health 
Survey Questionnaire
NR
Rosenberg Self Esteem 
scale was used
Yang et al., 2011
Surgeon:
Excellent 31%
Good 52%
Fair 15%
Bad 2%
Patient:
Excellent 38%
Good 45%
Fair 15%
Bad 2%
At 12 months post operatively. 
Overall result evaluated
1. Global aspect, two breasts
2. Shape
3. Size
4. Scars
5. NAC position and shape
6. Breast symmetry
7. Post irradiation sequelae
Scale from excellent to bad (4-1)
Patient appraisal also recorded
NR NR NR
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of cosmetic outcome and the moment of cosmetic assessment. A detailed description of 
the used methods used and the results for cosmetic outcome can be found in Table 3.
Patient satisfaction
Only one study described patient satisfaction and Chan et al. used a single question 
related to patient satisfaction with the appearance of their breast.37 Of 162 patients, 94% 
were satisfied or very satisfied with the appearance of their breasts. However, patient 
satisfaction dropped significantly when the percentage of breast volume excised was 
greater than 20% of the whole breast.
Quality of life
Quality of life outcomes were only described in the study by Veiga et al.27 These authors 
compared the results following OPBS with the results following BCS, using two validated 
questionnaires (Short Form-36 and the Rosenberg-EPM Self-Esteem Scale). Twelve months 
postoperatively, the oncoplastic group showed significantly higher scores than in the BCS 
group on the items health perception, vitality, social functioning, role emotional and 
mental health.
Operative time, postoperative stay and complications (Table. 4)
Operative time was reported in 3 studies.30,32,38 In these studies, OPBS required more time 
than standard BCT, with a reported mean duration of at least twice that of regular BCS 
(1 hour and 30 minutes vs 45 minutes). Concomitant contralateral symmetrisation was 
an important factor requiring more operative time.
Most patients undergoing regular BCS leave the hospital on the day of the operation. This 
contrasts strongly with the average postoperative stay of 3 to 6 days following OPBS.30,32,34,38
Early complications (<2 months postoperatively) and late complications (>2 months 
postoperatively) were described in 7 studies.29,30,32-34,36,38 Complication rates varied widely 
among studies and an early complication rate of 20% in the OPBS group was the most 
commonly described effect.
Postoperative treatment
Several studies described the administration of adjuvant chemotherapy and postoperative 
radiotherapy according to local protocols. Clough et al. reported that a number of patients 
underwent preoperative radiotherapy until 1994, an approach that has since been 
abandoned due to poor cosmetic results.30 Radiotherapy boost for margin involvement 
was mentioned in 3 studies.29,30,32 However, none of these studies provided their definition 
of a tumour bed in the context of the larger volume of radiotherapy boost was required 
for the larger wound bed resulting from OPBS.
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DISCUSSION
Although oncological safety remains the primary concern, breast cancer surgery 
today is increasingly focussing on improved cosmetic outcomes. Oncoplastic surgery 
has evolved to meet this need and the extensive body of literature published in recent 
years demonstrates the widespread use of these techniques. This systematic review was 
stimulated by the need for an objective evaluation of the diverse aspects of current 
approaches to oncological safety and cosmetic outcomes in oncoplastic procedures.
Despite the current popularity of oncoplastic techniques, this systematic review failed to 
identify a single randomised controlled trial evaluating the effectiveness of OPBS, leaving 
only a relatively small number of prospective observational and comparative studies of 
sub-optimal quality to be considered. Methodological disparities between these studies 
made the direct comparisons of results difficult, with some comparative studies even 
including patients undergoing quadrantectomy as their BCS controls, despite the fact 
that this is not standard procedure for patients undergoing BCS. Few studies reported 
both oncological and cosmetic outcomes with sufficient follow-up (of at least 2 years). 
Furthermore, a complete description of the used OPBS techniques, radiation techniques 
and adjuvant systemic therapy were not reported in all studies, even though these factors 
have the potential to influence oncological and cosmetic outcomes.
Only Clough et al.30 presented fairly complete data and used satisfactory methodology for 
assessment of oncological and cosmetic outcomes. The incomplete reporting of current 
data and the low number of published studies might be related to the fact that OPBS is a 
relatively new approach, this conclusion being supported by the restriction of available 
literature to the last decade.
Breast surgeons and plastic surgeons
One of the problems faced by oncoplastic surgeons is the division of the surgical 
procedure into two parts (oncological and reconstructive), and the difficulty in combining 
techniques from different specialties in OPBS. Some papers described collaborations 
between breast surgeons and plastic surgeons when performing OPBS, whereas others 
described the performance of the procedure by breast surgeons trained in plastic surgery. 
No clear guidelines are currently available on requirements for performance of OPBS by 
breast surgeons, especially with regard to immediate reconstruction. Despite this lack, 
it is clear that a plastic surgeon, or a breast surgeon with plastic surgery training - thus 
with an extensive knowledge of volume displacement and replacement techniques - 
should always take part in any reconstruction.
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Indications and characteristics of the interventions
It is often reiterated that accurate preoperative evaluation of both the tumour and patient 
characteristics are key components in the success of any oncoplastic operation for breast 
cancer. However, current decision making in OPBS appears to depend predominantly 
on surgeon preference.
Most papers in this review describe volume displacement procedures, with a predilection 
for bilateral reduction mammaplasty in patients with large or ptotic breasts. Volume 
replacement techniques are mainly used in the management of smaller breasts. Besides 
invasive tumours, these studies also noted that younger patients with extensive DCIS 
should be candidates for delayed-immediate reconstruction, due to patient risk factors 
related to positive margin rate and tumour recurrence.
Oncological results
One proposed benefit of OPBS is the ability to achieve wide surgical margins, with a 
greater chance of obtaining tumour-free resection margins than with standard BCS. It 
is therefore surprising to note that tumour-free margins ranged from 78% to 93% with 
OPBS, resulting in a conversion to mastectomy in 3% to 16% of all OPBS cases. The large 
specimen volumes described in these studies (with mean weight ranging from 157g to 
948g), do not therefore always guarantee the attainment of tumour-free surgical margins.
Overall, the oncological results of the studies evaluated for this review corroborate 
the retrospective work of Fitoussi et al., which is the single largest retrospective study, 
describing the oncological and cosmetic outcomes of 540 patients over a period of two 
decades.39 This study described clear margins in 438 patients (81%), focal involvement 
in 77 patients (14%) and tumour-involved margins in 25 patients (5%). Eleven patients 
underwent re-excision (2%), 40 patients received an additional radiotherapy boost (7%) 
and 51 patients required a mastectomy (9% overall).
Historical data from major studies describe a variety of approaches to the treatment of 
margin involvement following BCS; Jacobson et al.40 allowed two excisions and obtained 
a mastectomy rate of only 0.83%. Fisher et al.4 allowed only a single attempt before 
proceeding to mastectomy and reported a 10% mastectomy rate. As OPBS allows wider 
margins, margin involvement in up to 22% of the cases seems very disappointing, 
especially when considering that clear margins in OPBS are a prerequisite for direct 
reconstruction and that a second excision may be hampered by the displacement of 
mammary tissue.
Local recurrence rates of the prospective studies included in our review (0% to 3%) 
are similar to the previously reported 2% to 5% local recurrence rates with BCT.4,13 The 
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prospective studies selected described survival rates between 92% and 99%. However, 
local recurrence was observed in 7% of cases in the large retrospective study of Fitoussi 
et al. with a 5-year survival rate of 93% and an overall and disease-free survival rate of 
88% after OPBS with additional treatment.39 A possible explanation for this difference 
may be the follow-up time of 5 years that was achieved by Fitoussi et al., compared with 
the approximatly 24 months follow-up in the studies in this review.
Cosmetic results
According to Vrieling et al.41 and personal experience, the most appropriate time to 
assess cosmetic outcome is at least 2 years postoperatively, due to the long-term effects 
of radiation. Frequently used methods to evaluate cosmetic outcome are patient self-
evaluation, panel evaluation, and Breast Retraction Assessment (BRA). Patient self-
evaluation is valuable because the subjective experience of the patient is central to 
assessment of quality of life. However, patients consistently report better scores than 
professionals.42,43 A very reliable alternative is panel-evaluation, which consists of 
evaluation of 4-point view pictures of the breasts by a panel of six professionals and 
non-professionals.16,44 A truly objective method is the measuring of changes in breast 
symmetry with BRA. In general, a combination of cosmetic assessment methods will 
produce the most reliable results. 
Oncoplastic surgery claims to improve cosmetic results by integrating plastic surgery 
techniques immediately after oncological resection of the tumour. Interestingly, cosmetic 
outcomes were reported in only 4 of 11 studies; these studies reported good cosmetic 
outcomes in 84% to 89% of patients. Only one of these four studies showed appropriate 
evaluation of cosmetic results, that of Clough et al., using an independent panel format 
and a follow-up time of at least 2 years.30
Fitoussi et al. retrospectively used the same cosmetic evaluation method as Clough et al., 
with a panel made up of a surgeon, a nurse and a layman, using a five-point scale from 
excellent to poor.39 The cosmetic outcome in this retrospective study was satisfactory 
in 98% of patients at 12 months, and in 90% of patients at 5 years following surgery.
Although there is a large disparity in follow-up periods and cosmetic evaluation methods 
between the prospective studies described here, the cosmetic outcomes following OPBS 
seem encouraging, compared to the 60% to 80% rate of acceptable cosmetic results 
generally achieved with standard BCT.
These studies also differed with regard to the timing of contralateral symmetrisation. 
Immediate contralateral breast symmetrisation was often part of OPBS procedures, 
despite an earlier report by Gray et al. describing an association between breast 
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irradiation in large breasted or heavy women and greater retraction at 5 years and 
an inferior overall cosmetic result. 45 It is worth noting that Fitoussi and colleagues 
performed symmetrisation 6 months after lumpectomy following neoadjuvant treatment, 
as they suspected an unpredictable effect of radiotherapy on the breast and a fluctuation 
of body weight during chemotherapy, although these effects were not objectified in the 
study. 39
Postoperative treatment
Radiotherapy is an essential adjunct to BCS. Both whole breast irradiation and additional 
radiotherapy boost in BCT reduce the risk of local recurrence in all patient groups by 
50%.46 While OPBS might theoretically present a problem for radiotherapy boost in terms 
of volume delineation as translation or rotation of the boundaries of the surgical cavity 
is often performed, none of the articles described the method of radiotherapy boost 
administration i.e. the definition of the tumour bed or the administration of larger 
boost volumes. Some papers mentioned the placement of surgical clips by the surgeon 
at the time of tumour resection, marking the boundaries of the surgical cavity. In their 
review on quality indicators of radiotherapy for breast cancer, Poortmans et al. stated 
that the position of surgical clips can be misleading in cases where oncoplastic surgical 
techniques are used, especially where the boost region is not the entire surgical cavity 
but the rim of residual breast tissue that surrounded the primary tumour.47 This often 
results in larger boost volumes than actually necessary and potentially leading to greater 
fibrosis and poorer cosmetic results. 47,48
As OPBS is increasingly performed, new techniques and solutions are being proposed to 
resolve the problem of greater boost volumes. Kirova et al. described a multidisciplinary 
approach for precise localisation of the breast tumour bed by placement of three or more 
clips into the tumour bed and a detailed report of the surgical procedure. 49 They also 
proposed deformation maps using deformable image fusion software to obtain a better 
definition of the tumour bed.50 However, the size of OPBS boost volumes compared to 
those used in BCT, and the concomitant long-term oncological and cosmetic outcomes 
have yet to be published.
Nevertheless, an ideal tumour bed volume may be difficult to achieve, due to the use 
of remodelling techniques in OPBS on a larger part of the breast than the tumour bed 
alone. The greater challenge in the administration of radiotherapy boost may in part 
explain the higher local recurrence rate of 6.8% described by Fitoussi et al. (compared 
to 2% to 5% in BCT).39
Postoperative surveillance is not significantly affected by the rearrangement of mammary 
tissue, according to Losken et al.51 These results corroborate with the findings of Roberts et 
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al. concerning the incidence of abnormal mammograms after reduction mammography 
and these authors stated that, despite the substantial mobilisation of tissue, postoperative 
mammography did not lead to more diagnostic interventions compared to non-operative 
controls.52 Finally, little evidence is available to suggest that greater complications 
following OPBS lead to delayed administration of chemotherapy and radiotherapy with 
only Meretoja et al. reporting no delays in adjuvant treatments.36
CONCLUSIONS
A standard claim for OPBS is that it allows wider resection margins, thereby improving 
oncological outcomes, while achieving a good cosmetic result with the breast. 
Surprisingly, this systematic review showed that large specimen volumes do not 
guarantee tumour-free surgical margins and OPBS results in only a slight improvement 
of clear margins when compared to the historical data on BCT. Moreover, as the size of 
the microscopically tumour-free resection margin is unrelated to local recurrence or 
overall survival, there is no need to excise a large volume of adjacent breast tissue with 
a tumour.7-10 As adequate administration of an additional radiotherapy boost is more 
difficult following OPBS, it is reasonable to conclude that surgeons should be reticent 
when considering OPBS techniques.Thus, more stringent patient selection is required 
and greater attention should be paid to tumour characteristics and localisation in order 
to minimise the incidence of positive margins.
Although the emerging role of OPBS holds promise, many questions remain. The first 
of these is that current indications for oncoplastic surgery are unclear. No uniform 
algorithm exists for OPBS, and decision-making often depends on surgeon preference. 
This is an important issue, as oncoplastic procedures require more extensive surgery 
with additional operation time and higher costs. The ability to identify patients at risk 
for poor cosmetic outcome at time of consultation would allow more informed choices 
in surgery. A uniform management algorithm is clearly required, and its use would 
help surgeons to adequately inform patients at the time of consultation on the surgical 
approach most likely to provide an optimal cosmetic result and highest possible patient 
satisfaction.
Secondly, adequate tumour resection should receive greater attention and oncoplastic 
surgery in particular should strive to minimise the incidence of positive margins, as 
these will often prompt a subsequent mastectomy.
The results of OPBS could be improved by the use of intra-operative tumour localisation 
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tools to visualise the breast cancer during the surgery. Ultrasound guidance during 
surgery is known to be the most accurate imaging modality currently available and is 
reported to result in high rates of tumour-free resection margin. Results of an ongoing 
randomised controlled trial (COBALT) comparing ultrasound-guided surgery to traditional 
palpation-guided surgery for palpable breast tumours, including an assessment of the 
cosmetic outcome of either technique, are expected soon.53  This study hypothesizes 
that the intra-operative use of ultrasound during standard BCS allows smaller excision 
volumes and an improved cosmetic outcome. If the tumour volume to mammary volume 
ratio is low, ultrasound-guided surgery might be sufficient to achieve both tumour-free 
surgical margins and a good cosmetic result. Consequently, the future of BCS may lie in 
ultrasound-guided surgery where it is possible to achieve reduced margin involvement 
and better cosmetic results, through minimising resection volumes. OPBS can be applied 
in cases where high excision volumes / breast volume ratios are expected, even with the 
use of intra-operative ultrasound. In these cases, the breast may still be preserved and a 
good cosmetic outcome achieved, ensuring an improvement of quality of life and overall 
psychological well-being of the patients.
Implications for research
A variety of algorithms for OPBS have been proposed with patient selection based on 
tumour location, tumour size and breast size.54-56 Patients with tumours in the lower 
quadrants were offered oncoplastic surgery more frequently, since these tumours are 
prone to poor cosmetic outcomes in regular BCS.
Although the various algorithms are well described and appear useful, they have yet to 
be studied in a well-designed, randomised controlled trial comparing OPBS with BCS.
While conducting a randomised trial could help obtain valuable evidence, many 
authors maintain that randomisation is neither feasible nor ethical when there is a 
clear preference for one treatment option over another (on the part of either the patient 
or surgeon).57,58
As this review clearly shows that there is currently insufficient evidence to support 
OPBS over BCS, we feel that randomisation between standard BCS and OPBS following 
a predefined algorithm, is easily defensible.
In conclusion, prior to the worldwide introduction of OPBS, reliable randomised clinical 
trials should be conducted to compare both the oncological and cosmetic outcomes of 
OPBS with standard BCS.
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SUMMARY
The main advantage of BCS, when compared to mastectomy, is preservation of the breast 
with concomitant improvements in the cosmetic outcomes. In addition to adequate 
tumour excision, a secondary but important goal in BCS is therefore to obtain a 
satisfactory cosmetic outcome. However, BCS is associated worldwide with high rates 
of tumour-involved resection margins, while the rates of cosmetic failure are substantial 
(up to 40% of patients). The total volume of resected breast tissue has proven to be the key 
determinant of cosmetic outcome. The adequacy of BCS therefore depends on achieving 
a complete tumour excision, while removing as little healthy breast tissue as possible. 
In Chapter 2 our doubts regarding the adequacy of BCS were confirmed in a retrospective, 
multicentre study. BCS was shown to result in high rates of tumour-involved resection 
margins and excessively large excision volumes. Outcomes were evaluated in 726 
consecutive patients undergoing BCS for invasive palpable (72%) or nonpalpable (28%) 
breast cancer, in four affiliated institutions. Excess breast tissue resection was assessed 
using the calculated resection ratio (CRR), which is the total resection volume divided 
by the optimal resection volume (tumour volume plus a margin of 1 cm healthy breast 
tissue). In an ideal situation, the total resection volume is equal to the optimal resection 
volume and CRR is 1.0. If the total resection volume is twice the size of the optimal 
resection volume, CRR is 2.0 and the excision volume is twice as large as it should be. Our 
study clearly showed that in many cases an unnecessarily large volume of healthy breast 
tissue is excised along with the tumour, while still not assuring clear margins. This was 
illustrated by the median CRR of 2.5 (0.01 – 42.93), implying that resection volumes were 
two and a half times as large as they should be. In over a third of all patients excision 
volumes exceeded 85 cm3, clearly leading to a deterioration in cosmetic outcome. A 
remarkable finding was that despite the large amount of normal breast tissue resected 
in many cases, the tumour was often located eccentrically in the surgical specimen, 
and the margins were positive or focally-positive for invasive carcinoma in over 20% of 
patients. Even in excessively large resections, corresponding to four times the optimal 
excision volume, 10.7% of the surgical margins were still positive or focally-positive. 
Interestingly, the involved margin rate was higher for the excision of palpable carcinomas 
than for the excision of nonpalpable carcinomas (22.5% and 17.4%, respectively; P = 
0.13). We concluded that concerns about inadequate resection margins and the risk of 
subsequent re-excision probably lead to an unnecessarily large resection of adjacent 
healthy breast tissue along with the tumour. The study findings suggest that a smaller 
volume of breast tissue can be excised without compromising the oncological margin 
status. Improvement of surgical accuracy is not easily accomplished however, and surgical 
factors should be modified.
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CHAPTER 2
BCS IS ASSOCIATED WITH HIGH RATES OF TUMOUR-INVOLVED 
RESECTION MARGINS (>20%), WHILE THE EXCISION VOLUMES ARE 
EXCESSIVELY LARGE (OVER 2.5 TIMES THE OPTIMAL RESECTION 
VOLUME)
In Chapter 3, the efficacy of the three most commonly used methods of BCS for 
nonpalpable invasive breast cancer, wire localisation (WL), ultrasound (US)-guided surgery 
(USS), and radio-guided occult lesion localisation (ROLL), was evaluated. Once again, 
the primary outcomes were excess tissue resection, defined as CRR, and the status of 
the surgical resection margins. A total of 201 consecutive patients undergoing BCS for 
nonpalpable invasive breast cancer in four affiliated institutions were retrospectively 
analysed. Of the 201 excisions, 117 were guided by WL, 52 by US, and 32 by ROLL. 
The median CRRs were 2.8 (WL), 3.2 (US), and 3.8 (ROLL) (WL versus ROLL, P < 0.05), 
representing a median excess tissue resection of 3.1 times the optimal resection volume. 
Interestingly, the rate of focally-positive and positive margins for invasive carcinoma was 
significantly lower with US (3.7%) compared with WL (21.3%) and ROLL (25%) (P = 0.023). 
It could be concluded that intra-operative guidance by US is the most efficient method 
of obtaining tumour-free margins in patients undergoing BCS for nonpalpable breast 
cancer. Most importantly, USS optimises the surgeon’s ability to obtain adequate margins. 
Intra-operative US is strongly recommended for the accurate intra-operative assessment 
of all echogenic nonpalpable breast tumours, and intra-operative localisation with WL 
or ROLL should be fully replaced by intra-operative US. 
CHAPTER 3
US-GUIDED SURGERY IS THE MOST ACCURATE METHOD FOR 
NONPALPABLE BREAST CANCER EXCISION, RESULTING IN EXTREMELY 
HIGH RATES (>96%) OF TUMOUR-FREE RESECTION MARGINS 
In Chapter 4, the physical changes in breast specimens in the period from excision to 
pathological evaluation were recorded, taking special note of the influence of formalin 
fixation. Previous studies have suggested that a physical deformation (‘shrinkage’) 
of the breast specimen occurs in the period between the surgical procedure and the 
pathological examination, interfering with the accuracy of the final margin assessment. 
We conducted an observational study to test these findings, including 68 breast specimens 
of consecutive patients undergoing BCS for palpable T1-2 N0-1 breast cancer in three 
affiliated hospitals. Each specimen was weighed and its volume calculated with the 
specimen length, width, and height, both immediately following excision, and after 
Proefschrift_Nicole_v17.indd   170 04-12-12   15:25
Summary and future perspectives
C
h
ap
te
r 
10
171
arrival at the pathology department. Volume displacement was used to measure the 
actual specimen volume. Pre- and post-fixation closest distances of the tumour-free 
margin were compared. It was shown that the surgical specimen weight was grossly 
similar to the actual specimen volume, and remained equal in time between the surgical 
and pathological measurements (P = 0.94). The mean (range) distance of the closest 
tumour-free margin did not change with formalin fixation (P = 0.1). We concluded that 
surgical breast specimens do not shrink in the time between the surgical procedure 
and the pathological examination, and formalin fixation does not change the size of 
the resection margin. The margin analysis and volume measurements as given in the 
pathology report are, therefore, not affected by any changes in specimen size or shape. 
An additional finding was that calculations of specimen volumes are unreliable, and 
the use of water displacement or specimen weight is recommended for accurate volume 
measurement.
CHAPTER 4
RESECTION MARGIN ANALYSIS AND BREAST SPECIMEN VOLUME 
MEASUREMENTS AS GIVEN IN THE PATHOLOGY REPORT ARE NOT 
AFFECTED BY ANY CHANGES IN BREAST SPECIMEN SIZE OR SHAPE
The efficacy of intra-operative US during the resection of nonpalpable tumours has been 
clearly demonstrated. USS allows real-time localisation of the breast carcinoma and 
subsequent planning of surgical margins. Although the surgical excision of palpable 
breast cancer can be performed with guidance from intra-operative palpation, the use of 
intra-operative US during palpable breast cancer excision may also lead to an improved 
surgical accuracy. Chapter 5 described a randomised controlled trial protocol, in which 
it was hypothesized that the use of US during the excision of palpable breast cancer 
would improve the ability to spare healthy breast tissue, while maintaining or even 
improving the oncological margin status. This randomised controlled trial (COBALT trial) 
compared US-guided breast-conserving surgery for palpable breast cancers to standard 
palpation-guided surgery (PGS), in terms of the extent of healthy breast tissue resection, 
the percentage of tumour-free margins, cosmetic outcomes and quality of life.
CHAPTER 5
THE USE OF ULTRASONOGRAPHY FOR PALPABLE BREAST CANCER 
EXCISION MAY IMPROVE HEALTHY BREAST TISSUE SPARING, WHILE 
MAINTAINING OR EVEN IMPROVING THE STATUS OF THE RESECTION 
MARGINS
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In Chapter 6, the performance of surgeons was evaluated during training for US-guided 
excision of palpable breast cancer. A hands-on training period was initiated in which 
surgeons could perform US-guided BCS for palpable breast cancer. Thirty female patients 
undergoing BCS for palpable T1-T2 invasive breast cancer were recruited. Three individual 
breast surgeons, assisted by US, targeted and excised the tumours. The main objective was 
to obtain adequate resection margins with optimal resection volumes. All tumours were 
correctly identified during surgery, and 29 of 30 tumours were removed with adequately 
negative margins. Only one tumour was removed with focally-positive margins. The 
median (range) CRR was 1.0 (0.4 – 2.8), and for all breast surgeons, the CRR improved 
during the training period. By the 8th procedure, all surgeons showed proficiency in 
performing intra-operative breast US. It was shown that surgeons can easily learn the 
skills needed to perform intra-operative US for palpable breast cancer excision. The 
technique proved to be simple, safe and effective in obtaining adequate resection margins. 
Over the training period, resection volumes improved markedly and reached optimal 
volumes, thereby presumably resulting in an improvement in cosmetic outcomes. 
CHAPTER 6
SURGEONS CAN EASILY LEARN THE SKILLS NEEDED TO PERFORM 
INTRA-OPERATIVE US FOR PALPABLE BREAST CANCER EXCISION; 
THE TECHNIQUE IS NON-INVASIVE, SIMPLE, SAFE AND EFFECTIVE IN 
OBTAINING ADEQUATE RESECTION MARGINS. 
In Chapter 7, the results were reported of a multicentre, randomised, controlled trial 
comparing USS with standard palpation-guided surgery (PGS) for palpable breast cancer, 
in terms of margin status and extent of healthy breast tissue resection. A total of 134 
patients with palpable T1-T2 invasive breast cancer were randomized to either USS (n 
= 65) or PGS (n=69). This trial clearly showed that intra-operative US guidance during 
palpable breast cancer excision results in a significant improvement in surgical accuracy. 
A dramatic difference in margin involvement was seen, with an exceptionally high rate 
of 96.9% tumour-free margins with USS, compared to 83.3% with PGS (P = 0.009), thereby 
resulting in a significantly reduced number of re-excisions, mastectomies, and irradiation 
boosts due to the use of intra-operative US. Even with the obvious improvement in 
resection margin status with USS, there were also clear benefits in excision volumes. 
While the PGS group showed excessively large specimen volumes of almost twice optimal, 
the specimen volumes with USS were significantly smaller. In fact, optimal volume 
resection was obtained with USS (38 vs. 58 cc and 1.0 vs. 1.7, respectively; both, P < 
0.002). We concluded that USS significantly lowers the unacceptably high rate of tumour-
involved resection margins following palpable breast cancer excision, thus reducing the 
need for further surgery or radiotherapy treatment. In addition, through the achievement 
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of optimal resection volumes, USS significantly reduces unnecessary healthy breast 
tissue resection and may therefore contribute to improved cosmetic results. Given the 
overwhelming advantages of USS, the results from this trial indicate that intra-operative 
US is an indispensible adjunct during palpable breast cancer excision. It is therefore 
strongly recommended that surgeons learn the skills needed to perform USS of palpable 
breast cancer. 
CHAPTER 7
ULTRASOUND-GUIDED SURGERY CAN SIGNIFICANTLY LOWER THE 
UNACCEPTABLY HIGH RATES OF TUMOUR-INVOLVED RESECTION 
MARGINS FOLLOWING PALPABLE BREAST CANCER EXCISION, WHILE 
REDUCING UNNECESSARY HEALTHY BREAST TISSUE RESECTION. 
A major obstacle to the use of USS is the additional expenditure required; in particular, 
the costs of purchasing a high-end US system and of the extra time needed for USS. On 
the other hand, improvements in margin clearance save the expense of subsequent 
re-excisions, mastectomies, or radiotherapy boosts. Chapter 8 reports an economic 
evaluation, alongside the randomised trial, of the cost-benefit of USS compared to PGS 
for patients with palpable invasive breast cancer. On the costs side, higher costs were 
found in the USS group due to use of the US system (€193 [95% CI €153€233]). However, 
on the benefit side, higher costs were found in the PGS group due to a larger number 
of re-treatments. In total, the sum of the differences in costs and benefits amounted to 
a decrease in costs of -€154 (95% CI -€388 to €81) with USS. The return on investment 
was 1.80 (95% CI 0.64 to 3.01). Above a threshold of 30 patients, use of a US system in 
BCS is cost-saving compared to PGS. We concluded that USS is both highly effective and 
cost-sparing. 
CHAPTER 8
ULTRASOUND-GUIDED SURGERY IS BOTH HIGHLY EFFECTIVE AND 
COST-SPARING COMPARED WITH PALPATION-GUIDED SURGERY
The excision of certain breast cancers still presents a considerable challenge, and 
specialized approaches combining oncological surgery and plastic surgery techniques 
- collectively referred to as oncoplastic breast surgery – are widely used to improve 
both the cosmetic and oncological outcomes of these breast cancers. The choice of the 
technique should rely on a well-defined algorithm that takes into account the size of 
the tumour in relation to breast size, location of the tumour and minimal postoperative 
complications. Chapter 9 provides a summary of the various oncoplastic techniques 
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with their advantages, limitations and indications. Furthermore, the oncological and 
cosmetic outcomes of the various oncoplastic procedures, and the morbidity, quality of 
life and applied algorithms were systematically reviewed and evaluated. A total of 2090 
abstracts on the topic of oncoplastic breast surgery published between 2000 and 2011 
were evaluated, and 88 articles were identified for potential inclusion and reviewed 
in detail by the lead authors. No randomised controlled trials were identified. Eleven 
prospective observational or comparative studies fulfilled inclusion criteria and were 
selected. In these studies, 80% to 93% of the tumours were invasive breast cancers. 
Tumour-free resection margins were observed in 78% to 93% of cases, resulting in a 
3% to 16% mastectomy rate. Local recurrence was observed in 0% to 7% of the patients. 
Good cosmetic outcome was achieved in 84 to 89% of patients. Decision-making for 
the indications and type of surgery often depended on surgeon preference, without 
the use of a uniform algorithm. Most studies also showed significant weaknesses that 
negatively influenced generalizability, including lack of adequate design and important 
methodological shortcomings. We concluded that current evidence supporting the 
efficacy of oncoplastic breast surgery is based on poorly designed and underpowered 
studies. Given the increasing importance and application of oncoplastic breast surgery, 
a well-defined indication algorithm should be applied, thus allowing informed decision-
making on the most appropriate surgical technique for the treatment of a specific breast 
cancer case. In conclusion, there is a pressing need for robust comparative studies of 
oncoplastic breast surgery, including both randomized controlled trials and well-
designed, multicenter prospective longitudinal studies.
CHAPTER 9
THERE IS A PRESSING NEED FOR WELL-DESIGNED COMPARATIVE 
TRIALS TO EVALUATE THE RESULTS OF ONCOPLASTIC BREAST SURGERY 
AND ASSESS INDICATONS
 
FUTURE PERSPECT IVES
Intra-operative ultrasonography to eliminate surgical inaccuracy 
The results from this thesis clearly show that breast-conserving surgery (BCS) for 
both palpable and nonpalpable breast cancer is highly inaccurate. Current rates of 
tumour-involved resection margins are unacceptably high and lead to a huge number 
of re-excisions, mastectomies, or additional radiation boosts. In addition, the very 
high rates of excessive healthy breast tissue resection contribute to the frequently 
unsatisfactory cosmetic results. This inaccuracy of  BCS procedures is universal and 
present in institutions worldwide, affecting all surgeons, and applies to both standard 
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BCS and oncoplastic breast surgery. Consequently, there is an urgent need for a dramatic 
improvement in surgical techniques.
The intra-operative use of US has been proven to significantly improve the surgical 
accuracy of BCS. Firstly and most importantly, the problem of tumour-involved resection 
margins is virtually resolved through the continuous visualisation of the breast cancer 
with intra-operative US. Secondly, US-guided BCS results in optimal breast volume 
resection. The capability to guide procedures, through real-time tumour visualisation, 
is a unique feature of intra-operative US for which no other localisation technique can be 
substituted. Given the overwhelming advantages of intra-operative US, this tool should 
be considered an essential adjunct during BCS for both nonpalpable and palpable breast 
cancer excision. All ‘blind’ palpation-guided procedures should be fully abandoned and 
replaced by US-guided surgery. In cases where US-guided surgery is impossible other 
localisation methods, such as wire-localisation or radio-guided occult lesion localisation 
should be applied. 
The future role of intra-operative ultrasonography
The future role of intra-operative US will be brought about by a combination of 
technological advances and surgical experience with US. Some predictable issues 
concerning intra-operative US include improvement in instrumentation and 
incorporation of new US technology. New, small probes, suitable for small mammary 
wounds, and more user-friendly, portable scanners will be developed (i.e. an I-phone 
App); the resolution of US will further improve, and the refinement of three-dimensional 
images will simplify the use of intra-operative US for planning and guiding tumour 
excision.1 Furthermore, a wireless connection between the operating room and the 
radiology department should become available, enabling surgeons to consult the 
radiologist at any time during the surgical procedure. 
Ultrasound-training
Although the surgeon performing adequate US will clearly achieve a better surgical 
performance, the main obstacle to the wider use of intra-operative US among surgeons 
is the fact that most surgeons have little experience of the technique. Despite the clear 
benefits of intra-operative US in breast cancer surgery, this lack of personal experience 
with the US technique may cause surgeons to be hesitant in the use of US. Indeed, if intra-
operative US is carried out without sufficient specific preparation qualified training, the 
advantages of the technique will be lost. It is also important to be aware that the surgeon 
should not be required to distinguish benign from malignant lesions; the surgeon’s 
aims should be to target the breast tumour intra-operatively with US and to carry out a 
precise excision by delineating the tumour volume. 
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US-guided BCS is a relatively new technique for most surgeons, and requires a 
combination of knowledge and judgment of US images in order to be able to translate 
the US images into the technical ability of tumour excision. Intensive education of 
surgeons in the use of US will help to alleviate problems, and studies have shown that, 
with appropriate instruction and experience, surgeons can easily learn the skills needed 
to perform USS.2-9 Educational issues will undoubtedly be quickly resolved when surgeons 
become convinced of the value of intra-operative US and are sufficiently interested in 
performing intra-operative US themselves. 
In the coming years, both surgeons and patients should therefore be actively informed 
of the benefits of US-guidance during BCS. Furthermore, increased formal training and 
credentialing in US of surgeons will emerge as an important issue. US-training could be 
considered as early as in medical school, while training and credentialing in US should 
be introduced for surgical residents and surgeons, as these are essential aspects for the 
worldwide implementation of intra-operative US. Only through an active educational 
program will the intra-operative use of US by surgeons steadily increase to become an 
everyday tool for acquiring intra-operative information, and eventually US will lead to 
surgeons being able to ‘see’ in a new dimension
Improvement of cosmetic results
Although oncological safety remains the primary concern, breast cancer surgery today 
is increasingly focusing on improved cosmetic outcomes. The goal of BCS is therefore to 
provide a treatment as effective as mastectomy, with the added benefits of a preserved 
breast and an improved cosmetic result. BCS is increasingly used for ductal carcinoma 
in-situ and for larger breast cancers following neo-adjuvant chemotherapy. In patients 
with these large, ill-defined, or poorly situated tumours, even a highly accurate US-
guided excision may not result in a satisfactory outcome. For this reason, - next to the 
introduction of intra-operative US - the emerging role of oncoplastic breast surgery 
offers promise, although many questions on the field of oncoplastic surgery remain 
unanswered, the first of which is the current lack of clarity surrounding the indications 
for oncoplastic surgery. No uniform algorithm yet exists for oncoplastic surgery, and 
decision-making often depends on surgeon preference. This is an important issue, as 
oncoplastic procedures indicate more extensive surgery with additional operative time 
and costs. The ability to identify patients at risk for poor cosmetic outcome at the time 
of consultation may allow for informed choices prior to surgery. A uniform management 
algorithm should be developed for this purpose, allowing surgeons to inform patients at 
the time of consultation on the type of surgery that will produce the best cosmetic result 
and the highest patient satisfaction possible. However, the introduction of US-guided 
surgery can be expected to reduce need for oncoplastic surgery, particularly because 
most invasive breast cancers present as relatively small (<2.5 cm) tumours.
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The second issue is that more attention should be paid to adequate tumour resection. It is 
more even more imperative to minimise the incidence of positive margins in oncoplastic 
breast surgery, as positive margins often prompt a subsequent mastectomy. Intra-operative 
US could therefore also be very helpful during oncoplastic excisions for breast cancer.
Most importantly, prior to the worldwide introduction of oncoplastic surgery, reliable 
randomised clinical trials should be performed in which the oncological and cosmetic 
outcomes of standard US-guided surgery are compared to those of oncoplastic surgery.
In addition to oncoplastic breast surgery, delayed plastic reconstruction can be used in 
patients with poor cosmetic results following BCS. Indeed, many patients consult plastic 
surgeons for surgical correction subsequent to BCS, sometimes years after their initial 
treatment. The techniques of delayed reconstruction following BCS include scar revision, 
contralateral reduction mammaplasty, or volume displacement procedures such as local 
tissue rearrangement, lipofilling, implants, or fasciocutaneous or musculocutaneous 
flaps. The decision for a specific type of reconstruction is made following expert opinion 
at the outpatient clinic, and depends on a variety of factors such as the size and shape 
of the breast, the availability of tissues at other sites, and complicating factors such 
as surgery on an irradiated breast. Because of the wide variety of surgical procedures 
for delayed reconstruction, it would also be helpful to develop surgical guidelines or 
algorithms for surgical reconstruction of the breast following breast-conserving therapy. 
This is an important issue to be addressed in the coming years.  
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Ontwikkelingen binnen de borstkanker chirurgie:
De cruciale rol van per-operatieve echografie
Borstkanker wordt de laatste decennia steeds vaker in een vroeg stadium opgespoord, 
mede dankzij de toenemende alertheid van vrouwen en de introductie van de landelijke 
screening. Hierdoor komt ruim drie kwart van de patiënten met borstkanker in 
aanmerking voor borstsparende chirurgie in combinatie met radiotherapie. 
Het voordeel van een borstsparende behandeling ten opzichte van een mastectomie 
is het behoud van de borst met daarmee een beter cosmetisch resultaat en een betere 
kwaliteit van leven. Het cosmetische resultaat na een borstsparende behandeling blijkt 
evenwel teleurstellend bij ruim 30% van de vrouwen. De belangrijkste factor van invloed 
is het volume weefsel dat tijdens de operatie wordt verwijderd. 
Het streven bij een borstsparende operatie zou daarom moeten zijn om de kwaadaardige 
tumor in zijn geheel (ofwel: radicaal) uit te nemen en tegelijkertijd zo min mogelijk 
gezond weefsel te verwijderen. Volgens de Nederlandse richtlijnen is de resectie van een 
minimale marge van 1 mm gezond mammaweefsel rondom de tumor voldoende. In de 
dagelijkse praktijk is een dergelijk krappe marge niet realiseerbaar en wordt gestreefd 
naar een ruimere ideale marge van 0,5-1,0 cm gezond mammaweefsel om een zekere 
radicaliteit te verkrijgen. 
In hoofdstuk 2 is de kwaliteit van de huidige mammasparende chirurgie op twee 
specifieke aspecten beoordeeld: 1) het volume verwijderd mammaweefsel in 
verhouding tot de tumorgrootte en 2) het percentage radicaliteit. Hiertoe werden alle 
vrouwen geïncludeerd die borstsparend geopereerd waren voor een primair, invasief 
mammacarcinoom in de periode januari 2006-december 2008 in het VU medisch 
centrum en 3 regionale ziekenhuizen. De postoperatieve pathologieverslagen werden 
verzameld. Met de driedimensionale afmetingen van het ellipsvormige excisiepreparaat 
kon het gehele excisievolume berekend worden. Met behulp van de tumordiameter werd 
het optimale excisievolume berekend, gedefinieerd als het bolvormige tumorvolume 
met hierbij opgeteld een door ons gekozen ‘optimale’ tumorvrije resectiemarge van 1 
cm. Door het gehele excisievolume te delen door het optimale excisievolume kon de 
berekende resectieratio (CRR) bepaald worden. Bij een ideaal uitgevoerde excisie is het 
excisievolume gelijk aan de CRR; de CRR is dan 1.0. Wanneer het excisievolume 2 maal 
groter dan het optimale excisievolume is de CRR 2.0. De chirurgische resectiemarges 
werden geregistreerd als radicaal, focaal irradicaal, of irradicaal voor invasief carcinoom, 
volgens de Nederlandse Richtlijn Mammacarcinoom. 
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In totaal voldeden 726 vrouwen aan de inclusiecriteria. Bij 525 (72,3%) patiënten bleek het 
carcinoom voelbaar en bij 201 (27,7%) niet-voelbaar. De mediane CRR van alle 726 excisies 
bedroeg 2.5 (CRR bij voelbare tumoren: 2.2; bij niet-voelbare tumoren: 3.1; p < 0,05). Bij 
153 patiënten (21,1%) was de invasieve tumor niet geheel (niet radicaal) verwijderd. Het 
percentage irradicale excisies bij de voelbare tumoren was 22,5% (138 van 525) en bij de 
niet-voelbare tumoren 17,4% (35 van 201) (p = 0,13). Bij ruim 60% van de excisies bleek 
de tumor zeer excentrisch in het preparaat gelokaliseerd. Ter illustratie: bij de vrouwen 
met een CRR > 4,0 bleek nog altijd ruim 10% niet radicaal verwijderd te zijn. 
Deze studie laat duidelijk zien dat bij de borstsparende chirurgie, voor zowel het 
voelbare als het niet-voelbare mammacarcinoom, een overmaat aan gezond weefsel 
wordt verwijderd. Dit zal resulteren in een verslechtering van het cosmetisch resultaat 
van de borst en daarmee het zelfbeeld en van het psychisch welbevinden van de vrouw. 
Ondanks de te grote excisievolumina is toch 1 op 5 excisies niet radicaal. De excentrische 
tumorlokalisatie in veel excisiepreparaten toont de ineffectiviteit van de huidige 
chirurgische procedure. Zelfs bij de zeer ruime excisies, waarbij meer dan 4 maal teveel 
weefsel wordt verwijderd, is meer dan 10% niet radicaal. Het bereiken van radicaliteit 
is essentieel. Een irradicale excisie moet gevolgd worden door een radiotherapeutische 
boost, danwel een re-excisie of soms zelfs een mastectomie om een oncologisch goed 
resultaat te bereiken. Deze aanvullende behandelingen leiden, naast verhoogde stress 
voor de vrouw, ook tot een verslechtering van het cosmetische resultaat. 
Opvallend is dat de voelbare tumoren vaker irradicaal verwijderd worden dan de niet-
voelbare tumoren, terwijl de excisie van een voelbaar mammacarcinoom doorgaans 
als eenvoudiger wordt beschouwd. Een voelbare tumor wordt alleen op basis van het 
preoperatieve beeldvormende onderzoek en op het gevoel van de chirurg verwijderd. 
Blijkbaar wordt de procedure bemoeilijkt door het gebrek aan een hulpmiddel, zoals 
gebruikt bij de niet-voelbare tumoren. 
HOOFDSTUK 2
BIJ BORSTSPARENDE CHIRURGIE WORDT DE TUMOR DOORGAANS 
TE RUIM VERWIJDERD (GEMIDDELD 2.5 MAAL TE RUIM), TERWIJL 
DE EXCISIE TE VAAK NIET RADICAAL IS (GEMIDDELD 22.5% NIET 
RADICAAL)
In hoofdstuk 3 is de kwaliteit van drie verschillende peroperatieve lokalisatiemethoden 
voor niet-voelbare borsttumoren vergeleken. Wederom werden deze beoordeeld op de 
volumina verwijderd weefsel in verhouding tot de tumorgroottes en het percentage 
radicaliteit. Hiertoe werd dezelfde methode gebruikt als in hoofdstuk 2.
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De draadgeleide chirurgie, de echogeleide chirurgie, en de radio-occulte laesielokalisatie 
(ROLL) werden met elkaar vergeleken. Bij de draadlokalisatie plaatst de radioloog vóór 
de operatie een röntgendraad nabij de maligne tumor en de chirurg excideert de tumor 
op geleide van deze draad. Met echogeleide chirurgie lokaliseert de radioloog het 
mammacarcinoom op de operatiekamer met echografie. Een recent ontwikkelde methode 
is de ROLL. Hierbij wordt radio-actief technetium-99m nabij de tumor geïnjecteerd, 
gevolgd door resectie met behulp van een gammaprobe. 
Van de niet-voelbare tumoren waren 117 draadgeleid, 52 echogeleid en 32 ROLL-geleid 
verwijderd. ROLL-geleide chirurgie resulteerde in de grootste CRR (respectievelijk, CRR 
2.8, 3.2, 3.8). Met echogeleide chirurgie werd een aanzienlijk hoger percentage radicaliteit 
bereikt dan met draadlokalisatie of ROLL (respectievelijk, 96%, 79% en 75% radicaal). 
Uit een recente landelijke enquête blijkt dat in ruim drie kwart van de Nederlandse 
ziekenhuizen draadgeleide chirurgie wordt gebruikt. Desondanks wordt deze 
techniek door de meeste chirurgen als lastig ervaren. Bovendien is de draadplaatsing 
een extra belastende interventie en kan de draad verplaatsen. Onder de nieuwere 
lokalisatiemethoden wint vooral ROLL aan populariteit, maar bekende nadelen van 
deze techniek zijn dat de grenzen van de tumor niet in beeld worden gebracht en dat 
het excisievolume groter wordt wanneer de radioactieve vloeistof in de borst vervloeit. 
Onmiskenbaar is de grote bijdrage van echografische controle aan de radicaliteit. 
Echografie heeft het voordeel dat de tumor op eenvoudige wijze continu in beeld kan 
worden gebracht. Hierdoor ontstaat een gecontroleerde excisie en kan de tumor met een 
duidelijk afgrensbare marge verwijderd worden. Additionele interventies zijn niet nodig. 
Na de excisie kunnen de randen van het excisiepreparaat met echografie gecontroleerd 
worden op mogelijke macroscopische tumorinvasie. Peroperatieve echografie kan dus 
de aangewezen methode zijn om de huidige borstsparende chirurgie te optimaliseren.
HOOFDSTUK 3
HET GEBRUIK VAN ECHOGRAFIE TIJDENS DE BORSTSPARENDE OPERATIE 
VAN NIET-VOELBAAR MAMMACARCINOOM LEIDT TOT EEN ZEER HOOG 
PERCENTAGE RADICALITEIT (>96%) EN LIJKT DUS DE AANGEWEZEN 
METHODE OM EEN ACCURATE EXCISIE TE BEWERKSTELLIGEN
Eerdere studies suggereerden dat het excisiepreparaat van een borstsparende procedure 
verandert in vorm en grootte (krimp of afplatting) in de periode tussen de excisie en 
de pathologische beoordeling. Hierdoor zou de pathologische beoordeling van de 
resectiemarges op radicaliteit niet meer betrouwbaar zijn. In hoofdstuk 4 zijn alle 
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fysieke veranderingen van het excisiepreparaat binnen dit tijdsbestek onderzocht, met 
medeneming van de invloed van formaline fixatie. In een observationele studie zijn 68 
mammasparende excisiepreparaten van invasief, palpabel mammacarcinoom geëvalueerd 
in 3 verschillende ziekenhuizen. Ieder excisiepreparaat werd op de operatiekamer en bij 
de pathologie afdeling gewogen en vervolgens werd de lengte, hoogte en breedte gemeten 
om daarmee het volume te berekenen. Tevens werd het volume van het preparaat op 
de operatiekamer met een maatbeker gemeten (volumeverplaatsing), wat geldt als de 
‘gouden standaardmethode’ van volumemeting. Bij de pathologieafdeling werd de kortste 
afstand tot de tumorvrije marge gemeten vooraf en na de formaline fixatie.
Uit de metingen bleek dat het gewicht van het excisiepreparaat gelijk was aan het 
gemeten volume (de gouden standaard). Tevens bleek dat het gewicht gelijk bleef in de 
periode tussen de excisie en de pathologische beoordeling (p = 0.94). De kortste afstand 
tot de tumorvrije marge vooraf en na de formaline fixatie veranderde niet (p = 0.1).  
Geconcludeerd werd dat de excisiepreparaten van mammasparende operaties niet 
krimpen in de tijd tussen de excisie en de pathologische beoordeling en dat de 
kortste afstand tot de tumorvrije marge niet verandert door formaline fixatie. Een 
aanvullende bevinding was dat berekeningen van excisievolumina onbetrouwbaar zijn. 
Volumeverplaatsing of gewichtsmeting worden daarom aanbevolen als methoden om 
het excisievolume te meten.
HOOFDSTUK 4
DE PATHOLOGISCHE BEOORDELING VAN DE RESECTIEMARGES EN 
EXCISIEVOLUMINA WORDT NIET BEINVLOED DOOR VERANDERINGEN 
VAN DE GROOTTE OF VORM VAN HET EXCISIEPREPARAAT
De effectiviteit van de echogeleide excisie van het niet-voelbare mammacarcinoom is 
inmiddels bewezen. Hoewel voelbare tumoren verwijderd kunnen worden op geleide 
van het gevoel van de chirurg en de beelden van de pre-operatieve diagnostiek, zou 
continue tumor visualisatie met behulp van echografie ook bij deze voelbare tumoren 
van aanzienlijke aanvullende waarde kunnen zijn. Hoofdstuk 5 betreft het studieprotocol 
van een prospectief gerandomiseerde studie, waarbij de hypothese is dat echogeleide 
chirurgie voor voelbaar mamacarcinoom resulteert in het sparen van gezond weefsel, 
terwijl de radicaliteit van de excisie behouden blijft of zelfs verbetert. In deze prospectief 
gerandomiseerde studie zal echogeleide chirurgie voor voelbaar borstkanker vergeleken 
met de standaard palpatiegeleide methode (excisie op het gevoel van de chirurg), op 
de criteria: het teveel verwijderd weefsel, het percentage radicaliteit, het cosmetisch 
resultaat en de kwaliteit van leven.
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HOOFDSTUK 5
ECHOGELEIDE CHIRURGIE VOOR HET VOELBARE MAMMACARCINOOM 
ZOU GEZOND MAMMAWEEFSEL KUNNEN SPAREN, TERWIJL DE 
RADICALITEIT BEHOUDEN BLIJFT OF ZELFS VERBETERT
In hoofdstuk 6 is de leercurve van chirurgen voor de echogeleide excisie voor van 
voelbare mammatumoren onderzocht. Tijdens een ‘hands-on’ trainingsperiode werden 
30 patiënten met een voelbaar mammacarcinoom echogeleid borstsparend geopereerd 
door 3 verschillende chirurgen. Het doel was om een radicale excisie te bewerkstelligen 
met medeneming van zo min mogelijk gezond mammaweefsel.
Alle tumoren werden adequaat herkend tijdens de operatie en 29 van 30 tumoren (97%) 
werden radicaal verwijderd. Slechts 1 tumor werd verwijderd met focaal irradicale marges. 
De mediane CRR was 1.0 (0.4 – 2.8). De CRR verbeterde gedurende de trainingsperiode. Na 
8 operaties waren alle chirurgen vaardig in het verrichten van een echogeleide excisie. 
Geconcludeerd werd dat de techniek voor echogeleide chirurgie simpel, veilig en effectief 
is in het bereiken van een radicale excisie, waarbij de excisievolumina gedurende de 
trainingsperiode aanzienlijk verbeterden en gemiddeld een optimaal excisievolume 
werd bereikt.
HOOFDSTUK 6
CHIRURGEN KUNNEN HET ECHOGELEID OPEREREN VAN VOELBAAR 
BORSTKANKER MAKKELIJK AANLEREN; DE TECHNIEK IS NIET 
INVASIEF,  SIMPEL, VEILIG EN BOVENAL EFFECTIEF IN HET BEREIKEN 
VAN EEN RADICALE EXCISIE
Hoofdstuk 7 presenteert de resultaten van de multicentrische prospectief gerando-
miseerde studie, waarbij echogeleide chirurgie voor voelbaar mammacarcinoom is 
vergeleken met de standaard palpatiegeleide chirurgie op het percentage radicaliteit en 
het teveel verwijderd mammaweefsel. In totaal werden 134 patiënten met een voelbaar 
T1-T2 invasief mammacarcinoom gerandomiseerd tussen ofwel echogeleide (n = 65), ofwel 
palpatiegeleide (n = 69) chirurgie. Een enorme verbetering in de radicaliteit werd gezien 
met een exceptioneel hoog percentage van 97% radicale excisies in de echogroep, ten 
opzichte van 83% in de palpatiegroep (p = 0.009), leidend tot een afname in de noodzaak 
tot re-excisie, mastectomie, of extra radiotherapeutische boosts met echogeleide 
chirurgie. En ondanks de drastische verbetering in de radicaliteit, was het volume 
verwijderd weefsel in de echogroep significant kleiner. Sterker nog: in de echogeleide 
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groep werden een gemiddeld optimaal excisievolume bereikt (respectievelijk, 38 vs 58 
cc, en CRR 1.0 vs 1.7; beide p < 0,05). 
Deze trial heeft overduidelijk laten zien dat de peroperatieve begeleiding met echografie 
resulteert in een verbetering van de chirurgische effectiviteit. Echogeleide chirurgie kan 
daarom een einde maken aan het onacceptabel hoge percentage aan irradicaliteit bij 
de excisie van het voelbare mammacarcinoom, waardoor minder vaak noodzaak is tot 
een aanvullende operatie of extra radiotherapie. Tevens draagt echogeleide chirurgie bij 
aan een drastische vermindering van het teveel verwijderd mammaweefsel en worden 
zelfs optimale excisievolumina verkregen, zodat het uiteindelijke cosmetisch resultaat 
van de geopereerde borst hoogstwaarschijnlijk beter is.
Gezien de overweldigende bijdrage van echogeleide chirurgie in deze studie, kunnen 
we echografie beschouwen als een onmisbare aanvulling bij de excisie van voelbaar 
borstkanker. Het wordt chirurgen dan ook ten zeerste aangeraden om de echogeleide 
techniek voor de excisie van het voelbare mammacarcinoom aan te leren.
HOOFDSTUK 7
ECHOGELEIDE CHIRURGIE VOOR HET VOELBARE MAMMACARCINOOM 
LEIDT TOT EEN ZEER HOOG PERCENTAGE RADICALITEIT, IN 
TEGENSTELLING TOT PALPATIEGELEIDE CHIRURGIE
ECHOGELEIDE CHIRURGIE VOOR HET VOELBARE MAMMACARCINOOM 
LEIDT TEVENS TOT EEN DRASTISCHE AFNAME VAN HET VOLUME 
TEVEEL VERWIJDERD GEZOND MAMMAWEEFSEL, WAARBIJ ZELFS EEN 
GEMIDDELD OPTIMAAL EXCISIEVOLUME WORDT BEREIKT
Bij de implementatie van echogeleide chirurgie kunnen de kosten die gepaard gaan 
met deze nieuwe techniek mogelijk een probleem vormen; met name de kosten voor de 
aanschaf van een geavanceerd echo-apparaat kunnen een obstakel zijn. Aan de andere 
kant zal een afname in het percentage niet radicale excisies de kosten sparen die gemaakt 
worden voor aanvullende behandelingen zoals re-excisies, masectomieën, of additionele 
radiotherapeutische boosts. Hoofdstuk 8 is een economische evaluatie van de kosten en 
baten van echogeleide chirurgie voor voelbaar mammacarcinoom. Met name de primaire 
kosten, zoals de aanschaf van het echo-apparaat, de kosten voor extra operatietijd en de 
kosten voor re-operaties of radiotherapie zijn meegerekend. Een echogeleide operatie 
bleek 193 euro te kosten [95% CI E153 to E233], terwijl palpatiegeleid opereren 349 euro 
kostte [95% CI E103 to E591]. Het verschil werd met name bepaald door het hoger aantal 
aanvullende behandelingen dat nodig is met palpatiegeleide chirurgie. De som van de 
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kosten-baten analyse liet zien dat echogeleid opereren leidt tot een afname in kosten 
van totaal E154 (95% CI E388 tot E81) per patiënt. Boven een geopereerd aantal van 30 
patiënten per jaar is het gebruik van de echografie kosten sparend. Geconcludeerd werd 
dat echogeleide chirurgie niet alleen zeer effectief is, maar ook nog eens kosten sparend.
HOOFDSTUK 8
ECHOGELEIDE CHIRURGIE VOOR HET VOELBARE MAMMACARCINOOM 
IS NIET ALLEEN ZEER EFFECTIEF, MAAR OOK NOG EENS KOSTEN 
SPAREND VERGELEKEN MET PALPATIEGELEIDE CHIRURGIE
Sinds enkele jaren is de oncoplastische chirurgie in opkomst. Oncoplastische chirurgie 
combineert de oncologische procedure met een plastische reconstructie met het doel 
om de oncologische en cosmetische resultaten van de mammasparende chirurgie 
te verbeteren. Oncoplastische chirurgie is een zeer breed begrip waaronder veel 
verschillende soorten technieken worden verstaan. De keuze voor een oncoplastische 
procedure en de soort oncoplastische techniek is gebaseerd op factoren zoals de grootte 
van de borst, de grootte van de tumor en de locatie van de tumor. Hoofdstuk 9 geeft een 
overzicht van de verschillende oncoplastische technieken met de voordelen, nadelen 
en indicaties van iedere procedure. Daarnaast zijn de oncologische en cosmetische 
resultaten, de morbiditeit, kwaliteit van leven en de toegepaste indicaties van de 
verschillende oncoplastische technieken systematisch gereviewed.
Tussen 2000 en 2011 werden in totaal 2090 abstracts over dit onderwerp gepubliceerd, 
waarvan 88 artikelen werden geïdentificeerd voor mogelijke inclusie. Deze 88 
artikelen werden allen opnieuw geanalyseerd, waarna 11 prospectief observationele en 
vergelijkende studies werden geselecteerd. Prospectief gerandomiseerde studies werden 
niet gevonden. In deze studies waren 80 tot 93% van de tumoren invasief en in totaal was 
78 tot 93% van de excisies radicaal. Het mastectomie percentage was 3 tot 16%. Bij 0 tot 
7% van de patiënten werd een lokaal recidief gevonden. Het cosmetisch resultaat werd 
als ‘goed’ beoordeeld bij 84-89% van de patiënten. De beslissing voor een type operatie 
werd voornamelijk bepaald door de voorkeur van de chirurg, waarbij de specifieke 
indicaties voor (het type) oncoplastische procedure onduidelijk bleven. Een algemene 
beslisboom werd niet gebruikt. Helaas toonden alle studies duidelijke methodologische 
zwaktes, wat vanzelfsprekend een negatieve invloed heeft op de generaliseerbaarheid 
van de uitkomsten. Geconcludeerd werd dat de huidige studies naar de effectiviteit van 
oncoplastische chirurgie te zwak en underpowered zijn. 
Aangezien oncoplastische chirurgie in toenemende mate wordt toegepast moet de 
effectiviteit van deze procedures nu op valide wijze onderzocht  worden. Tevens moet 
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een gestructureerde beslisboom voor de indicatiestelling samengesteld worden, zodat 
men een gefundeerde beslissing kan maken over de meest geschikte operatiemethode 
voor iedere afzonderlijke patiënte. Derhalve is het noodzakelijk om correct opgezette 
vergelijkende (prospectief gerandomiseerde of prospectief longitudinale) oncoplastische 
studies op te zetten.
HOOFDSTUK 9
DE INDICATIES EN EFFECTIVITEIT VAN ONCOPLASTISCHE CHIRURGIE 
ZIJN VOORALSNOG NIET OP VALIDE WIJZE ONDERZOCHT
DERHALVE MOETEN VERGELIJKENDE STUDIES WORDEN OPGEZET 
VOORDAT ONCOPLATISCHE CHIRURGIE V ERDER WORDT 
GEIMPLEMENTEERD 
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Chapter 2, and Chapter 5. Figure 1.a, Figure 1.b 
1.a. An optimal resection volume. The tumour is centrally located with an adequate resection margin. 
1.b. Large total resection volume. The tumour is eccentrically located with a close resection margin (0.2 cm).
1.a. 1.b.
A PPENDICES
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Appendices
Chapter 5, Figure 4; Chapter 6, Figure 2. 
The ultrasound is applied repeatedly in and around 
the wound from different angles to determine the 
attainment of adequate margins
Chapter 5, Figure 6; Chapter 6, Figure 4.  
Following excision, completeness of the specimen is 
checked by ultrasonography to determine complete 
tumour excision. 
Chapter 5, Figure 5. Chapter 6, Figure 3.  
The plane of dissection is clearly visible on the US 
image. US visible plane of dissection (arrow); the 
distance from the tumour to the plane of dissection 
indicates that an appropriate margin is obtained. 
Chapter 5, Figure 3; Chapter 6, Figure 1. 
Medial tumour localisation. The tumour margins can 
be precisely marked on the skin, and the skin marks 
connected. 
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Dankwoord
DANKWOORD
Allereerst wil ik alle patiënten en hun familie bedanken dat zij in een tijd van ernstige 
ziekte bereid zijn geweest om mee te werken aan dit onderzoek. Het is bijzonder om te 
zien hoe zij vaak zelf ook zo begaan zijn met onze studie. De follow-up van de COBALT 
studie loopt nog altijd door en wij zullen alle patiënten op de hoogte houden van de 
vorderingen van het onderzoek en de behaalde resultaten.
Het is zover: mijn proefschrift is voltooid! Het is eigenlijk vreemd dat enkel mijn naam op 
de voorkant van dit boekje staat. Ik heb dit proefschrift namelijk zeker niet in mijn eentje 
geschreven. Alleen dankzij het vertrouwen en het enthousiasme van een groot aantal 
mensen om mij heen heb ik mijn onderzoekstijd succesvol en met zoveel plezier kunnen 
volbrengen. Dit is dan ook een mooi moment om mijn dank aan hen uit te spreken. 
Prof.dr. S. Meijer, promotor. Beste prof. Als enthousiaste, maar onwetende arts-assistent 
kwam ik naar u toe met de mededeling dat ik onderzoek wilde doen om de cosmetiek 
na borstkankeroperaties te verbeteren. U zal zeker uw bedenkingen hebben gehad of 
we dit project tot een succesvol einde zouden kunnen brengen. Toch gaf u mij het 
vertrouwen om met deze studie aan de slag te gaan. Dankzij uw enthousiasme werd 
ons studieprotocol een succes. U inspireerde mij om verder te denken dan de huidige 
standaarden. U stimuleerde mij om steeds zelfstandiger te werken. U heeft mij gevormd 
tot een ware wetenschapper. Ik zal me altijd blijven verwonderen. Uw wetenschappelijk 
inzicht, uw geniale ideeën, maar ook uw levenswijsheden hebben de afgelopen jaren 
enorme indruk op mij gemaakt. Groot was mijn blijdschap toen u mij zei dat ‘mijn 
kostje was gekocht’. U heeft namelijk -bijna- altijd gelijk! Het is voor mij een eer om bij 
u te mogen promoveren. U zult altijd mijn grote voorbeeld blijven. 
Dr. M.P. van den Tol, co-promotor. Lieve Petrousjka. Wat hebben wij een mooie tijd samen 
gehad. Onze ritjes met de echo in de kofferbak, scheurend door het hele land, voor de 
zoveelste keer een afslag missend omdat we zo aan het kletsen waren, en natuurlijk onze 
reis naar Stockholm. Maar boven alles heeft dit onderzoek zonder jou nooit kunnen 
slagen. Ik ben je dan ook oneindig veel dank verschuldigd. Je hebt je altijd voor de volle 
100% ingezet voor de studie en in je enthousiasme beoordeelde je mijn geschreven 
stukken altijd razendsnel. Je bent de ideale co-promotor. Daarnaast is de manier waarop 
jij jezelf de echogeleide chirurgie eigen hebt gemaakt bewonderenswaardig. Je bent 
een fantastisch chirurg met een warm hart voor het vak, voor je patiënten en voor het 
onderzoek. Ik kan alleen maar hopen dat ik ooit zo goed in mijn vak mag worden als jij 
dat bent. Het is geweldig geweest om dit onderzoek samen met jou te kunnen volbrengen 
en ik hoop nog vaak met je samen te mogen werken.
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Dr. H.A.H. Winters, co-promotor. Beste Hay. Een paar jaar geleden bij liep ik je kamer 
binnen met de mededeling dat ik in opleiding wilde tot plastisch chirurg. Ongetwijfeld 
was ik het zoveelste blondje dat op deze manier bij jou langs kwam. Desondanks heb 
je mij gesteund en mij over de juiste manier van aanpak geadviseerd. Ook tijdens mijn 
onderzoekstijd ben je mij blijven steunen. En ondanks mijn gedram dat ik echt zo snel 
mogelijk met die opleiding wilde beginnen vond jij dat ik eerst mijn onderzoek af moest 
ronden. Achteraf geef ik toe dat je mij geen betere raad had kunnen geven. Ik ben blij 
dat ik de opleiding tot plastisch chirurg nu met mijn volle aandacht kan volgen en kijk 
er heel erg naar uit om dit onder jouw leiding te mogen doen.
Geachte leden van de promotiecommissie, prof.dr. E. Boven, prof.dr. E. van der Wall, 
prof.dr. C. van Kuijk, prof.dr. P.M.N. Werker, dr. M.B.E. Menke-Pluymers en dr. E. Barbé, 
hartelijk dank voor het beoordelen van dit proefschrift en het zitting nemen in de 
promotiecommissie.
Prof.dr. J. Bonjer, hoofd van de afdeling chirurgie. Beste professor Bonjer. Uw komst 
naar het VUmc heeft veel goeds meegebracht. Een belangrijk aspect is natuurlijk 
de sportiviteit, waarvan wij zeker het fanatisme delen. Maar ook uw visie op het 
wetenschappelijk onderzoek heeft een positieve draai aan de afdeling gegeven. 
Slechts enkele weken na uw komst in het VUmc spraken wij elkaar over het opzetten 
van een studie op het gebied van borstkanker. Blijkbaar zag u in mij een potentiële 
wetenschapper, want u steunde mij om een subsidie aanvraag op te stellen. Zonder u 
had dit onderzoek nooit van de grond kunnen komen en daar wil ik u nadrukkelijk 
voor bedanken. Mijn onderzoeksperiode is nu volbracht, maar de grote onderzoeksgroep 
die intussen mede door uw leiding is ontstaan zal chirurgie VUmc zeker tot een nog 
succesvollere wetenschapsafdeling maken.
Max Haloua, paranimf. Beste Max. De afgelopen jaren hebben voor mij volledig 
in het teken gestaan van de COBALT studie. Ik vind het dan ook moeilijk om ‹mijn 
onderzoekskindje› aan een ander af te moeten staan. Daarom ben ik blij dat jij de studie 
van mij overneemt. Jij hebt je motivatie en enthousiasme inmiddels duidelijk laten 
zien en ik hoop dat jij de komende jaren met net zoveel passie en voldoening aan 
het onderzoek blijft werken als ik dat heb gedaan. Daarnaast hoop ik zoveel mogelijk 
betrokken te kunnen blijven met alle follow-up vraagstukken en de artikelen die nog 
voort zullen komen uit deze studie. Lieve Max, dankjewel voor je inzet, en dankjewel 
dat je mijn paranimf wil zijn.
Rose Funke Küpper, paranimf. Lieve lieve Rose. Jaargenoot, huisgenoot, bestuursgenoot... 
Maar bovenal natuurlijk mijn superleuke, lieve en altijd geïnteresseerde vriendinnetje 
met wie ik alles kan delen en die altijd op de hoogte is van alles om mij heen. Zelfs van 
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dit onderzoek weet je alles af! En dat voor een Meester in de Rechten. Ik vind het een 
eer dat je mijn paranimf wil zijn, dankjewel daarvoor!
Beste chirurgen die deel hebben genomen aan de COBALT studie: Alexander Lopes 
Cardozo, Anne Marie Bosch, Wilfred de Roos, Henk van der Veen, Sandra Muller, 
Herman Rijna, Louise de Widt en Pieter Poortman. Ontzettend veel dank voor jullie 
enthousiasme. Jullie zijn natuurlijk essentieel geweest voor deze studie. Het is niet 
niks om een nieuwe operatiemethode aan te moeten leren, enkel in het kader van een 
onderzoek. Toch hebben jullie je vanaf het begin enorm ingezet voor deze studie. Eerst 
de oefenperiode, vervolgens de selectie en de inclusie van patiënten, het echogeleid 
opereren, en tenslotte de follow-up. Medewerking aan een studie vergt veel energie, maar 
ik hoop dat jullie net als ik veel plezier beleefd hebben aan dit onderzoek. Daarnaast 
hoop ik dat de studie jullie overtuigd heeft van het belang van echogeleide chirurgie. 
Beste Roos de Wit, Paulien Staal, Truus Smit en Aukje Cnossen, dank voor jullie inzet 
bij het includeren van de patiënten en het verzamelen van de gegevens.
Lieve Margôt de Graaf. Wat is het toch een mooie samenloop van omstandigheden 
dat jij ons nu kunt helpen bij dit onderzoek. Niet alleen is het geweldig dat je weer 
wekelijks met ons de VU bijeen komt, maar ook kan ik mij niemand indenken die de 
follow-up van de COBALT studie beter op zich zou kunnen nemen dan jij. Dankjewel voor 
je professionaliteit, je betrokkenheid, je lieve whats-appjes, je inzet en enthousiasme.
Elly de Lange. Beste Elly, hartelijk dank voor jouw statistische kennis en kunde. Wat moet 
ik zonder jouw perfecte statistische analyses? Een mailtje naar jou en het antwoord is 
vliegensvlug daar. Geweldig. Dankjewel daarvoor.
Mecheline van der Linden. Beste Mecheline. Vanaf het moment dat ik jouw kamer binnen 
stapte met dit onderzoeksidee ben jij onvoorwaardelijk enthousiast en gemotiveerd 
geweest om mee te werken aan de studie. Dankjewel voor je inzet en expertise op het 
gebied van de medische en oncologische psychologie. Ik hoop dat we in de toekomst 
vaker samen mogen werken.
Annette Taets van Amerongen en Liesbeth Bergers. Beste Annette en Liesbeth, ontzettend 
veel dank voor jullie hulp, begeleiding en geduld bij het 'aanleren' van de echografie. 
Zonder jullie hadden we dit onderzoek nooit mogelijk kunnen maken.
Ellis Barbé. Beste Ellis, dankjewel voor je onderzoeks enthousiasme en je hulp bij alle 
mogelijke vraagstukken op het gebied van de mamma pathologie.
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Derek Rietveld. Beste Derek, dankjewel voor het delen van de kennis binnen jouw 
vakgebied en jouw geduld om alles (keer op keer) aan ons uit te leggen.
Beste overige co-auteurs, Hein Stockmann, Hermien Schreurs, Henk Jan van Slooten, 
Herman Bril, Veerle Coupé, Judith Bosmans en Frank Bloemers, dank voor jullie 
medewerking, expertise en enthousiasme.
Ilvy van den Berg. Lieve Ilf, dankjewel voor het ontwerpen van het mooie COBALT logo. 
Je hebt geen idee hoe vaak we die gebruikt hebben...
Borstkankerstichting Pink Ribbon. Zonder de onderzoekssubsidie die wij van de stichting 
Pink Ribbon verkregen had de COBALT studie nooit opgezet kunnen worden. Dank 
hiervoor.
Mark Osinga. Door de opbrengsten van jouw prachtige boek konden wij een echo-
apparaat aanschaffen voor de COBALT studie. Wat hadden we zonder jou moeten 
beginnen?! Ontzettend veel dank. 
Toshiba Medical Systems, Marcel Boschker en Bianca Hesselius. Hartelijk dank voor 
de echo-apparaten die wij voor de duur van de studie konden gebruiken en dank voor 
jullie medewerking aan de COBALT studie. 
Lieve onderzoeksmaten, Kirsten Maas, Dorothee Nieuwenhuis, Karin Nielsen, Gabor 
Abis, Erienne de Cuba, Marjolein Ankersmit, Dieuwertje van Dam en alle anderen. 
Dank voor de gezelligheid, de afleiding en de wetenschappelijke hulp tijdens de afgelopen 
periode.
Lieve secretaresses en poli assistentes van heelkunde VUmc, lieve Ilse Kruit, Ron de 
Hoon en Wendy van Kolk. Dank jullie wel voor de ondersteuning, kennis, wijze raad 
en natuurlijk de gezelligheid.
Oud-collega’s en stafleden van heelkunde VUmc, dank voor de mooie tijd die ik drie 
jaar lang heb gehad. Ik heb niet alleen heel veel geleerd, maar ook een onvergetelijke 
tijd gehad door de fantastische skivakanties, de wilde heelkunde feestjes en natuurlijk 
de 3 x kampioens-chirurgencup! 
Collega’s en stafleden van het Slotervaartziekenhuis, dank voor de plezierige 
vooropleiding die ik bij jullie mag volgen. Dank ook voor jullie begrip als ik weer 
eens afwezig was door een congres, of af en toe vermoeid was door mn nachtelijke 
schrijfuurtjes…
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Dankwoord
Ivar de Bruin, renmaat. Lieve Ivar. Dank voor alle rondjes Ouderkerk. Het marathon-
doel is bereikt!!
Tjarko Erdtsieck, tennismaat. Lieve Tjark, dank voor die oneindig veel potjes ‘elven’. 
Tennis is toch het leukste wat er is! Niet alleen voor ons publiek, ook voor onszelf...
Lieve pappa en mamma. Mams, het is zover, mijn ‘werkstuk’ is af! Dank jullie wel voor 
jullie medeleven. Dank jullie wel voor het lezen van mijn Nederlandse artikeltjes, hoewel 
het voor jullie af en toe abacadabra moet zijn geweest. Dank jullie wel dat jullie mij alle 
mogelijkheden hebben gegeven om mij op mijn eigen manier te ontwikkelen. Dank dat 
jullie mij altijd steunen bij de dingen die ik doe en bij de keuzes die ik maak. Dank dat 
ik altijd bij jullie terecht kan. En boven alles dank voor jullie onvoorwaardelijke liefde, 
jullie steun en stimulans.
Liefste zusjes, Angelina en Annefleur. Dank voor jullie begrip, gezelligheid, relativerings-
vermogen en altijd goede grappen! Jullie zijn top-zussen!!!
Lieve, lieve Lucas. Het afgelopen jaar is zeker niet makkelijk geweest: het afronden van 
dit proefschrift, het begin van mijn opleiding, het kopen van een huis, het verhuizen en 
de verbouwing. Het heeft mij bloed, zweet en tranen gekost. Gelukkig ben jij het relaxte 
rustpunt in mijn leven. Met jouw positieve levenswijze dwing je mij om af en toe te 
ontspannen en gewoon met vakantie te gaan. Dankjewel voor je medeleven, je steun en 
het vertrouwen. Dankjewel dat jij als orthopeed zo’n enorme fan bent van dit mamma 
onderzoek! Dankjewel dat jij in mijn leven bent gekomen. Ik hoop dat we samen altijd 
zo gelukkig zullen blijven. Ik hou van jou.
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